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Chapter 1
Introduction
The following sections present the main motivations and purposes that led to the design
and implementation of this study as part of a larger project resulting from the collab-
oration between the Eurecat Foundation, the Program for Predictive and Personalized
Medicine of Cancer at the Health Science Research Germans Trias i Pujol (PMPPC-
IGTP) and the Polytechnical University of Catalonia (UPC).
1.1 Motivation & Purpose
The heritability of a trait or disease is defined as the fraction of phenotypic 1 variability
attributable to genetic variation 2 [8]. This topic has been the focus of research of many
studies in genetics in the past several years. Initially these studies consisted of analyzing
a group of ‘candidate genes’ and their effect to a certain trait. Other studies were based
on family-based linkage, analyzing inheritance patterns in thousands of genomic markers.
In 2003 a new approach called the genome-wide association (GWA) method, appeared
as a promise to identify many of the genes involved in complex diseases. In these GWA
studies (GWAS), hundreds of thousands of single nucleotide polymorphisms (SPNs) 3
of individuals were analyzed to understand the genetic architecture of complex diseases.
They are case-control studies based on a comparison of allele frequencies between groups
of affected and unaffected individuals from a population. A particular allele 4 is said to
be associated with the trait (risk allele) if it occurs at a significantly higher frequency
among affected individuals as compared with those in the control group. The odds ratio
1traits or characteristics that can be observed
2variation in the DNA sequence of an individual genome.
3Difference at one base-pair in the DNA sequence.
4the variant form of a given gene.
1
2of the trait in individuals is then assessed as the ratio of the frequency of the allele in
the affected population compared with the unaffected population [9].
Figure 1.1: Feasibility of identifying significant genetic variants by risk allele fre-
quency and strength of genetic effect (odds ratio). Adapted from [1].
Figure 1.1 shows the known likelihood of identifying significant genetic variants by risk
allele frequency and strength of genetic effect (odds ratio). As Manolio et al. states,
GWAS’s underlying rationale is the ‘common disease, common variant’ hypothesis, refer-
ring to the fact that common diseases are attributable in part to allelic variants present
in more that 1-5% of the population [1]. But even though these studies have identi-
fied hundreds of genetic variants and genes linked to a trait, providing valuable insights
into their complexity, both the individual and cumulative effects of these variants have
been disappointingly small and very far of explaining the heritability estimates of these
traits. According to Maher, in the analysis of the whole genome with respect to com-
plex diseases with population samples ranging between two thousand and five thousand
individuals, there has been no way to explain more than 5% of the genetic variation of
these traits, when it is known that the inheritance constitutes 40% up to 60% of the
variability. The latter arose an important question, unexplained until now, known as
the problem of “missing heritability”: Why so much of the heritability is apparently
unexplained by initial GWAS findings? This has been an important question to solve,
focus of many researches, including this, because understanding the genetic variations
3between individuals with complex diseases may contribute to better prevention, diag-
nosis and treatment of these diseases. Many hypothesis have been suggested to explain
this missing heritability in complex diseases [1] [10]:
• The statistics used behind these GWAS studies are very basic. SNPs (single-
nucleotide polymorphisms) 5 are analyzed one by one even though it is known
that complex diseases are related to variations in several variants simultaneously.
• These studies use a lot of samples and perform a lot of statistical tests, including
statistical corrections, that lead to finally keep for study, very few of the initial
variables. The rest of the variables mathematically can not be taken into account,
but surely explain a part of the inheritance of the disease.
• Low power to detect gene-gene interactions (epistasis), among others.
Finally, there are still many doubts revolving around missing heritability, and it is clear
that the GWAS is a powerful method, but in order to mathematically justify it and
validate it, it loses or ignores valuable information along the way.
1.2 Objectives
A common alternative of methodological approximation to tackle the missing heritability
problem is to use machine learning (ML) methods to discover epistatic and non-epistatic
polygenic 6 effects (i.e. variants) in complex diseases. The latter is part of the global
objectives of a common large project executed between Eurecat, PMPPC-IGTP and
UPC called “Health Forecast”, and corresponds to the specific objectives accomplished
in the presented study. More specifically the following objectives were defined and
attained:
Discover relevant associations, of bio-markers (e.g. SNPs) as well as environmental
and epidemiological factors in two large-scale genetic datasets. In order to do so, the
following tasks were proposed:
1. Design and implement a framework based on a pipeline of ML-based steps, de-
veloped in a centralized environment (i.e. using single node, taking advantage
of multi-core architecture and parallel library implementations), and compare the
classical GWAS results with ML-based framework results.
5variation in a single nucleotide that occurs at a specific position in the genome.
6one of a group of nonallelic genes that together control a quantitative characteristic in an organism.
42. Classify the individuals according to the response or predisposition to the studied
diseases.
3. Identify relevant/important combinations of variants (SNPs) that enabled the clas-
sification model to distinguish among case/control individuals.
The previously defined objectives were applied to different datasets related to common
complex diseases that fall into expected different genetic architectures shown in Figure
1.2:
• Dataset 1 : this is a dataset of cancer patients and it is desired to analyze whether
or not the patient responds to a certain treatment to which he/she is subjected
to. In this scenario, a much more penetrating effect is expected, i.e. it is assumed
that there are few variants that have a stronger effect because the target being
analyzed is closer to the effect (responds or does not respond to treatment).
• Dataset 2 : this is a dataset that comprises individuals from general population
with a self-diagnosis of diabetes (type 2) and/or three main comorbidities (hy-
percholesterolemia, hypertension and/or cardiovascular diseases). There are also
patients with complex diabetes. The objective is to identify and classify patients
based on the presence/absence of the previously mentioned comorbidities. Three
main comparisons are presented regarding main outcome (type 2 diabetes) and
presence/absence of comorbidities:
– Case 1: Type 2 Diabetes vs. Healthy (D2 vs. Healthy): Case-Control. Case
are individuals with a self-reported clinical diagnosis of Type 2 Diabetes.
Controls are all other individuals. This scenario approximates the case of
genetic effect of common variants with low penetrance.
– Case 2: Type 2 diabetes vs. Comorbidity and no Type 2 Diabetes (D2 vs.
CD2F): Case-Control. All individuals are affected. Case are individuals with
a self-reported clinical diagnosis of Type 2 Diabetes. Controls are all other
individuals with no reported diabetes, but with at least one year of the con-
sidered comorbidities. This scenario approximates the case of genetic effect
of low-frequency-common variants with higher penetrance.
– Case 3: Complex type 2 Diabetes vs. Comorbidity and no type 2 Diabetes
(CD2W vs. CD2F): Case-Control. All individuals are affected. Case are
individuals with a self-reported clinical diagnosis of Type 2 Diabetes and at
least one year of the considered comorbidities. Controls all other individu-
als with no reported diabetes, but with at least one year of the considered
5comorbidities. This scenario approximates the case of genetic effect of low-
frequency-common variants with higher penetrance.
Both, case 2 and case 3 deal with observed phenotype correlation, causality and pleiotropic
7 effect of the genetic variants, involved in several conditions.
Figure 1.2: Feasibility of identifying significant genetic variants by risk allele fre-
quency and strength of genetic effect (odds ratio). Adapted from [1].
1.3 Derived Publication
From part of the results of this study a paper has been derived and accepted for presen-
tation and publication. The paper is attatched at the end of this report.
• Valde´s M. G., Rafael-Palou X., Galva´n-Femen´ıa I., Duran X., Yokota J., Gavalda`
R., de Cid R., Ribas Ripoll V. Pipeline design to identify key features in prognosis
biomarker analysis using a real lung cancer data-set. To be presented at the
5th International Work-Conference on Bioinformatics and Biomedical Engineering
(IWBBIO). April 2017.
7producing more than one effect.
61.4 Thesis Outline
In Chapter 1 the motivation and purpose of the study is presented. Then, Chapter 2
outlines the theoretical background information of both bioinformatics/genetics and ma-
chine learning areas, that is required to understand the proposed methodology and the
application to GWAS data. Chapter 3 outlines the complete methodological description
of the study and the data to which the methodology was applied. Afterwards in Chapter
4 the experimental setup is presented followed by the description of the results (using
tables and plots that support them) obtained for each of the experiments. Each subsec-
tion corresponds to a different dataset use case defined in this chapter. Finally, Chapter
5 presents detailed conclusions for each dataset use case as well as overall remarking
observations. Also suggestions of future work are presented in the last chapter.
Chapter 2
Background
This section describes the most relevant concepts, algorithms and methods related to the
methodological approach presented in this study, and its implementation. The following
sections show all the contextual information needed to understand the design of the
methodology, type of data used, experiments and results obtained.
2.1 Bioinformatics
Bioinformatics is an interdisciplinary field that mainly involves molecular biology and
genetics, computer science, mathematics, and statistics. The main goal of the field is
to address from a computational point of view, data intensive, large-scale biological
problems [11]. A common use of bioinformatics include the analysis of genomic data,
in order to better understand the genetic basis of diseases, unique adaptations, desir-
able properties or differences between populations [12]. In the following subsections we
describe fundamental concepts used in bioinformatics needed to understand the kind of
data used in this study.
2.1.1 Genomics and Diseases
Berrar et al. broadly defines genomics as the systematic study of genes, their functions,
and their interactions [13]. Its main goal is to understand the structure of the genome
to figure out how genes interact with each other and with the environment. The study
of the genome also helps researchers understand how complex or multi-factorial diseases
are formed, to ultimately find ways to diagnose, treat, and prevent theses diseases.
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8To better understand what a multi-factorial disease is we first introduce a series of basic
genetic terminology, definitions and concepts:
SNP Data and Encoding
The human genome is organised in 23 chromosome pairs (22 pairs + 1 pair to determine
the sex) each half corresponding to the mother and father. The four basic building blocks
of DNA are called nucleotides. Each nucleotide is composed of a nitrogen-containing
nucleobase (either guanine (G), adenine (A), thymine (T), or cytosine (C)) as well
as a sugar component called deoxyribose. A base-pair is formed by the combination
of two nucleobases. Changes on a single base-pair at a given position in the DNA
sequence that occur above some frequency in the population (typically 1%) are genetic
variations that distinguish human beings from one another (except monozygotic twins,
which have exactly the same DNA) [2]. This kind of changes are called single nucleotide
polymorphisms (SNP, pronounced “snip”, Figure 2.1). As Ban et al. comment, the
human genome contains about 10 to 30 million SNPs with an average SNP every 100 to
300 bases. More than 5 million human SNPs have been identified and the information
is publicly available (NCBI dbSNP Build 129) [14].
Figure 2.1: A single nucleotide polymorphism; a change in single base-pair in the
DNA sequence [2].
9An allele is a variant of a gene, i.e. a slightly different version of some gene. Diploid
organisms like humans, have two alleles (each inherited by a parent). In a pair of
chromosomes (Figure 2.2), a person can either have two different alleles (heterozygous)
or two of the same [15] [3].
Figure 2.2: An allele is one of two or more versions of a gene. An individual inherits
two alleles for each gene, one from each parent [3].
There are typically two, but sometimes more, different base-pairs involved in a SNP. The
least common base-pair (i.e. expressed less often in a given population) is called the mi-
nor allele, and is used as the reference point to calculate a numerical representation of
expression of alleles in the population. The SNP data can be represented as nominal/-
categorical features ( e.g., AA, AG or GG), or numerical. There are different ways to
encode SNPs to represent different biological modes of action (additive, codominant,
dominant, recessive, overdominant and log-additive) [16]. In this study we are using
SNP data under the additive model, where each genotype is encoded as a single numeric
feature that reflects the number of minor alleles. Homozygous major, heterozygous and
homozygous minor are encoded as 0, 1 and 2, assuming an additive effect of the derived
allele encoded gene products. This results in a minimal number of generated features
while preserving all information [16].
As said before, a SNP is a difference at one base-pair in the DNA sequence. Since a gene
is a range of base-pairs in the DNA, SNPs can be located within or near it. Base-pairs
located before and after a gene are considered associated with the expression of the gene,
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and so a SNP can be related to it without being located exactly in between the range
of base-pairs that conform the gene. This also means that SNPs can be associated with
more than one gene and genes can be associated with more than one SNP. Figure 2.3
shows a graphical demonstration of the latter concepts [2].
It is important to remark that SNPs are only one of several measures of genetic varia-
tions: epigenetic variation and structural variations, such as copy-number variation and
deletions, inversions, insertions and duplications are other types of genetic variations
among humans that occurs on different scales [17].
Figure 2.3: Gene (pink) and SNP (purple) association. The SNP 1 is not located
within a gene but close to Gene 1 and might be associated with it. The SNP 2 is located
within two genes, Gene 1 and 2, and will be associated with both. SNPs 3 and 4 are
both located within the same gene, Gene 3, and both will be associated with it [2].
Diseases
Today we know that all human diseases are influenced to some extent by genes, and yet
much of these genetic consequences are still not fully characterized [18]. First studies
done by medical geneticists were focused on single-gene disorders, which result from mu-
tations in a single gene and as a result, any individual with a mutant allele of these gene
has the disease with 100% probability. Whenever the latter case occurs, such mutation
is called 100% penetrant. This type of disorders tend to be rare in the population. When
the percentage of penetrance is lower, there are individuals who have the predisposing
genotype, but do not have the disease. This happens when other genes play a role in
the determination of the disease, or also because of environmental effects. This kind
of diseases are called multi-factorial or complex disorders. The proportion of determi-
nation of the disease that is caused by genetic mutations rather than environmental
effects is called ‘heritability’. Multi-factorial disorders have much higher frequencies in
the population and have reduced heritability rates.
In this study we analyzed genetic datasets on two common complex conditions, cancer
and diabetes.
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Lung Cancer
According to Sarah S. Knox, cancer is a complex disease that involves a sequence of gene-
environment interactions in a progressive process that cannot occur without dysfunction
in multiple systems, including DNA repair, apoptotic 1 and immune functions [19].
The term lung cancer (LC) is used for tumors arising from the respiratory epithelium
(bronchi, bronchioles, and alveoli). There are several histopathological 2 distinct forms,
with different prognosis and survival significance for the patients. Most LCs are caused
by carcinogens and tumor promoters ingested via cigarette smoking [20]. Smoking is a
documented risk factor that it is responsible for about 130,000 anual deaths from active
and 22,200 from passive smoking. Only 10% to 15% of smokers actually develop LC,
even though between 80% to 90% of LC patients are current or former tobacco smokers.
About 15% of men and 53% of all women with LC worldwide were never smokers. The
previous statements suggest that etiological 3 risk factors may influence the susceptibility
of suffering from LC and the likelihood of a smoker/non-smoker of developing LC.
Type 2 Diabetes
Kasper et al. states that diabetes mellitus (DM) comprises a group of common metabolic
disorders that share the phenotype of hyperglycemia. Several distinct types of DM exist
and are caused by a complex interaction of genetics, environmental factors, and life-style
choices. Depending on the etiology of the DM, factors contributing to hyperglycemia
may include reduced insulin secretion, decreased glucose utilization, and increased glu-
cose production. There are two broad categories of DM: type 1 and type 2. Type 1
DM (T1D) is related to the autoimmune beta cell destruction, which leads to insulin
deficiency. Type 2 DM (T2D) is a heterogeneous group of disorders characterized by
variable degrees of insulin resistance, impaired insulin secretion, and increased glucose
production [20].
Roglic. et al. conducted a study in 2000 that revealed that 5.2% of the global mortality
in that year was due to diabetes, becoming the fifth cause of death. The authors stated
that the prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in
2000 and is projected to be 4.4% in 2030 (most of which will be T2D). According to Das
et al., the recent global epidemic of T2D almost certainly indicates the importance of
environmental triggers/factors such as sedentary lifestyle and dietary changes over last
1Apoptosis: A natural process of self-destruction by degradative enzymes in certain cells.
2anatomical changes in diseased tissue.
3Causing a disease or a pathological condition.
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several decades. Nonetheless, T2D is among many complex diseases caused by mutations
in more than one gene [21].
2.1.2 Genome-Wide Association Studies
Thus Genome-Wide Association Studies (GWAS) arise with the goal of better approach
the analysis of common multi-factorial diseases and the genes that predispose people to
have these diseases [22].
The standard approach to GWAS is based on univariate hypothesis tests, where the
potential association of each genetic marker is assessed in isolation of the others through
the computation of p-values based on statistical assumptions about the data distribution
[23] [24]. The aim of GWAS is to statistically analyze the distribution (frequencies) of
the variants between two populations: case (affected by a certain trait) vs. control
(healthy) individuals [25] [26]. These case/control traits are generally analyzed using
either contingency table methods or logistic regression (LR). In this study we focused
only on the logistic regression analysis which is an extension of linear regression where
the outcome of a linear model is transformed using a logistic function that predicts the
probability of having case status given a genotype class. This method is preferred over
the contingency table because it allows to include in the analysis, clinical covariates
and other factors. LR can also provide adjusted odds ratios that can be interpreted
as measure of the effect size of a variant. Without a doubt, LR has been extensively
developed, and numerous diagnostic procedures are available to aid interpretation of the
model, which makes it a very popular alternative [27].
For each single-locus statistic test, from the series executed in GWAS, a p-value (which
is the probability of seeing a test statistic equal to or greater than the observed test
statistic if the null hypothesis is true) is generated. Lower p-values indicate that the
chance of seeing an association with the studied disease is extremely small [27].
A single statistical test is considered significant whenever the null hypothesis is rejected,
i.e. when the obtained p-value falls bellow a predefined alpha value, which is almost
always set to 0.05. Setting the alpha to this value means that 5% of the time, a false
positive is detected and the null hypothesis is rejected when in fact it is true. The
problem arises when hundreds of thousands to millions of statistical tests are conducted,
as GWAS studies do, because each statistical test has its own false positive probability,
so the cumulative likelihood of finding one or more false positives over the entire analysis
is accordingly much higher. For this type of multiple testing, Bonferroni correction is
the typical and simplest approach applied to deal with this problem [27].
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This studies try to identify common genetic variants that are associated with the risk
of a disease or a human phenotype. They are based upon the principle of linkage
disequilibrium (LD) at the population level. When two SNPs are located close to one
another on a chromosome, and they remain linked rather than being broken apart over
generations, a linkage between these SNPs is said to exist. Reference is made to LD,
each time two SNPs are linked on a population scale. Hartl et al. define LD more
formally as the nonrandom association between alleles at different loci and it is created
by evolutionary forces such as mutation, drift, and selection and is broken down by
recombination. Generally, loci that are physically close together exhibit stronger LD
than loci that are farther apart on a chromosome. The larger the (effective) population
size, the weaker the LD for a given distance [28] [2]. Figure 2.4 shows a graphical
representation of the principle of LD.
Figure 2.4: An ancient DNA sequence is found in modern DNA with accumulated
sequence variants. Nonrandom recombination produces haplotypes with blocks of LD
in modern DNA [4]. Genes are pink blocks and SNPs are purple blocks.
To the present day, there is no doubt of the heritability of lung cancer susceptibility, but
it is also known that the genetic influence on lung cancer is at best moderate, suggesting
that familial cases of lung cancer cannot be attributed only to shared smoking habits
[29] [9]. The opposite way, a huge study conducted by Czene et al. [30] suggests that
heritable effects of genes governing smoking behaviour play a more important role than
individual susceptibility to carcinogenesis, which makes sense, since tobacco smoking is
by far the strongest environmental cause of lung cancer.
Valuable insights into lung cancer susceptibility genes have been identified using the
GWAS approach [31] [32] [33] [34]; however, the loci identified account for an extremely
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small proportion of the familial risk, and there is considerable overlap between the result
for lung cancer and those for COPD, and lung function [9].
There are several studies that focus on analyzing the genetic effect in treatment of LC
(predictive effect on prognosis and treatment of LC) to define genetic profiles of different
prognostic and medical application.
Regarding type 2 diabetes disease (T2D), there is strong evidence that the individual
risk of type 2 diabetes (T2D) is strongly influenced by genetic factors, but according to
Fuchsberger et al., most of the studies conducted until now show that the variants driving
known association signals are common (minor allele frequency (MAF) > 5%) and known
loci explains only a minority of observed T2D heritability [35]. Some associations with
T2D were found by Scott et al. [36], contributing to to define the genetic architecture of
the disease and identify biological pathways involved with it. Other T2D-related studies
[37], uncovered loci in association with fasting glucose.
GWAS have led the way towards scientific discoveries enabling the understanding of
the genetic architecture of complex diseases as LC and T2D and their related traits.
With the development of HapMap and 1,000 Genomes, biologists have the ability to use
imputation to combine different genotyping platforms and continue international collab-
orations involving multiple cohorts [37]. At the same time, many people have pointed
to various problems and perceived failures of this experimental design [28] [14]. Botta
et al., highlight some intrinsic limitations: (i) it does not directly account for correla-
tions among the explanatory variables, while in the context of GWAS this correlation
is often very strong, because of linkage disequilibrium (LD) or artifacts induced by the
experiment design; (ii) it does not account for genetic interactions, i.e. causal effects
that are only observed when specific combinations of mutations and/or non-mutations
are jointly present; (iii) it does not directly provide predictive models for the genetic
risk [25].
Some of these limitations are specifically addressed by advanced multivariate statisti-
cal and machine learning techniques, resulting in several promising studies of machine
learning applications to GWAS data.
2.2 Machine Learning
According to Rob Schapire, machine learning (ML) is a core subarea of artificial intel-
ligence that studies algorithms that improve with (learn from) experience [38]. One of
its main goal is to devise automatic learning algorithms able to work without human
15
intervention or assistance. ML also intersects broadly with other fields, like statistics,
mathematics, theoretical computer science and others.
The ML discipline has become an everyday tool used by biologists and geneticists over
the past years that has proven to be successfully applied to various complex biological
data types: gene expression (mRNA), microRNA, protein lysate (protein), SNP, array
comparative genome hybridization (aCGH), mass spectra, etc. Inza et al. state that
these complex types of data are mainly characterized by: (i) having a limited number of
samples (curse of data set sparsity) and (ii) having several thousands of features char-
acterizing each sample (curse of dimensionality). Dealing with the latter conditions has
inspired the bio-informaticians and machine learning communities to develop machine
learning techniques capable of dealing with these curses [5]. Figure 2.5 shows a gen-
eral scheme of current common applications of machine learning techniques to different
bioinformatics areas.
Figure 2.5: General scheme of the current applications of machine learning techniques
in bioinformatics [5].
Depending on the different ways an algorithm can model a problem based on its expe-
rience (input data), machine learning algorithms can be grouped by their learning style
as: supervised, unsupervised and semi-supervised learning algorithms [39].
In the past years, authors such as Schwender et al. [40] and Szymczak et al. [41] have
published studies describing an overview of the most popular machine learning proce-
dures applied to genetic data. They describe the application of supervised classification
methods combined with feature selection approaches to predict whether a patient had a
certain disease or not.
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In this study we focus only on supervised methods to perform classification and feature
selection tasks.
2.3 Classification
Classification methods are supervised machine learning methods that build models that
make predictions (classification into a given set of categories), based on past observations
or labeled training instances. There are several ML classification algorithms in the
literature [42]. They use different learning strategies to discriminate samples of different
classes. In this study we applied algorithms that fall into three main categories: linear;
support vector machine (SVM), tree (non-linear); random forest (RF), and distance
based methods; k nearest neighbors (KNN) [43] explained in detail below.
Linear Kernel SVM
The support vector machine (SVM) is a popular classification method that maps the
training instances to a higher (maybe infinite) dimensional space, by employing a kernel
function (the space is determined by the choice of ‘kernel’), in order to find an optimal
linear separating hyperplane with maximal margin. As Schwender et al. say, the idea
is to maximize the distance of the hyperplane to the closest observation (from either
class). This margin is called the optimal separating hyperplane and the observations
lying on the two boundaries of the margin are called support vectors [40]. In line with
Schwender et al., the goal of SVM is to find the hyperplane of the form:
x : β0 + β
′x (2.1)
that provides the solution to the optimization problem:
minimize
β,β0
0.5‖β‖2 + ν
n∑
i=1
ξi
subject to ξi ≥ 0, yi(x′iβ + β0) ≥ 1− ξi i = 1, . . . , n.
(2.2)
When some observations end up in the wrong side of the margin (i.e. mis-classified),
this means the groups are not perfectly separable. In ?? the ν is the regularization
parameter used to define the degree of importance given to points mis-classified. As a
result of this optimization problem, whenever ξi = 0 this means that the observation i
is on the right side of the margin [40].
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When the two groups of observations are non-linearly separable, the construction of the
optimal separating hyperplane can be done using a kernel trick. The kernel function is
responsible of mapping original features to a new feature space. This mapping function
guarantees that all the needed calculations can be computed easily in terms of dot
products of the variables in the original space. In the case of a Linear Kernel SVM, the
kernel function consists of the plain dot product between instances (Equation 2.3) [44]
[45].
K(xi, xj) = x
T
i · xj (2.3)
The SVM is a very popular classification method used in bioinformatics. It has been
highly used on microarray expression data [46] [47] [48] [49] rather than in SNP data.
Some few examples of applications use the non-linear radial basis function (RBF) kernel
SVM to analyze the importance of gene-gene interactions on T2D risk [14] and prostate
cancer [50] and to predict hypertension (HT) [51], breast cancer susceptibility [52] and
chronic fatigue syndrome (CFS) [53]. SVM also has been used as a feature selection
method, relying on the SVM weights as importance measures for the phenotype predic-
tion [54] [55] [43] [56] [57] [58].
Random Forests
Random Forest is defined by Breiman as an ensemble learning method 4 used for classifi-
cation that uses bootstrap samples 5 of the observations to create several CART decision
trees [59]. The final classification is done by voting among several trees trained with
different samples. This decreases the variance of the model without increasing the bias
[60]. To avoid the most powerful features being selected too frequently in each tree,
making them more correlated to each other, only a random subset of the features are
considered at each node of the decision trees, to identify the best split among this sub-
set, and the subsets are all different in each node [40]. Each tree is fully grown without
pruning. RF uses a greedy method that finds the locally optimal maximum likelihood
estimation. This means that it chooses a variable and the best threshold to split on for
that variable by minimizing a given cost, in this case the Gini index [25] [2] [18] [61].
RF has shown an increasing use in computational biology. It is a very popular method
used due to its unique advantages in dealing with small sample size, high-dimensional
4Ensemble learning methods are models composed of multiple “weaker” models (that individually
tend to under-perform) that are independently trained and whose predictions are combined in a way to
make the overall prediction of the ensemble model.
5Bootstrap samples are samples taken using random sampling with replacement.
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feature space, and complex data structures [62]. Another benefit of RF commented by
Upstill-Goddard et al. is that RFs are quite resistant to overfit the data because as the
number of trees in the RF increases, the prediction error converges to a limiting value
[18].
Its applications to SNP data has been wide. It has been applied to highlight significant
SNPs for analysis with other methods [63] [64] and for selecting informative sub-groups
of SNPs potentially associated with complex diseases like Parkinson’s and Alzheimer’s
diseases [65] [66].
It has shown considerable promise in both low and high-dimensional data (from <100 to
>650K SNPs) identifying associations [67] [68] and disease risk of ischemic heart disease
(IHD) and myocardial infarction (MI) [69], as well as classification of T2D [2] or rheuma-
toid arthritis (RA) [70]. It is also very common to see implementations of variations
of RF such as the T-Trees, that take into account the correlation structure among the
genetic markers implied by LD in GWAS data for prediction and loci identification [25].
Most of the modifications implemented have been used to identify gene-gene interactions
[71]; e.g. SNPInterForest [72] and Random Jungle (RJ) [73] [74].
K-Nearest Neighbors
Cosine and correlation distance based methods are simple classifiers that calculate the
distance (usually the Euclidean distance) to all of the training samples and predicts
the class of a test sample by assigning the label of the closest training sample [43]. K-
nearest neighbors is a slightly more complex version of this classifiers, that considers the
k nearest samples from the training set that are closest to the test observation being
used. Once this subset Lk of close samples are identified, the prediction cˆ of the class of
the new observation is decided by a majority voting as follows [40]:
cˆ = arg max
c
∑
i∈Lk
I(yi = c) (2.2)
This classification method is not very popular in the bioinformatics area, but still it has
been used on microarray [75] and gene expression [56] [76] data. It has been also applied
to detect selenium resistance of cancer patients [43] and breast cancer classification [77].
There is a popular term in ML known as the “curse of dimensionality” which is basically
the expression of all phenomena that appear with high-dimensional data [78]. The main
problem is that the amount of data needed obtain a statistically sound and reliable
results, often grows exponentially with the dimensionality [79]. When we have a high
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number of features and not enough samples, colinearity and over-fitting problems start
to appear. A common ML solution to tackle this kind of problems is to apply feature
selection techniques to reduce the number of features to work with, while keeping the
same amount of samples to train and test the models.
2.4 Feature Selection
Feature selection is the process of selecting a subset of features to use during model
construction [80]. In contrast to other dimensionality reduction techniques like those
based on projection (e.g. principal component analysis) or compression (e.g. using
information theory), Saeys et al. comment in their feature selection review, that these
techniques do not alter the original representation of the variables. Thus, they preserve
the original semantics of the features, offering the advantage of interpretability by a
domain expert [81].
In general this process is not decoupled from the process of creating an accurate predic-
tive model, and it focuses on finding irrelevant/noisy or redundant features that do not
contribute to increase the accuracy/performance of the classification methods.
According to Saeys et al. the most important objectives of feature selection are: (a) to
avoid/reduce over-fitting and improve model performance and generalization, i.e. pre-
diction performance in the case of supervised classification and better cluster detection
in the case of clustering, (b) to provide faster and more cost-effective models, (c) to
gain a deeper insight into the underlying processes that generated the data and (d) to
simplify models to make them easier to interpret by domain users, using only a small
subset of the original set of features. However, as Daelemans et al. state, the advantages
of feature selection techniques come at a certain price, because the search for a subset
of relevant features introduces an additional layer of complexity in the modelling task.
Instead of just optimizing the parameters of the model for the full feature subset, we
now need to find the optimal model parameters for the optimal feature subset, as there
is no guarantee that the optimal parameters for the full feature set are equally optimal
for the optimal feature subset [80] [81] [82] [56] [83] [84] [85].
From a machine learning point of view, the selection of bio-markers in this context can
be stated as a feature selection problem for a classification task, where the aim is to find
a small set of features (markers/variants) that best explains the difference between the
disease and the control samples. [82]
From a biological viewpoint Haury et al. remark that applying feature selection to
biological case/control datasets, allows to inspect the genes selected in the signature
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and evaluate the relationship to biological processes involved in the disease and suggest
novel targets [56].
Feature selection methods are usually classified into three categories, depending on how
they combine the feature selection search with the construction of a classification model:
filter, wrapper and embedded methods. Below is a brief explanation of each technique
and its most prominent advantages and disadvantages.
2.4.1 Filter Methods
Filter feature selection methods basically apply a statistical measure in order to obtain
a certain score and assign it to each feature. By only looking at intrinsic properties
of the data, filter methods can assess the relevance of features [82]. The selection of a
subset of features is done as a pre-processing step, i.e. after the score of each feature is
calculated, the low-scored features are removed and the remaining are used as predictors
in the model construction [81] [56].
Advantages:
• They are easily scalable to very high-dimensional data sets.
• They are computationally fast and simple.
• They are independent of the classification algorithm used in the further model
construction.
Disadvantages:
• They do not interact with the classification algorithm.
• Most of this methods are univariate, this is, they consider features independently
or only with regard to the target feature, thereby ignoring feature dependencies.
Filter feature selection methods are highly used in bioinformatics due to their simplic-
ity. Examples of this methods and its uses in bioinformatics are: information gain,
chi-squared [53], ANOVA [43], Student’s t-test and Wilcoxon sum-rank test [56], Pear-
son correlation, mutual information (MI) [86], correlation-based feature selection (CFS),
fast correlation-based filter (FCBF), INTERACT algorithm, ReliefF and minimum re-
dundancy maximum relevance (mRMR) [57].
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A very classic method that can be used to define a filter feature selection is the analysis
of variance (ANOVA). This method is a collection of statistical models used to analyze
the differences among group means. ANOVA uses the F-test (F-Statistic test) to review
the variability among and between groups [87].
The method treats each variable as independent, and the target as a dependent variable.
On a binary problem, the method sees if the mean of the class 0 and class 1 groups
are equal or not with respect to the modalities of each of the independent variables.
It calculates the F-test by dividing the variation between groups with the variation
within groups. This means that if the means between groups vary a lot, and the mean
within a group varies little, i.e. the groups are heterogeneous between them, and similar
internally, the value of the F-statistic is higher meaning the independent and dependent
variables will be related.
2.4.2 Wrapper Methods
Wrapper feature selection methods generate several feature subsets that are evaluated
according to their predictive power when used with a specific classification method [82].
As described by Saeys et al., a search procedure in the space of possible feature subsets
is defined, and various subsets of features are generated and evaluated. The evaluation
of a specific subset of features is obtained by training and testing a specific classifi-
cation model. To search the space of all feature subsets, a search algorithm is then
‘wrapped’ around the classification model. The application of wrapper methods to
high-dimensional datasets requires special attention because as the number of features
increases, the space of feature subsets grows exponentially and turns computationally
impossible. To tackle this problem, heuristic greedy search methods are used to guide
the search for an optimal subset of features. These search methods can be divided in
two classes: deterministic and randomized search algorithms. [56] [81].
Advantages:
• They include the interaction between feature subset search and the classification
algorithm that is “wrapped”.
• They take into account feature dependencies.
Disadvantages:
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• They are very computationally intensive, especially if the “wrapped” classifier has
a high computational cost.
• The assumptions and analysis made by the “wrapped” classifier may be different
from the ones of the final classification model, and this could affect the performance
of the latter.
From all types of feature selection methods, wrapper methods are surprisingly exten-
sively used in medical applications, specifically the RFE explained in detail later. The
most common classification algorithm matched up with this method is the SVM. Guyon
et al. [88] was the first to use SVM-RFE to perform feature selection and cancer classifi-
cation. The basic idea behind it is to use the weight magnitude of each feature from the
SVM, as ranking criterion during the iterative process of the RFE. It has been applied
ever since to various types of datasets [82] [56] [43] [57] [55] [58].
Guyon et al. defines recursive feature elimination (RFE) as a wrapper method that
consists of initially building a predictive model using all of the available features and
based on a feature subset ranking calculated according to their influence on the predic-
tion model, a subset of features are dropped, at the expense of possible classification
performance degradation, and the process is executed again [88] [89].
From the biological point of view, SNPs are known to interact in many different ways
influencing the risk of complex diseases. On the other hand, performing feature selec-
tion in this kind of large dimensional input spaces involves greedy algorithms. Recursive
feature elimination appears as a good alternative to tackle the latter by performing a
greedier backward feature elimination, removing several features at a time, but measur-
ing the joined relevance of sets of markers using a ranking criterion [82] [88]. Algorithm
1 shows the different steps followed by the RFE to perform feature selection.
Algorithm 1: Recursive Feature Elimination
1 step = number of features to remove at each iteration;
2 keep = number of features to select;
3 S = set of all features;
4 Tune/train the model on the training set using S features;
5 Calculate feature weights;
6 while | S |≥ keep do
7 Remove step features from S whose absolute weights are the smallest;
8 Tune/train the model on the training set using the S remaining features;
9 Recalculate feature weights;
10 end
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2.4.3 Embedded Methods
Embedded feature selection methods search for an optimal subset of features during the
construction/training of the prediction model. This methods learn which features best
contribute to the accuracy of the model during the process of training [56] [43] [81] [82].
Advantages:
• They include the interaction between feature subset search and the final classifi-
cation model constructed.
• They take into account feature dependencies.
• They are computationally faster than wrapper methods.
Disadvantages:
• They depend on the specific learning method of the final model constructed.
Several studies have remarked the power of regularized classical statistical methods such
as logistic regression and linear/quadratic discriminant analysis. To overcome multicol-
inearity and over-fitting, these methods rely on penalization to shrunk towards zero or
a very small number, the majority of the coefficients. Park et al. [90], Sun et al. [91],
D’Angelo et al. [92] and Szymczak et al. [41] successfully applied this kind of methods
to various complex disease SNP datasets as well as microarray data [93] [94] [95]. Reg-
ularized logistic regression is still being recently used for both classification and feature
selection [96] [97] [98], specifically applied to a T2D [99] case control cohort.
Before describing regularized logistic regression, we first define logistic regression as a
binary classifier that uses the binary logistic model to estimate the probability of a
binary response based on one or more independent predictor features. The LR model
is:
p(y = 1|x; θ) = 1
1 + exp(−θTx) (2.3)
where y = 0, 1 is the class label, x is a training point, θ is the parameter vector.
Regularization is added to a learning algorithm to avoid over-fitting, since its main
objective is to penalize the complexity of the model.
24
One way to describe regularized logistic regression is by solving the following optimiza-
tion problem, and finding the θ parameters:
arg max
θ
m∑
i=1
log p(y(i)|x(i); θ)− αR(θ) (2.4)
where R(θ) is a regularization term that is used to penalize large weights/parameters.
We can see that if R(θ) ≡ 0, this model corresponds to the standard, un-regularized,
logistic regression model, with its parameters fit using the maximum likelihood criteria.
There are two types of regularization, the L1 regularization that uses a penalty term
which encourages the sum of absolute values of the parameters to be small:
R(θ) = ‖θ‖1 =
n∑
i=1
|θi| (2.5)
and the L2 regularization that encourages the sum of the squares of the parameters to
be small:
R(θ) = ‖θ‖22 =
n∑
i=1
θ2i (2.6)
When L1 regularization is applied, a sparse parameter vector is obtained and many
parameters are forced to be equal to zero. This is why it has been commonly and
naturally used as a feature selection technique in bioinformatic applications. We will be
using the L1 regularization in our experiments.
2.5 Sampling
It is common that complex disease case/control datasets suffer of imbalance class distri-
bution, were the number of diseased patients representing the class of interest (cases) is
much lower than the number of healthy individuals (controls). Over the past years sev-
eral strategies have been proposed and developed to address this problem, and Branco
et al. [6] propose a taxonomy of modelling approaches seen in Figure 2.6
Re-sampling strategies are a broad research area due to the diverse set of techniques
available such as: random under/over-sampling, distance methods, data cleaning ap-
proaches, clustering algorithms, synthesising new data or evolutionary algorithms [6].
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Figure 2.6: Main modelling strategies for imbalanced domains [6].
Due to the extensive number of strategies, in this study we will only focus on the pre-
processing strategy of re-sampling, specifically random under/over-sampling and syn-
thesising new data using SMOTE-sampling, being these the most commonly used [57]
[6] [100] [101] [102] [103].
The main goal of sampling techniques is to adjust the class distribution of a data set.
This process shouldn’t be decoupled from the process of creating an accurate predictive
model, the same way as the discussed before in the feature selection step. These methods
help to create a model using a balanced training data set and avoid bias of many standard
classifier learning algorithms towards the class with a larger number of instances [57]
[104].
According to Branco et al., applying this and other data pre-process techniques has
several advantages: (i) it can be applied to any existing learning tool; and (ii) the
chosen models are biased to the goals of the user (because the data distribution was
previously changed to match these goals), and thus it is expected that the models are
more interpretable in terms of these goals. The main inconvenient of this strategy is that
it may be difficult to relate the modifications in the data distribution with the target
loss function. This means that mapping the given data distribution into an optimal new
distribution according to the user goals is not easy [6].
2.5.1 Under-sampling
This method consists of performing sampling without replacement over the instances of
the over-represented class, until the number of instances of this class balances with the
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Figure 2.7: Under-sampling
method.
Figure 2.8: Over-sampling
method.
Figure 2.9: SMOTE-sampling
method.
Figure 2.10: Sampling methods.
number of instances of the under-represented class. The final number of instances of the
over-represented class will end up being smaller.
2.5.2 Over-sampling
This method consists of performing sampling with replacement over the instances of
the less represented class, until the number of instances of this class balances with the
number of instances of the over-represented class. The final number of instances of the
under-represented class will end up being larger.
2.5.3 SMOTE-sampling
This method consists of creating synthetic/artificial samples of the under-represented
class instead of creating copies, as the over-sampling method does. The main idea
behind this method is to detect similar/neighbor instances using a distance measure,
and performing perturbations to this instance, one feature at a time, at random, within
the difference to the neighboring instances [105].
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2.6 Model Selection and Model Evaluation
2.6.1 Model Selection
When performing supervised classification, it is important to be able to distinguish
between model selection and model evaluation. Each task has a different clear purpose
and uses different sets or portions of the entire original dataset.
Initially we divided the original dataset into training and test sets. The latter is set aside
to be used only during model evaluation to estimate the generalization performance of
our final model (obtained after model selection). The purpose of these test set is to
simulate new data that the model has not seen before [106] [7].
The process of finding the best-performing model from a set of models that were pro-
duced by different hyper-parameter settings is called model selection. A common tech-
nique in machine learning practice used for model selection is k -fold cross-validation.
It is a well-established reliable solution to avoid over-fitting during model selection and
provide less biased estimates of the performance in the training data [40] [97].
It consists of performing k iterations using different splits of the training dataset. At
each iteration the dataset is split in k parts; k - 1 parts are merged and used to train
the model, and the remaining kth part is used as hold-out validation set to validate
the model. In our study, this process is combined with hyper-parameter tuning so that
for a given hyper-parameter setting, a k -fold cross-validation is executed and the overall
performance is taken to be the average of the performance on all k folds. This procedure
is repeated for all of the hyper-parameter settings that need to be evaluated (grid-search).
Then the hyper-parameter setting that resulted in the highest k -fold average is chosen
and the final model is trained with the entire training set [40] [7]. The whole process is
shown in detail in Figure 2.11.
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Figure 2.11: Model selection: cross-validation and hyperparameter tunning process [7].
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Predicted
Positive Negative
True
Positive TP FN
Negative FP TN
Table 2.1: Confusion matrix structure.
It is important to remark that each of the splits done in the k -fold cross-validation
were performed with stratification in order to avoid dataset shift, and to preserve the
percentage of samples of each class from the original dataset, in each of the k folds [57].
As already mentioned in Section 3.2.1.1, the growing complexity of the data and the
urge to improve available methods have led to the development of procedures combining
feature selection and model building. Feature selection is often used to limit the amount
and dimensionality of the data or to select features that correlate well with the target
class [107]. Having said this, any pre-processing step of standardization, data imputa-
tion, re-sampling or feature selection, should be performed inside k -fold cross-validation
loop, in contrast to applying these steps to the whole dataset upfront before splitting
the data into folds. Including these steps inside the cross-validation loop reduces the
bias through over-fitting, since it avoids looking at the validation data information dur-
ing model selection. A down-side to this, is that it may lead to an overly pessimistic
estimates, since less data is available for training [7].
Figure 2.11 refers to a model, as the combination of a specific hyper-parameter setting
with one instantiation of the pipelines designed in this study and described in Sections
3.2.1 and 3.2.2.
The same idea applies to the initial split into training and test sets performed prior
model selection. In order to correctly evaluate a model, the entire final model has to be
evaluated against an independent test set. In other words, the test set must not be used
during model selection [107] [108].
2.6.2 Model Evaluation
Given a binary (positive and negative) problem like ours, a confusion matrix (Table
2.1) is a table that provides for each class, the number of instances that were correctly
classified, i.e. true positives (TP) and true negatives (TN ), and the number of instances
that were incorrectly classified, i.e. false positives (FP) and false negatives (FN ). The
latter are basic values used to compute different measures useful for model evaluation
[5].
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The typical metric used to evaluate a model and estimate the performance of classifica-
tion problems is the Accuracy (Equation 2.7). In imbalanced domains like ours, Branco
et al. suggests that Accuracy is not a suitable metric to use, because the impact of
the least represented, but more important class, is reduced when compared to that of
the majority class. Accordingly, a classifier could have a very high Accuracy by always
predicting the most represented class for all of the observations, but for the end user,
the more interesting cases (all the minority class observations) will be misclassified [6].
accuracy =
TP + TN
TP + FN + TN + FP
(2.7)
Some popular metrics used in imbalanced domains that consider the user preferences
and, thus, take into account the data distribution are Precision (P) also known as
Positive Predictive Value (PPV ), Negative Predictive Value (NPV ), Recall (R) also
known as True Positive Rate (TPR) or Sensitivity and True Negative Rate (TNR) also
known as Specificity, defined as follows [6] [57]:
P =
TP
TP + FP
(2.8)
NPV =
TN
TN + FN
(2.9)
R =
TP
TP + FN
(2.10)
TNR =
TN
TN + FP
(2.11)
In other words, the Precision corresponds to the proportion of examples classified as pos-
itive that are truly positive (Equation 2.8), the Negative Predictive Value corresponds to
the proportion of examples classified as negative that are truly negative (Equation 2.9),
the Recall corresponds to the proportion of truly positive examples that are classified
as positive (Equation 2.10) and the True Negative Rate corresponds to the proportion
of truly negative examples that are classified as negative (Equation 2.11) [109].
From the definition of the previous metrics we can see a clear relationship between P
and NPV and between R and TNR. They each measure the same metric with respect
to a specific class. From now on, we will refer to P as the Precision of class 1 (Precision
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(1)), NPV as the Precision of class 0 (Precision (0)), R as the Recall of class 1 (Recall
(1)) and TNR as Recall of class 0 (Recall (0)).
Another popular and practical metric, that simultaneously measures the impact of sev-
eral measures is the F-measure (Fβ). It combines the Precision and the Recall by a
ratio specified by the β parameter [109].
Fβ =
(1 + β)2 · R · P
(β2 · R) + P (2.12)
In Equation 2.12, if β = 1, then Precision and Recall are considered as being equally
important. If β = 2, then Recall is considered to be twice as important as Precision. If
β = 0.5, then Precision is considered to be twice as important as Recall [109]. In this
study we’ll use the F-measure with β = 1 denoted from now on as F1.
Using Precision (1), Recall (1) and the Fβ equation 2.12, we define the F1 of class 1
(F1 (1)), and applying the same logic using the class 0 measures we obtain the F1 of
class 0 (F1 (0)).
We define the weighted version of any measure M as the average of the measure M
for each class, weighted by the support, i.e. the number of true instances for each
class [110]. Given the number of observations of class 1 and class 0, denoted as n1, n0
respectively, and using the previously defined measures we define the weighted versions
of the Precision, Recall and F1 :
F1 =
(n1 · F1(1)) + (n0 · F1(0))
n1 + n0
(2.13)
Precision =
(n1 · Precision(1)) + (n0 · Precision(0))
n1 + n0
(2.14)
Recall =
(n1 ·Recall(1)) + (n0 ·Recall(0))
n1 + n0
(2.15)
Most of the classification algorithms used in this study compute a probability of belong-
ing to each class along side with the final class prediction. In the case of non-probabilistic
algorithms, estimations of these probabilities are computed. Using a specific threshold
and these probabilities, classifiers can predict an observation as belonging to class 1 or
class 0. The typical value for this threshold used by classifiers is 0.5, so that when the
predicted probability is greater or equal than 0.5, the final class prediction is 1 and 0
for the contrary.
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Setting different threshold values between 0 and 1 define the classification boundaries
between the two classes and thereby define different the decision rules. This also defines
different values of the confusion matrix (TP, FP, TN and FN ) used to compute metrics
like the Sensitivity and the specificity. Using the latter measures, a receiver operating
characteristic (ROC) curve can be constructed, plotting the Sensitivity and 1 - Specificity
(i.e. false positive rate (FPR)) against each other, for a range of thresholds as an
implicit function of the threshold (Figure 2.12) [2] [5]. The ROC curve is useful since
it shows the intrinsic trade-off between Sensitivity and Specificity. Remember that the
Sensitivity is the proportion of positive observations that are correctly considered as
positive. The higher the value, the fewer positive observations are missed. On the other
hand, the Specificity measures the proportion of negative observations, that are correctly
considered as negative, therefor, in a similar way, the higher the value, the fewer negative
observations are missed, but the higher positive observations are misclassified. This is
why the ROC curve plots the Sensitivity versus 1 - Specificity, because the Sensitivity
and Specificity are measures that are inversely related.
Figure 2.12: Example of different model ROC curves: model that perfectly separates
classes (purple), random model (black dotted), common realistic example of fairly good
model (pink). The striped area represents the AUC of the latter model.
Using ROC curves to compare several models is not an easy task unless one of the
curves dominates all the others. Moreover, ROC curves do not provide a single-value
performance score which leads us to another popular measure that can be computed
using the ROC curve [6]. The area under the curve (AUC ) is basically, as the name
denotes, the area under a ROC curve. It ranges between 0 and 1. An AUC below
0.5 it is associated to a negative or bad classification model. An AUC value close to
0.5 refers to a completely random model and an AUC equal to 1 means the model is
able to separate the classes perfectly, consequently a higher AUC is better. It has been
shown [111] that the AUC is equal to the probability that a randomly drawn positive
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observation has a higher score than a randomly drawn negative observation, thus the
AUC measures the ability to rank items correctly [2]. The AUC measure is independent
of the distribution of the test set; this makes it useful for evaluating the performance of
classifiers on unbalanced data sets. Lately, it has been criticized and questioned upon
some research that shows the AUC is a noisy measure for classification and has some
other problems when used to compare models [2] [112] [113] [114].
Chapter 3
Methodology and Datasets
As mentioned in the introduction, the purpose of this study was to analyze SNP data
of patients suffering from a certain complex diseases (LC or T2D) to create a classifi-
cation model (estimation of disease probability and classification of genetic data into
a two-class problem) for further use with new patients. During the training process
of this classification model, we wanted to identify relevant/important combinations of
genetic variants that enabled the model to distinguish among groups of individuals with
different clinical or biological characteristics (variants that have the most significant
pathogenic/protective influence) [69].
Challenges arose from the complexity of genome-wide datasets used, consisting of a
limited number of samples with several thousands of features characterizing each sample
(curse of dimensionality). On the other hand, this type of data is commonly imbalanced,
and the minority class is usually the one that has the highest interest from a learning
point of view and it also implies a great cost when it is misclassified [115]. Our case is
not out of the ordinary and the minority class was the most important concept to be
learned.
In order to fulfill our main goals, we designed a pair of frameworks/pipelines consisting
of several different steps, each intending to deal/solve with these challenges. The final
output of the framework consists of a classification model and a list of relevant variants
ranked in order of importance.
This chapter covers the description of the datasets used to test our frameworks/pipelines.
It also outlines the main methodological aspects of the proposed frameworks/pipelines
based on ML techniques. For each step of the frameworks, we present the main problem
it intends to solve and the reasoning supporting the different methods and algorithms
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selected. Each step is comprehensively described, including technical details and limi-
tations. The chapter also introduces the classical approach applied to SNP data based
on statistical inference in order to finally compare the obtained results of the latter
approach with the results of the proposed ML approach.
3.1 Datasets
3.1.1 Characteristics of Lung Cancer Dataset
The first study dataset comprises clinical and genomic data and results from a GWAS
analysis conducted by a team in PMPPC-IGTP. The dataset contains a series of pa-
tients with advanced NSCLC 1. Subjects are classified according to RECIST 2 as Non
responders (Disease progression) and Responder (partial/complete response and sta-
ble disease). Some relevant clinical and socio-demographic variables were included in
the analysis. Genome-wide genotypes were generated using arrays-SNP technology us-
ing the Infinium HTS Assay, HumanCoreExome-24v1-0 BeadChip, (ILLUMINA, San
Diego, CA) at the Genomic Units of PMPPC-IGTP. A total of 325,762 SNPs remain af-
ter systematic quality control on the raw genotyping data (overall call rate of 99.89%). In
silico methods were used for genome wide imputation to generate a dataset of 24,873,940
SNPs, from which 10.307,177 SNPs were retained for the association analysis. We con-
sider only SNPs from chromosome 12, where several significant GWAS signals were
identified. Raw genotype data from 423,929 common variants (hg19 assembly, minor al-
lele frequency > 0.01) and the p-values from uni-variate analysis (additive model) were
analyzed. Responders and non responders to treatment were labeled as class 0 and 1
respectively.
General Characteristics
Table 3.1 shows the general characteristics of the LC dataset.
# of individuals 178 samples
# of epidemiological features 6
# of SNP features 423,929
# of Non responders individuals 41
# of Responder individuals 137
Table 3.1: General characteristics of LC dataset.
1non-small cell lung cancer.
2response evaluation criteria in solid tumors.
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The dataset did not have any missing values, so there was no need to perform imputation.
All SNP variables were encoded using the additive model (discrete values between 0 and
2) described in Section 2.1.1. The rest of the clinical and socio-demographic variables
were either binary variables or categorical variables with maximum 4 modalities (discrete
values between 1 and 4). There was no need to standardize the data since we are dealing
with categorical variables using the same measurement units.
3.1.2 Characteristics of GCAT Dataset
The GCAT dataset comes from the GCAT cohort. This is a prospective cohort study
that was designed to recruit general population from the northeast region of Spain,
Catalonia, with a reference population of 7.522.596 inhabitants. With the aim to identify
chronic disease events in midterm, the study covers a middle-age population (40 to 65
years old) corresponding to 30% of the Catalonian population. Participants that agree to
take part in the study complete an epidemiologic questionnaire, donate a blood sample,
and undergo blood pressure, cardiac frequency, and anthropometry measurements.
Genomic profiles have been characterized by comprehensive array genotyping with the
Infinium Multi-Ethnic Global (MEGAEX2) array; a multi-purpose, multi-ethnic geno-
typing array with two million selected markers such as germline mutations, insertions-
deletions (InDels), and single nucleotides polymorphisms (SNPs). Genome-wide geno-
types have been generated using SNP-array technology. The Infinium® HTS Assay
automated protocol was used on MEGAex2 BeadChips scanned with a HiScan confocal
scanner (Illumina, San Diego, CA). Genome Studio version 2011.1 has been used for raw
data analysis. Genotyping was performed at the Genomic Units of the PMPPC-IGTP,
in Badalona, Spain.
The data has been collected since April 2014 and will be ongoing until until December
2017. The latest version of the questionnaire given to participants is available in the
following link: http://bbmri-lpc.iarc.fr/mica/?q=content/baseline-gcat.
The dataset used in this study consists of a sub-sample of 4073 individuals with both
epidemiological and genomic data.
Type 2 Diabetes Datasets
From the previously defined GCAT dataset, we created several smaller binary datasets
that combined both the questionnaire (referred from now on as epidemiological features)
and the genotyped data (SNP features) of individuals, giving particular importance to
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features related to T2D and associated comorbidities such as: hypercholesterolemia,
hypertension and cardiovascular diseases (stroke, heart attacks and angina).
General Characteristics
Table 3.2 shows the general characteristics of the T2D dataset from which the smaller
use-case datasets are created. All of them share the same number of features, both
epidemiological and SNP features, and differ in the number of individuals.
# of individuals 4073 samples
# of features 755,089
# of epidemiological features 258
# of SNP features (from all 22 chromosomes) 754,830
# of missing values 3,274,658 (0.1% of the whole dataset)
Table 3.2: General characteristics of type 2 diabetes datasets.
Type 2 Diabetes vs. Healthy (D2 vs. H)
The first dataset consisted of T2D individuals versus completely healthy individuals (all
questions from the questionnaire related to any disease marked as “false”) denoted from
here on as D2 vs. H. Table 3.3 shows some general characteristics of the dataset.
# of individuals 1,723 samples
# of male individuals 868 samples
Avg. age of male individuals 51 years
# of female individuals 854 samples
Avg. age of female individuals 51 years
# of D2 individuals 107 samples
# of H individuals 1,616 samples
# of missing values 1,349,404 (0.1% of the whole dataset)
Table 3.3: D2 vs. H dataset characteristics.
Type 2 Diabetes vs. No Type 2 Diabetes and Comorbidities (D2 vs. CD2F)
The second dataset consisted of T2D individuals versus individuals with one or more
comorbidity but no T2D, denoted from here on as D2 vs. CD2F. Table 3.4 shows some
general characteristics of the dataset.
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# of individuals 1220 samples
# of male individuals 656 samples
Avg. age of male individuals 54 years
# of female individuals 564 samples
Avg. age of female individuals 54 years
# of D2 individuals 107 samples
# of CD2F individuals 1113 samples
# of missing values 877,052 (0.09% of the whole dataset)
Table 3.4: D2 vs. CD2F dataset characteristics.
Type 2 Diabetes and Comorbidities vs. No Type 2 Diabetes and Comorbidi-
ties (CD2W vs. CD2F)
The third dataset consisted of complex T2D individuals (individuals with one or more
comorbidity and T2D), versus individuals with one or more comorbidity but no T2D,
denoted from here on as CD2W vs. CD2F. Table 3.5 shows some general characteristics
of the dataset.
# of individuals 1187 samples
# of male individuals 633 samples
Avg. age of male individuals 54 years
# of female individuals 554 samples
Avg. age of female individuals 54 years
# of CD2W individuals 74 samples
# of CD2F individuals 1113 samples
# of missing values 860,760 (0.09% of the whole dataset)
Table 3.5: CD2W vs. CD2F dataset characteristics.
RStudio 1.0.136 [116] and R version 3.2.3 [117] were used to make some simple pre-
processing to create the latter datasets.
3.2 Pipeline Designs
In the following sections two pipeline configurations are described in detail. Both
pipelines were designed to be easily extensible to add new method alternatives to each
pipeline step.
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3.2.1 Preliminary Pipeline Configuration
This pipeline was designed to deal with several difficult problems: the first step consists
of a feature selection technique that deals with the high dimensionality problem, the
second step consists of applying a sampling technique to deal with class imbalance, and
finally, a learning classification method is applied to make predictions (Figure 3.1). We
also propose different metrics to rank and select a relevant subset of SNPs taken from
the final classification model. These ranked SNPs are compared with the ones obtained
using the p-value from the classical GWAS approach, which is usually based on single
SNP logistic regression.
Figure 3.1: Pipeline Configuration
3.2.1.1 Feature Selection
When dealing with high dimensional data such as GWAS SNP data (from thousands
up to millions of features), feature selection methods have almost become a must for
model building. We chose to use feature selection techniques rather than other dimen-
sionality reduction techniques because they do not alter the original representation of
the variables, but merely select a subset of them [81].
The main idea of feature selection methods is to find irrelevant (noisy) or redundant
features that do not contribute to the increase of the accuracy/performance of the final
classification model, discard them, and keep the relevant ones to move forward in the
pipeline process.
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As mentioned in Section 2.4, feature selection methods are usually classified into three
categories: filter, wrapper and embedded methods. We selected one method of each
type of feature selection to instantiate the first step of the pipeline: ANOVA as a filter
method, recursive feature elimination with logistic regression (RFE-LR) as a wrapper
method and regularized L1 logistic regression (RLR-L1) as an embedded method.
• Filter: ANOVA. It was selected due to its simplicity and statistical power.
• Wrapper: RFE-LR. This method was selected because it performs a greedy back-
ward feature, removing several features at a time, but measuring the joined rele-
vance of sets of markers using a ranking criterion elimination. We chose to combine
the RFE with logistic regression with an L1 penalty since this type of regularization
causes many of the feature coefficients to be zero.
• Embedded: RLR-L1. This method was selected because when applied using a
L1 penalty the method shrinks towards zero the majority of the coefficients of
the features (sparse model), reducing the number of features to work with (the
ones with non-zero regression coefficients), at the same time it overcomes multi-
colinearity and over-fitting.
3.2.1.2 Sampling
The class distribution of the datasets used in this study were imbalanced, especially
knowing that the class we were interested in predicting best was the one less represented.
For this reason we applied sampling techniques to change the data distribution and make
standard algorithms focus on the cases that are more relevant for the user [57].
We tried down-sampling, up-sampling and SMOTE-sampling explained in detail in Sec-
tion 2.5, to instantiate the second step of the pipeline. We also tried as a possibility,
keeping the data as it came from the previous pipeline step by not performing any
sampling.
3.2.1.3 Classification
The final step of the preliminary pipeline configuration consists of a machine learning
supervised classification model.
As a linear method, we tried support vector machines with a linear kernel (Linear SVM)
[44]. We choose this method because in the past years it has proven to be successful in
several bioinformatics and computational biology applications [14]. According to Man et
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al. and Friedman et al., another advantage of using the linear SVM is that it is suitable
for classifying high dimensional data, even though it does not completely escape from
the curse of dimensionality when dealing with too much noisy/irrelevant features [48]
[118].
As a non-linear classification method we chose to use the tree-based Random Forest
(RF). It is an attractive choice since it does not overfit the data, and more precisely,
as the number of trees in the RF increases, the prediction error converges to a limiting
value. It also returns a measure of importance for each feature.
The distance-based classification method applied in this study was the k-nearest neigh-
bors (KNN). It is computationally efficient and is easy to visualize and understand [48].
It is especially successful when the decision boundaries are irregular, or a class has mul-
tiple prototypes, because it does not make any assumption about the underlying data.
In concordance with Yao et al., a main weakness of this technique is that its performance
is subject to the often ad hoc choice of similarity metric, especially for heterogeneous
datasets from which the derived features are of different types and scales, and are corre-
lated. In addition, the standard KNN methods suffer from the curse of dimensionality.
The neighborhood of a given point becomes very sparse in a high dimensional space,
resulting in high variance [75]. We will be avoiding the latter disadvantage, since the
dimension of the input data will be previously reduced by a feature selection method.
3.2.2 Extended Pipeline Configuration
In order to be able to apply our pipeline design to bigger complex disease case/control
cohorts, some steps were added to the preliminary pipeline configuration in order to deal
with new challenges that arise from these new datasets.
In the presence of a small percentage of missing values in the dataset, imputation was
necessary. For this reason, an imputation step was added as a new step at the beginning
of the pipeline, consisting of replacing any missing value with the mean of the column
where the missing value is.
Just as an improvement step, a variance filter step was added to the pipeline after the
imputation step. This is a very simple filter that removes all low-variance features,
keeping all features with non-zero variance, i.e. removing the features that have the
same value in all samples and do not provide interesting information to the dataset.
When dealing with data coming from different sources, normalization was a crucial
step to make measurements comparable. In order to avoid that the variance of one
feature (that is orders of magnitude larger than other features) dominates the objective
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function of certain classification methods, and make the estimator unable to learn from
other features correctly as expected, we standardize all the features by removing the
mean and scaling to unit variance [119]. This is also known as z-score normalization.
This type of data transformation removes statistical errors in repeated measured data.
Data are scaled to fall within a small, specified range, thus allowing a fair comparison
between different data samples [5].
It is important to stand out, that this standardization step is first applied to the training
dataset, and the mean and standard deviation of each column of this dataset is stored
to be used later during model evaluation, on the test dataset.
The following steps of the extended pipeline configuration correspond to the ones belong-
ing to preliminary pipeline configuration described in Section 3.2.1: feature selection,
sampling and classification. Figure 3.2 shows the new configuration of the extended
pipeline.
Figure 3.2: Extended Pipeline Configuration
3.3 Model Selection and Model Evaluation
From all of the combinations of each of the pipeline steps explained above, 36 (three
feature selection methods, by four sampling techniques, by three classification algo-
rithms) different pipelines where validated using k -fold cross-validation, along with F1
weighted measure as scoring function. We use the latter scoring function due to the
nature and distribution of the data, since we know a priory that classes are imbalanced
and we want to give equal importance to the precision and recall of both classes. Hyper-
parameter tuning or grid-search was combined during k -fold cross-validation to find the
best hyper-parameter setting for a specific pipeline using a training set, and afterwards
having chosen a specific setting (the one with highest CV F1 score), we test the predic-
tive power of the model with a separate and independent test set (for which sampling has
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not been applied, preserving the original distribution of the data). Using the confusion
matrix, we record the following metrics:
• CV F1 : Average of F1 weighted measure of each k fold during cross-validation,
using a different seed from the one used during model selection.
• Train F1 : F1 weighted by the support, using prediction of train set.
• Test F1 : F1 weighted by the support, using prediction of test set.
• Test AUC : AUC using prediction of test set.
• Test Accuracy : Accuracy using prediction of test set.
• Test Precision: Precision weighted by the support, using prediction of test set.
• Test Recall : Recall weighted by the support, using prediction of test set.
• Test F1 (1): F1 of class 1, using prediction of test set.
• Test Precision (1): Precision of class 1, using prediction of test set.
• Test Recall (1): Recall of class 1, using prediction of test set.
• Test F1 (0): F1 of class 0, using prediction of test set.
• Test Precision (0): Precision of class 0 (i.e. NPV), using prediction of test set.
• Test Recall (0): Recall of class 0 (i.e. TNR), using prediction of test set.
3.4 Feature Ranking
This section describes the different alternatives proposed in this study to rank the fea-
tures used by the final “best” model found with highest CV F1 score after model selec-
tion and evaluation. We introduce the definition of a stability score, used in different
ways by the two proposed frameworks (each using one of the two proposed pipelines)
described at the end of this chapter.
Stability Score
The stability score is a measure associated to each feature of the dataset that is calculated
following a simple iterative process that uses the intrinsic characteristics of the pipelines
described in sections 3.2.1 and 3.2.2. Initially each feature initializes its stability score
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with a zero value. Then, using S different samplings/shuﬄes without replacement of T
percent of the data of the training set [56] [120], the “best” pipeline model is re-trained
and only the features selected by the feature selection step of the pipelines, add 1 to
the stability score. At the end of this process, features that were consistently selected
S times, will have a score of S points. The larger the score, the more stable the feature
will be considered.
During this process of stability check, we also record other metrics useful to perform a
ranking over the SNPs, based on characteristics of specific instantiations of the classi-
fication step in the pipelines. For example, if the classifier of the pipeline in analysis
is a Linear SVM, we save the values of the weights assigned by the algorithm to each
feature. In a similar way, for the case of RF, we keep record of the variable importance
metric [121] associated to each feature while using this classification model. Regardless
of the ranking measure used, let us refer to these values as coefficients.
After the iterative process is finished, we define the following aggregated metrics to
compare the importance of each feature in terms of its coefficient measure:
• stability : stability score described above.
• MC : mean of the coefficients.
• MAC : mean of the absolute value of the coefficients, since some coefficients can
be equally important as positive and negative values.
• MSC : scaled version of the MAC.
Apart from the iterative process to calculate the stability score, from the final “best”
model found with highest CV F1 score (trained with the whole training dataset) we can
rank the features used by this model using the absolute value of the previously defined
coefficient values. In the case of KNN, since there is no intrinsic measure associated
to the method from which features can be ranked, we use measures associated to the
previous feature selection method applied to the data, for example, when using ANOVA
filter feature selection, we use the p-values calculated from the statistical test; when
using the RFE-LR wrapper method, we use the absolute value of the coefficients of the
wrapped LR associated to each feature. Similarly the absolute value of the coefficients
of the RLR-L1 embedded method are used. The signs of the coefficients were also stored
so that we could measure the effect of the feature in the final classification result.
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3.5 Framework Designs
3.5.1 Preliminary Framework Design
An initial framework was proposed and followed to classify a cohort of LC patients
(Section 3.1.1) and simultaneously identify a reduced set of SNPs with the highest
prognostic value in the cohort. The framework uses as input GWAS SNP data from a
single chromosome. As a consequence, if more data of the rest of the genome were given,
we would have a separate classifier model and a set of ranked SNPs per chromosome.
Figure 3.3 shows the whole general framework followed using the LC dataset described
in Section 3.1.1 corresponding to a single chromosome (chromosome 12). After executing
the 36 experiments using different pipeline configurations, the single “best” model, and
its corresponding feature ranking are given as the output of the framework. The “best”
model is the model with the highest CV F1 score.
Figure 3.3: General Framework
Challenges
Applying k -fold cross-validation and hyper-parameter tuning using the preliminary frame-
work design, and the extended pipeline configuration to the T2D datasets (approximately
700 times bigger in samples and almost twice as big in number of features, than the LC
dataset) required huge amounts of RAM memory, generating memory errors that made
impossible to process this new datasets under the same architecture (Section 3.8). This
was caused by the the drastic change of the characteristics of the dataset used as input
on the pipeline: huge increase on the number of features, since the new dataset includes
features from all the genome, and other epidemiological features too. Figure 3.4 shows
an example of the percentage of memory consumption using different percentages of the
training dataset of the largest T2D dataset of study (D2 vs. H with 1616 samples), using
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one of the simplest instantiations of the extended version of the pipeline: imputation +
variance filter + standardization + ANOVA + No sampling + KNN.
Figure 3.4: Maximum Memory Consumption vs. Percentage of Training Data.
Figure 3.4 shows that from the use of 30% or higher percentages of the training data,
the memory consumption drastically increases during model selection (cross-validation
and hyper-parameter tunning). When using up to 70% of the training dataset, we began
to have memory errors and the model selection process could not be finished.
3.5.2 Extended Framework Design
In order to overcome memory consumption problems, an extended framework was de-
signed. This framework splits the data in chromosomes, and applies the extended
pipeline configuration separately to each of the 22 chromosomes as an initial partial
analysis. We use the stability score calculated for each feature as a “filter” to select
the most important and “stable” features belonging to each chromosome and create a
“final” training and test datasets used to construct a unique final model of classifica-
tion that takes advantage of features from the whole genome. Our proposed extended
framework follows the same idea of model selection using k -fold cross-validation in both,
the partial analysis done with each chromosome and the final analysis done with the
“filtered/merged” final data.
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Using different instantiations of each of the steps conforming the extended pipeline con-
figuration, 36 different experiments were executed. For a certain pipeline configuration
P the following steps were executed:
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Algorithm 2: General framework applied using new pipeline configuration and stability
measure.
1 Split the whole dataset (containing features from the 22 chromosomes) into
pre training and test datasets;
2 Split the pre training dataset into training and stability datasets;
3 Split the training and stability by chromosome, denoted as trainingi and stabilityi,
for i = 1 . . . 22;
4 for i = 1 . . . 22 do
5 Using pipeline P , perform k -fold cross-validation with hyper-parameter tuning and
trainingi dataset, as explained in Section 2.6, to obtain pipeline Pbest partial;
6 For each feature f of stabilityi features, initialize a stability score denoted as fstab i
= 0;
7 for j = 1 . . . S do
8 shuf stabilityij = Sampling/shuﬄe without replacement of T of stabilityi;
9 Pret best partial = Re-trained Pbest partial pipeline using shuf stabilityij .;
10 for f ⊂stabilityi features do
11 if f was selected by feature selection step of Pret best partial then
12 fstab i = fstab i + 1;
13 end
14 end
15 end
16 end
17 stable features = ∅;
18 for i = 1 . . . 22 do
19 stable featuresi = features from stabilityi whose fstab i
≤W stable features=stable features∪stable featuresi;
20 end
21 filtered training, filtered test = Filter training and test datasets keeping only
features belonging to stable features;
22 Using pipeline P , perform k -fold cross-validation with hyper-parameter tuning and
training dataset filtered training, to obtain pipeline Pbest;
23 Use filtered test to evaluate the performance of pipeline Pbest recording evaluation
metrics (Test F1, Test AUC, Test Accuracy, Test Precision, Test Recall, etc.) and
feature metrics (MC, MAC, MSC ) explained in Section 2.6.
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Figure 3.5 shows a graphical version of the extended general framework followed using
the different T2D datasets described in Section 3.1.2 corresponding to the whole genome.
We are aware that filtering the features of each chromosome using the stability score (to
create a “filtered/merged” final training and test datasets), outside any cross-validation
loop, introduces bias to the process of model selection, because part of the data has
been seen before during model selection of each chromosome model. We propose the
use of an independent stability dataset to contribute to reduce this bias. This stability
score filtering was introduced mainly to be able to create a final model that uses features
from all chromosomes (the most stable ones), and be able to take into account possible
interactions and correlations between SNPs of different chromosomes in the final model.
It is important to stand out that the same instantiation of the extended pipeline is used in
the partial analysis by chromosome and in the final step using the “filtered/merged” final
training and test datasets. This is a criterion defined by us and not a limitation. Since
both pipelines are validated using k -fold cross-validation and grid-search (for hyper-
parameter tuning), each pipeline may have a different hyper-parameter setting.
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Figure 3.5: Extended General Framework.
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The general frameworks and pipelines were implemented using Python 3.5.2, and Scikit-
learn 0.19. Scikit-learn is a Python module that integrates a wide range of state of the
art machine learning algorithms for medium-scale supervised and unsupervised prob-
lems [119]. Even though everything was executed in a single node/computer, we took
advantage of Scikit-learn’s parallel implementations (in almost all of the algorithms and
techniques used), to reach the maximum potential of the architecture described above.
3.6 Functional In Silico Analysis
The evaluation of the potential functional impact of the higher ranked variants identified
with the “best” model of each of the frameworks, were analyzed by gene annotation on
the Genome Reference Consortium human genome:
• LC case: build 37 (GRch37, also known as hg19).
• T2D case: build 38 (GRch38, also known as hg38).
Both gene annotations were done using the seq2pathway R library [122]. Using this
library we were able to retrieve a list of genes associated to the given SNPs, and using
these genes, and the GWAS Catalog of the National Human Genome Research Institute
(NHGRI) [123], we searched for genome-wide significant matches of these genes with
certain traits.
3.7 GWAS Classical Approach
PLINK is a free, open-source toolset. It can be used to perform whole genome association
analysis, and a range of basic, large-scale analyses over genotype/phenotype data in a
computationally efficient manner [124]. In this study we used PLINK version 1.9 [125] to
perform a simple test of association using logistic regression assuming an aditive model
in the GWAS data [126]. This is statistical inference where the whole dataset is used to
perform the statistical test and there is no train and test splits of the data. The output
of applying this method gives a p-value associated to each SNP (Section 2.1.2). These
can be displayed as a function of the chromosomal position of each SNP and provide a
visual summary the association test results in a so called “Manhattan plot”. Using a
threshold = − log(p− value) we can filter the most significant SNPs by selecting those
whose nominal value is greater than this threshold.
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In our study we intend to compare the results of the most important features obtained
from the frameworks we proposed, with the results of the single SNP logistic regression
applied using the PLINK.
3.8 Hardware Architecture
All of the experiments were executed in a computer with the following characteristics: 48
GB of RAM and 32 GB of Swap Memory, 12 Intel®Cores™i7-5820K CPU @ 3.30GHz,
under Ubuntu 16.04.2 LTS Linux distribution.
Chapter 4
Experiments and Results
This section presents the experimental setup of all of the different methods and tech-
niques applied in this study. Finally it presents the results obtained using the different
datasets described in the previous section organized by approach: our proposed solution
based on machine learning techniques and the classical GWAS approach.
4.1 Experiments Setup
4.1.1 Data Setup
4.1.1.1 Pipeline Approach
To perform model selection and evaluation as explained in Section 2.6 in both of the
framework designs (Section 3.5) the different datasets were split into training, stability
and test sets as shown in Figure 4.5.
All of the different splits were performed in a stratified way to ensure the same proportion
of individuals of each class, in training, stability and test sets, as in the original dataset.
For example, in the LC case, the group of patients that respond to treatment correspond
to 77% of the whole data. When the entire dataset was split into 80%-20%, we preserved
the former percentage of samples for each class in each of the split, resulting in 109
responder patients in the training set, and 28 in the test set (that both correspond to
77% of the 142 and 36 patients respectively).
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Figure 4.1: Lung
Cancer dataset split.
Figure 4.2: D2 vs. H dataset split.
Figure 4.3: D2 vs. CD2F
dataset split.
Figure 4.4: CD2W vs. CD2F
dataset split.
Figure 4.5: Dataset splits for model selection and evaluation of Lung Cancer dataset
and T2D datasets. IR refers to the imbalance ratio between classes.
4.1.1.2 GWAS Classical Approach
In order to create the T2D datasets used in the tests of association, some pre-processing
of the data was done. Initially all the genomic data of the GCAT individuals was
given on a single file containing SNPs belonging to all 22 chromosomes. To simplify the
analysis sexual chromosomes were not considered in this study. The data was in PLINK
binary format (consisting of .bed, .bim and .fam files). As the file was rather large and
difficult to manage whole in memory, with the help of some PLINK data management
commands, the binary file was separated into smaller binary files, with information of
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each of the 22 chromosomes. These files were then converted to PLINK non-binary
format (.ped and .map) to be processed and filtered.
According to each of the groups of study: D2, H, CD2F and CD2W, files containing
the indexes of these individuals were created. Another file with the target variable
information of each subgroup was created (to use as an external phenotype file). The
index files were then used to filter each of the 22 chromosomes, and store the result in
the PLINK binary format back again. Finally all the 22 chromosome binary files were
merged together to obtain a unique binary file with information from all the genome. The
latter, along with the phenotype external file were used as input for PLINK association
test using logistic regression. Figure 4.6 shows a flow diagram of the whole pre-processing
done.
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Figure 4.6: Pre-processing steps done before performing GWAS classical approach to T2D use cases: D2 vs. H, D2 vs. CD2F and CD2W vs.
CD2F.
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4.1.2 Parametrization Setup
4.1.2.1 Pipeline Approach
Both pipelines were validated using k = 5 during the k -fold cross-validation along with
the F1 weighted measure as scoring function (Section 2.6, Equation 2.13). We use the
latter scoring function due to the nature and distribution of the data, since we know a
priori that classes are imbalanced and we want to give equal importance to the precision
and recall of both classes. The tuning of hyper-parameters associated to each step of the
pipelines was performed using a grid-search. The different parameters tried are shown
in Table 4.1.
Pipeline Step Parameter Options
ANOVA
PFD: percentile = 2% of total # of variables
EFD (Partial Analysis): percentile = 2% of total # of variables
EFD (Final Analysis): percentile = 10% of total # of variables
RFE-LR
LR
penalty = ’l1’
C = 1
RFE
PPD:
n features to select = 2000 variables,
step = 25%
EPD (Partial Analysis):
n features to select = 2% of total # of variables,
step = 4%
EPD (Final Analysis):
n features to select = 10% of total # of variables,
step = 10%
RLR-L1
penalty = ’l1’
PFD: C = [10, 50, 100, 500, 1000, 1500]
EFD (Partial Analysis): C = [100, 500, 1000, 1500, 5000, 10000]
EFD (Final Analysis): C = [100, 500, 1000, 1500, 5000, 10000]
threshold = 1e− 10
Linear SVM C = [0.001, 0.01, 0.1, 1, 10, 100, 1000]
RF n estimators = [30, 47, 75, 119, 189, 299, 475, 753, 1194, 1892, 2999]
KNN n neighbors = [5, 20, 35, 50]
Table 4.1: Parameters tested using grid-search and 5-fold cross-validation. PFD refers
to the “Preliminary Framework Design” described in Section 3.5.1. EFP refers to the
“Extended Framework Design” described in Section 3.5.2.
The percentile parameter in ANOVA corresponds to the percentage of features to keep
as a result of the feature selection step. For the RFE-LR, the parameters related to
the LR model “wrapped” by the RFE method remained static with a L1 penalty (that
contributes to reduce the number of features in the LR “wrapped” model) and the
default C value equal to 1, that refers to to the inverse of regularization strength. As
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for the RFE parameters, the n features to select refers to the percentage of features
to keep at the end of the iterative search, and the step parameter corresponds to the
number of features to drop at each iteration. In the case of RLR-L1, as the name
implies, a L1 penalty was used, and a range of values were tried for the regularization
parameter C. The threshold parameter refers to the threshold value used for feature
selection. Features whose LR coefficient is greater or equal are kept while the others
are discarded. For Linear SVM the C parameter refers to the penalty parameter of the
error term. In both of the latter cases using the C, the smaller the values, the stronger
the regularization. The n estimators parameter in RF refers to the number of trees in
the forest and n neighbors in KNN is the number of neighbors to take into account in
the neighbors voting step of the classifier.
As for the feature ranking output of the preliminary framework design, with S = 50
different samplings/shuﬄes without replacement of T = 80% of the training dataset,
the stability score was calculated for each feature. After experimentation and to avoid
being too restrictive, we select features with a stability score greater or equal to 40,
alongside other coefficient metrics recorded throughout this stability process (MC, MAC
and MSC ).
In the case of the extended framework design, S = 100 different samplings/shuﬄes
without replacement of T = 80% of the stability dataset were used to record the stability
score of all the features of each chromosome. Instantiating W = 100, features from
each chromosome were filtered and merged together to create a filtered/merged “final”
training and test datasets containing features from the whole genome. Setting W = 100
is more restrictive, but it is on purpose because we are aiming to keep the most stable
features from all of the 22 chromosomes.
4.2 Results
This section presents the results obtained in each of the main phases of the study with
respect to each dataset. First, results related to the classical GWAS approach are pre-
sented, using a Manhattan plot to visually see what are the SNPs identified as significant
using a specific threshold. This plot shows the significance of each SNP (− log(p-value))
as a function of the chromosomal position. The plot shows three lines corresponding to
different cut thresholds. The green line corresponds to a threshold of − log(0.01) = 2, the
red to a threshold of − log(0.001) = 3 and the blue to a threshold of − log(0.0001) = 4.
A numeric version of the latter is presented, showing a table with information of the
top 50 most significant SNPs and their corresponding p-value, obtained from the GWAS
analysis using logistic regression as described in Section 3.7. Then, the general results
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(specific metrics for each of the 36 experiments) of the machine learning approach are
presented. More detailed information about the “best” model (from our point of view) is
presented using a plot of the confusion matrix and histogram of the predicted probabil-
ities, in order to visually asses the results in a better way. Finally, the features selected
from the “best” model and its corresponding coefficients are compared with the results
obtained in the classical GWAS approach and presented in a table. Just for a subset of
the most significant SNPs, a final analysis is presented showing their possible associated
traits.
4.2.1 Lung Cancer Dataset Results
4.2.1.1 Pipeline Approach
Model Selection and Model Evaluation Results
A total of 36 1 experiments were executed following the general framework showed in
Figure 3.3 and explained at the end of Section 2.6. The obtained the results are shown
in Tables 4.2 and 4.3. The latter corresponds to results of metrics related to each class
of the target variable, which in this case represents the progression of the disease after
treatment (class 1 responds to treatment, class 0 does not respond). Both tables are
ordered by the CV F1 score.
Focusing on the most general results shown in Table 4.2, it can be seen that more than
80% of the pipeline instantiations have CV F1 scores above the mean = 0.6346, which
we consider is a fairly good value from the practical point of view, given the complexity
of the classification problem and the high number of features we are dealing with.
A common characteristic among almost all models is that the CV F1 score’s standard
deviations are very small (Table 4.2). This shows that the model selection process (cross-
validation) is robust and we can be sure that the real scores are very close to these values.
This is also a sign that the models are stable and trustworthy. Figure 4.7 shows these
results in a graphical way using an error bar plot. The purple dots represent the mean
CV F1 score and the black bars the standard deviation of the 5-fold cross-validation
process of the best setting found during grid-search.
In general, all Test F1 scores are very close to their corresponding CV F1 scores. In
some cases the Test F1 score has a value a few decimals higher to the CV F1 score, but
this is due to the particular sampling of the folds during cross-validation.
1Three feature selection methods: ANOVA, RFE-LR, RLR-L1, by four sampling techniques: No sam-
pling, Down-sampling, Up-sampling and SMOTE-sampling, by three classification algorithms: Linear
SVM, RF, KNN.
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For instance, comparing the first two models, they both have “high” and almost the
same CV F1 scores. We consider the first one to be a “better” model, since it has a
smaller standard deviation that makes it more stable and reliable. It also has a smaller
difference between the CV F1 and the Test F1 scores, which is a sign that it is not
over-fitting the data and has a better capability to generalize on unseen observations.
The first pipeline has a CV F1 score of 0.702 ± 0.099. It consists of the combination
of regularized L1 logistic regression embedded feature selection (of 5,464 features using
C = 1000) followed by performing down-sampling and finally using a random forest
classifier (with 30 decision trees).
Since we are dealing with an imbalanced class problem, the Recall is a very important
metric to take into account. From a medical and/or biological point of view, having
high values of false negatives (FN ) is bad. In this particular analysis, we want to avoid
predicting that a certain patient responds to treatment, when in reality he/she does not,
because this would imply making false conclusions about survival chances if incorrect
treatment is chosen. On the other hand, having too many false positives (FP) is not as
severe as the latter case. In these cases, what usually happens is that further medical
tests are done to corroborate the result before providing any treatment of choice.
Another reason why we consider the first pipeline to be the “best” model, is because
it presents less biased results towards the minority (and most relevant) class. Looking
in detail into Table 4.3, we can see that very few models are able to classify correctly
the test samples belonging to the positive class (Test F1 (1), Test Precision (1) and
Test Recall (1) scores). With the “best” model, half of the patients with a progressive
disease, were correctly classified as not responding to treatment (Test Recall (1) = 0.5).
Comparing feature selection methods, Table 4.2 shows that wrapper (RFE-LR) and
embedded (RLR-L1) methods tend to have better generalization scores than the ANOVA
filter method. This is not very surprising since the first two methods are not “pre-
processing” methods, but they rather analyze in different ways the interactions between
the features that are being selected.
RF as a classification method, tends to have higher generalization scores than Lin-
ear SVM. Its performance is in concordance with previous published results in similar
datasets like multiple sclerosis [67] [73], Crohn’s disease [74], rheumatoid arthritis [68]
and lung cancer [127] [128] that use RF or variations of the method for classification.
As for the “worst” pipeline models with the lowest CV F1 scores; they all use SMOTE as
a sampling method. The deficient performance of this pipeline models could be caused
by the sampling method, since the main idea of it is to generate artificial samples similar
to the one’s provided. It is important to point out that the majority of the features of
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the dataset correspond to genomic data and possibly, creating fictitious values for these
particular features could be the cause of the low performance of these models.
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FS Sampling Classifier
CV F1
Mean ± Std
CV Precision
Mean ± Std
CV Recall
Mean ± Std Train F1 Test F1 Test AUC
Test
Precision
Test
Recall
Test
Accuracy
1 RLR-L1 Down-sampling RF 0.702 ± 0.099 0.708 ± 0.097 0.7 ± 0.101 0.849 0.641 0.574 0.7 0.611 0.611
2 RFE-LR Up-sampling KNN 0.702 ± 0.112 0.69 ± 0.128 0.728 ± 0.108 0.751 0.592 0.382 0.601 0.583 0.583
3 RFE-LR Up-sampling Linear SVM 0.692 ± 0.057 0.676 ± 0.078 0.733 ± 0.048 1 0.606 0.5 0.577 0.639 0.639
4 ANOVA SMOTE-sampling RF 0.682 ± 0.043 0.637 ± 0.109 0.775 ± 0.024 1 0.681 0.478 0.605 0.778 0.778
5 RLR-L1 Up-sampling RF 0.681 ± 0.072 0.639 ± 0.12 0.755 ± 0.054 1 0.667 0.563 0.6 0.75 0.75
6 RFE-LR No sampling Linear SVM 0.68 ± 0.078 0.661 ± 0.12 0.734 ± 0.069 1 0.606 0.438 0.577 0.639 0.639
7 RFE-LR SMOTE-sampling Linear SVM 0.68 ± 0.078 0.661 ± 0.12 0.734 ± 0.069 1 0.606 0.429 0.577 0.639 0.639
8 RFE-LR SMOTE-sampling RF 0.679 ± 0.04 0.638 ± 0.107 0.768 ± 0.024 1 0.681 0.464 0.605 0.778 0.778
9 RFE-LR Up-sampling RF 0.676 ± 0.043 0.636 ± 0.108 0.761 ± 0.03 1 0.681 0.525 0.605 0.778 0.778
10 RFE-LR No sampling RF 0.675 ± 0.042 0.636 ± 0.108 0.761 ± 0.032 1 0.681 0.518 0.605 0.778 0.778
11 RLR-L1 Down-sampling KNN 0.675 ± 0.07 0.687 ± 0.102 0.705 ± 0.079 0.993 0.707 0.475 0.696 0.722 0.722
12 RLR-L1 Up-sampling KNN 0.674 ± 0.076 0.681 ± 0.115 0.712 ± 0.08 0.993 0.766 0.592 0.759 0.778 0.778
13 RLR-L1 No sampling KNN 0.673 ± 0.048 0.651 ± 0.105 0.74 ± 0.057 1 0.681 0.429 0.605 0.778 0.778
14 ANOVA No sampling RF 0.667 ± 0.016 0.59 ± 0.018 0.768 ± 0.012 1 0.681 0.699 0.605 0.778 0.778
15 ANOVA Up-sampling RF 0.667 ± 0.016 0.59 ± 0.018 0.768 ± 0.012 1 0.681 0.645 0.605 0.778 0.778
16 ANOVA No sampling KNN 0.667 ± 0.016 0.59 ± 0.018 0.768 ± 0.012 0.979 0.681 0.473 0.605 0.778 0.778
17 RFE-LR No sampling KNN 0.667 ± 0.016 0.59 ± 0.018 0.768 ± 0.012 0.667 0.681 0.569 0.605 0.778 0.778
18 RLR-L1 No sampling RF 0.667 ± 0.016 0.59 ± 0.018 0.768 ± 0.012 1 0.681 0.542 0.605 0.778 0.778
19 RLR-L1 SMOTE-sampling RF 0.667 ± 0.016 0.59 ± 0.018 0.768 ± 0.012 1 0.681 0.652 0.605 0.778 0.778
20 ANOVA Up-sampling KNN 0.663 ± 0.036 0.61 ± 0.062 0.74 ± 0.035 0.993 0.667 0.482 0.6 0.75 0.75
21 ANOVA Down-sampling KNN 0.661 ± 0.029 0.602 ± 0.05 0.74 ± 0.014 0.972 0.685 0.542 0.663 0.722 0.722
22 RLR-L1 No sampling Linear SVM 0.66 ± 0.052 0.631 ± 0.11 0.733 ± 0.06 1 0.722 0.518 0.729 0.778 0.778
23 RLR-L1 Up-sampling Linear SVM 0.66 ± 0.052 0.631 ± 0.11 0.733 ± 0.06 1 0.722 0.513 0.729 0.778 0.778
24 RLR-L1 SMOTE-sampling Linear SVM 0.66 ± 0.052 0.631 ± 0.11 0.733 ± 0.06 1 0.722 0.522 0.729 0.778 0.778
25 ANOVA No sampling Linear SVM 0.66 ± 0.01 0.587 ± 0.014 0.754 ± 0.021 1 0.681 0.442 0.605 0.778 0.778
26 ANOVA Up-sampling Linear SVM 0.66 ± 0.01 0.587 ± 0.014 0.754 ± 0.021 1 0.681 0.442 0.605 0.778 0.778
27 ANOVA SMOTE-sampling Linear SVM 0.66 ± 0.01 0.587 ± 0.014 0.754 ± 0.021 1 0.681 0.442 0.605 0.778 0.778
28 RFE-LR Down-sampling KNN 0.657 ± 0.09 0.666 ± 0.068 0.663 ± 0.109 0.716 0.552 0.333 0.58 0.528 0.528
29 RLR-L1 Down-sampling Linear SVM 0.657 ± 0.073 0.631 ± 0.091 0.698 ± 0.07 1 0.667 0.536 0.647 0.694 0.694
30 RFE-LR Down-sampling Linear SVM 0.639 ± 0.056 0.636 ± 0.065 0.655 ± 0.065 1 0.626 0.451 0.643 0.611 0.611
31 ANOVA Down-sampling Linear SVM 0.627 ± 0.021 0.575 ± 0.017 0.691 ± 0.038 1 0.722 0.451 0.729 0.778 0.778
32 RFE-LR Down-sampling RF 0.621 ± 0.09 0.68 ± 0.075 0.594 ± 0.1 0.856 0.657 0.576 0.683 0.639 0.639
33 ANOVA Down-sampling RF 0.613 ± 0.087 0.656 ± 0.062 0.598 ± 0.106 0.843 0.644 0.647 0.765 0.611 0.611
34 RFE-LR SMOTE-sampling KNN 0.491 ± 0.059 0.623 ± 0.061 0.452 ± 0.059 0.707 0.515 0.491 0.642 0.472 0.472
35 RLR-L1 SMOTE-sampling KNN 0.297 ± 0.051 0.652 ± 0.15 0.317 ± 0.027 0.657 0.21 0.411 0.51 0.25 0.25
36 ANOVA SMOTE-sampling KNN 0.088 ± 0.008 0.054 ± 0.005 0.232 ± 0.012 0.088 0.081 0.5 0.049 0.222 0.222
Table 4.2: Model selection and evaluation metrics of 36 possible instantiations of preliminary pipeline using lung cancer dataset (only chromosome
12 genomic features and some epidemiological features). They are ordered by CV F1.
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FS Sampling Classifier Test F1 (1) Test Precision (1) Test Recall (1) Test F1 (0) Test Precision (0) Test Recall (0)
1 RLR-L1 Down-sampling RF 0.364 0.286 0.5 0.72 0.818 0.643
2 RFE-LR Up-sampling KNN 0.118 0.111 0.125 0.727 0.741 0.714
3 RFE-LR Up-sampling Linear SVM 0 0 0 0.78 0.742 0.821
4 ANOVA SMOTE-sampling RF 0 0 0 0.875 0.778 1
5 RLR-L1 Up-sampling RF 0 0 0 0.857 0.771 0.964
6 RFE-LR No sampling Linear SVM 0 0 0 0.78 0.742 0.821
7 RFE-LR SMOTE-sampling Linear SVM 0 0 0 0.78 0.742 0.821
8 RFE-LR SMOTE-sampling RF 0 0 0 0.875 0.778 1
9 RFE-LR Up-sampling RF 0 0 0 0.875 0.778 1
10 RFE-LR No sampling RF 0 0 0 0.875 0.778 1
11 RLR-L1 Down-sampling KNN 0.286 0.333 0.25 0.828 0.8 0.857
12 RLR-L1 Up-sampling KNN 0.429 0.5 0.375 0.862 0.833 0.893
13 RLR-L1 No sampling KNN 0 0 0 0.875 0.778 1
14 ANOVA No sampling RF 0 0 0 0.875 0.778 1
15 ANOVA Up-sampling RF 0 0 0 0.875 0.778 1
16 ANOVA No sampling KNN 0 0 0 0.875 0.778 1
17 RFE-LR No sampling KNN 0 0 0 0.875 0.778 1
18 RLR-L1 No sampling RF 0 0 0 0.875 0.778 1
19 RLR-L1 SMOTE-sampling RF 0 0 0 0.875 0.778 1
20 ANOVA Up-sampling KNN 0 0 0 0.857 0.771 0.964
21 ANOVA Down-sampling KNN 0.167 0.25 0.125 0.833 0.781 0.893
22 RLR-L1 No sampling Linear SVM 0.2 0.5 0.125 0.871 0.794 0.964
23 RLR-L1 Up-sampling Linear SVM 0.2 0.5 0.125 0.871 0.794 0.964
24 RLR-L1 SMOTE-sampling Linear SVM 0.2 0.5 0.125 0.871 0.794 0.964
25 ANOVA No sampling Linear SVM 0 0 0 0.875 0.778 1
26 ANOVA Up-sampling Linear SVM 0 0 0 0.875 0.778 1
27 ANOVA SMOTE-sampling Linear SVM 0 0 0 0.875 0.778 1
28 RFE-LR Down-sampling KNN 0.105 0.091 0.125 0.679 0.72 0.643
29 RLR-L1 Down-sampling Linear SVM 0.154 0.2 0.125 0.814 0.774 0.857
30 RFE-LR Down-sampling Linear SVM 0.222 0.2 0.25 0.741 0.769 0.714
31 ANOVA Down-sampling Linear SVM 0.2 0.5 0.125 0.871 0.794 0.964
32 RFE-LR Down-sampling RF 0.316 0.273 0.375 0.755 0.8 0.714
33 ANOVA Down-sampling RF 0.462 0.333 0.75 0.696 0.889 0.571
34 RFE-LR SMOTE-sampling KNN 0.296 0.211 0.5 0.578 0.765 0.464
35 RLR-L1 SMOTE-sampling KNN 0.308 0.194 0.75 0.182 0.6 0.107
36 ANOVA SMOTE-sampling KNN 0.364 0.222 1 0 0 0
Table 4.3: Model evaluation metrics per class of 36 possible instantiations of preliminary pipeline using lung cancer dataset (only chromosome 12
genomic features and some epidemiological features). They are ordered by CV F1.
64Figure 4.7: CV F1 mean scores with their corresponding standard deviations for all 36 pipeline instantiations using lung cancer dataset.
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Figure 4.8: Confusion matrix of
lung cancer test dataset.
Figure 4.9: Predicted probabilities
of lung cancer test dataset.
Figure 4.10: Specific result plots of “best” pipeline model using lung cancer dataset:
RLR-L1 + Down-sampling + RF.
Figure 4.10 shows detailed results regarding the “best” pipeline model of this analysis
case, consisting of performing regularized logistic regression with the L1 norm (RLR-L1)
as the feature selection step, followed by performing down-sampling and using a random
forest classifier RF. Figure 4.8 shows that the classifier is able to classify almost perfectly
all of the test samples belonging to the negative class, but struggles with the positive
class, being able to predict correctly only half of the test samples.
Many binary classifiers can calculate predicted probabilities of class membership and
use them to calculate the final prediction class by choosing the one with the highest
probability. Most classifiers use a default classification threshold of 0.5, to decide weather
to predict class 1 (if predicted probability > 0.5) or class 0 (if predicted probability
< 0.5). These default threshold can be modified in order to increase sensitivity or
specificity, depending on the final user’s interest. Figure 4.9 shows a histogram of the
predicted probabilities for the test dataset. It can be seen that the majority of these
probability values are very close to 0.5. This reflects the complexity of the problem. On
one hand, it doesn’t show two clear groups of probabilities, which would correspond to
the ideal scenario. On the other hand, it doesn’t show a clear accumulation of probability
values around another threshold different from 0.5. The latter would imply a possibility
of using a different threshold on the classifier and obtain better classification results.
Feature Ranking Results
Regarding the feature ranking, S = 50 different samplings/shuﬄes without replacement
of 80% of the training dataset were executed and used to re-fit the “best” pipeline model
(RLR-L1 + Down-sampling + RF), to calculate the stability score of each feature. Table
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4.4 shows only features with a stability score greater or equal to 40, along side another
coefficient metric (‘MC’) recorded throughout this stability process. This column, as
explained in Section 3.4, represents the mean of the coefficients of the last step of the
pipeline, as this is RF, it represents the mean of the variable importance measure of all
of the 50 re-fits done to the model. The greater this value, the more important is the
variable. Column ‘p-value’ shows the associated p-value of a certain SNP obtained from
PLINK using logistic regression. In this case, the lower the value, the more significant
is considered the SNP. Only SNPs with p-value < 0.001 (corresponding to threshold =
3 defined in Section 4.2.1.2) are highlighted in Table 4.4.
Functional In Silico Analysis Results
With the help of the R library seq2pathway, we map genome features on the hg19
assembly (Section 3.6). Subsequently, using the GWAS Catalog of the National Human
Genome Research Institute (NHGRI) [123] using the following keywords: lung, cancer,
pulmonary, smoke and smoking, we were able to search associated traits or diseases to
these genes. The genes in the regions identified with the “best” pipeline model have
not been associated directly to lung cancer but other types of cancer (breast, ovarian,
prostate and colorectal), and lung-related functions (Tables 4.5 and 4.6).
4.2.1.2 GWAS Classical Approach
A simple test of association using logistic regression was applied to the lung cancer
dataset. Figure 4.11 shows the Manhattan plot from the obtained results. A total of
331 SNPs above the defined threshold = 3 (red line) are considered significant. Table
4.7 shows the top 50 most significant SNPs with their corresponding p-values.
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SNP stability MC p-value
Variant284392 49 5,94e-4 > 1e-3
Variant284393 49 1,59e-4 > 1e-3
Variant16548 49 1,42e-4 > 1e-3
Variant401048 47 1,07e-3 2,28e-4
Variant401046 47 4,84e-4 9,50e-5
Variant205529 46 1,60e-3 > 1e-3
Variant368015 46 7,40e-4 > 1e-3
Variant157034 46 6,09e-4 > 1e-3
Variant368012 46 4,33e-4 > 1e-3
Variant157172 45 5,18e-4 > 1e-3
Variant157031 45 3,06e-4 > 1e-3
Variant334174 45 1,79e-4 > 1e-3
Variant244144 44 3,38e-4 > 1e-3
Variant238740 44 1,63e-4 > 1e-3
Variant154732 44 4,97e-5 > 1e-3
Variant34863 44 2,44e-5 > 1e-3
Variant155434 43 1,67e-3 > 1e-3
Variant205492 43 5,88e-4 3,55e-4
Variant183069 43 4,38e-4 > 1e-3
Variant141605 43 3,83e-4 > 1e-3
Variant368020 43 3,21e-4 > 1e-3
Variant163125 42 8,95e-4 3,64e-4
Variant413959 42 5,02e-4 > 1e-3
Variant305531 42 2,97e-4 6,49e-4
Variant32681 42 2,84e-4 > 1e-3
Variant238772 42 1,37e-4 > 1e-3
Variant67581 41 6,35e-4 9,50e-4
Variant238752 41 6,27e-4 > 1e-3
Variant205489 41 3,95e-4 6,04e-4
Variant22058 41 3,52e-4 8,81e-4
Variant159388 41 3,23e-4 > 1e-3
Variant100212 41 3,12e-4 > 1e-3
Variant213868 41 2,85e-4 > 1e-3
Variant404269 41 2,76e-4 > 1e-3
Variant368034 41 2,60e-4 > 1e-3
Variant169760 41 2,56e-4 > 1e-3
Variant63751 41 9,61e-5 > 1e-3
Variant205556 40 1,26e-3 > 1e-3
Variant25935 40 7,93e-4 > 1e-3
Variant368025 40 7,26e-4 > 1e-3
Variant157109 40 7,03e-4 > 1e-3
Variant238734 40 6,19e-4 > 1e-3
Variant225429 40 5,92e-4 3,81e-4
Variant50559 40 5,12e-4 3,15e-4
Variant157114 40 4,16e-4 > 1e-3
Variant205527 40 4,15e-4 > 1e-3
Variant32129 40 2,76e-4 > 1e-3
Variant25938 40 1,85e-4 > 1e-3
Variant67591 40 6,94e-5 > 1e-3
Variant144240 40 3,74e-5 > 1e-3
Table 4.4: Top 50 SNPs with stability score higher than 40, according to “best”
pipeline model (RLR-L1 + Down-sampling + RF). Column ‘MC’ represents the mean
of the variable importance measure of all of the 50 re-fits done to the model. Column
‘p-value’ shows the associated p-value of a certain SNP obtained from a GWAS analysis
using logistic regression. Only SNPs with p-value < 0.001 (corresponding to threshold
= 3) are highlighted in bold.
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Associated Trait
Body mass in chronic obstructive pulmonary disease.
Pulmonary function in asthmatics.
Asthma or chronic obstructive pulmonary disease.
Asthma (bronchodilator response).
Bronchodilator response in asthma.
Bronchodilator response in asthma (inhaled corticosteroid treatment interaction).
Chronic obstructive pulmonary disease-related biomarkers.
Post-bronchodilator lung function in asthma (FEV1).
Post-bronchodilator lung function in asthma (FEV1/FVC).
Post bronchodilator FEV1.
Post bronchodilator FEV1 in COPD.
Post bronchodilator FEV1/FVC ratio.
Post bronchodilator FEV1/FVC ratio in COPD.
Pre bronchodilator FEV1/FVC ratio.
Pulmonary function.
Pulmonary function decline.
Lung function (FEV1).
Pre bronchodilator FEV1/FVC ratio.
3-hydroxy-1-methylpropylmercapturic acid levels in smokers.
3-hydroxypropylmercapturic acid levels in smokers.
Exhaled carbon monoxide levels.
MGMT methylation in smokers.
Smoking behavior.
Blood pressure (smoking interaction).
Fibrinogen levels (smoking status, alcohol consumption or body mass
index interaction).
Cancer.
Cancer (pleiotropy).
Adverse response to chemotherapy in breast cancer (alopecia).
Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule).
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+
doxorubicin+/-5FU).
Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+
epirubicin+/-5FU).
Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel).
Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel).
Breast Cancer in BRCA1 mutation carriers.
Breast cancer (early onset).
Breast cancer (estrogen-receptor negative).
Breast cancer (male).
Table 4.5: Some traits associated to genes with lung-related functions and cancer
responses.
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Associated Trait
Breast cancer (menopausal hormone therapy interaction).
Breast cancer (prognosis).
Breast cancer (survival).
Breast cancer in BRCA2 mutation carriers.
Breast cancer-free interval (treatment with aromatase inhibitor).
Breast size.
Disease-free survival in breast cancer.
Percent mammographic density.
Response to anthracycline-based chemotherapy in breast cancer (pathologic
complete response).
Response to chemotherapy in breast cancer (hypertension) (bevacizumab).
Response to chemotherapy in breast cancer hypertensive cases (cumulative dose)
(bevacizumab).
Survival in breast cancer (estrogen-receptor negative).
Survival in breast cancer (estrogen-receptor positive).
Survival in endocrine treated breast cancer (estrogen-receptor positive).
Breast cancer.
Neuropathy in taxane-treated breast cancer.
Progression free survival in serous epithelial ovarian cancer treated with
carboplatin and paclitaxel.
Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50).
Response to carboplatin and paclitaxel in ovarian cancer (MTT IC50).
Response to paclitaxel in ovarian cancer (MTT IC50).
Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant
prostate cancer.
Colorectal cancer (aspirin and/or NSAID use interaction).
Colorectal cancer (calcium intake interaction).
Colorectal cancer (diet interaction).
Colorectal cancer (interaction).
Colorectal cancer (menopausal hormone therapy interaction).
Colorectal cancer (oestrogen hormone therapy interaction).
Colorectal cancer (oestrogen-progestogen hormone therapy interaction).
Colorectal or endometrial cancer.
Colorectal cancer.
Survival in colorectal cancer.
Survival in colorectal cancer (distant metastatic).
Survival in colorectal cancer (non-distant metastatic).
Survival in microsatellite instability low/stable colorectal cancer.
Table 4.6: (cont.) Some traits associated to genes with lung-related functions and
cancer responses.
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Figure 4.11: Manhattan plot of SNPs from chromosome 12. Since the threshold of the blue line, filters too many SNPs, we will consider all SNPs
above the red line (p-value < 0.001) to be significant and are kept and stored for future comparison with the machine learning approach.
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SNP p-value
Variant225482 1,51e-5
Variant225496 1,51e-5
Variant225439 4,18e-5
Variant225466 4,18e-5
Variant225470 4,18e-5
Variant225558 7,76e-5
Variant401046 9,19e-5
Variant310104 9,50e-5
Variant401048 1,94e-4
Variant163897 2,28e-4
Variant163903 2,28e-4
Variant164012 2,28e-4
Variant164154 2,28e-4
Variant309840 2,53e-4
Variant158784 2,61e-4
Variant310182 2,69e-4
Variant164173 2,83e-4
Variant164180 2,83e-4
Variant164196 2,83e-4
Variant164197 2,83e-4
Variant57198 2,96e-4
Variant163849 3,02e-4
Variant163868 3,02e-4
Variant50558 3,15e-4
Variant50559 3,15e-4
Variant50560 3,15e-4
Variant205550 3,16e-4
Variant359900 3,51e-4
Variant205492 3,54e-4
Variant56806 3,55e-4
Variant56809 3,55e-4
Variant56811 3,55e-4
Variant56812 3,55e-4
Variant163125 3,59e-4
Variant225506 3,64e-4
Variant225515 3,64e-4
Variant225522 3,64e-4
Variant225529 3,64e-4
Variant225535 3,64e-4
Variant225536 3,64e-4
Variant225540 3,64e-4
Variant205549 3,67e-4
Variant225429 3,79e-4
Variant84711 3,81e-4
Variant163729 3,83e-4
Variant163733 3,83e-4
Variant163752 3,83e-4
Variant163769 3,83e-4
Variant163774 3,83e-4
Variant163781 3,83e-4
Table 4.7: Top 50 most significant SNPs, according to GWAS analysis using logistic
regression. They are ordered in ascending order by p-value.
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4.2.2 Type 2 Diabetes vs. Healthy (D2 vs. H) Dataset Results
4.2.2.1 Pipeline Approach
Model Selection and Model Evaluation Results
Using this diabetes dataset, specifically the D2 vs. H individuals, 36 2 experiments
were executed following the general framework explained at the end of Section 2.6.
The general results are shown in Table 4.10. The target variable in this analysis case
represents the disease diagnostic of type 2 diabetes. The results of metrics related to
each class of the target variable are shown in Table 4.11. Both of the latter tables are
ordered by the CV F1 score.
Regarding this specific use case dataset, it can be seen that more than 80% of the
experiments have CV F1 scores above 0.9, showing very high performances. Also, the
majority of the top pipeline models (with higher performance scores) use filter (ANOVA)
or embedded (RLR-L1) feature selection methods. Linear SVM was the most chosen
method of classification, among the top 10 pipelines. This points to the idea that the
model type that better fits the data, is the one that linearly separates the feature space.
The sampling technique applied does not seem to affect directly the performance of the
pipeline models, since there is no clear order of a specific sampling technique in the top
“best” pipeline models.
In general, all experiments show very low standard deviations of CV F1 scores. Almost
70% of the standard deviations are smaller than 0.01. These results support the idea
that the model selection process followed is robust and the final models are stable and
reliable for further use with unseen data. In Figure 4.12 it is ease to see the significant
decrease of the standard deviations of CV F1 score, with respect the previous LC case.
Even though it is a completely different disease and dataset, it is richer in the number
of epidemiological features (all questionnaire data) and also in the number of genomic
features, since there are SNPs from all of the 22 chromosomes, which makes the problem
harder due to the curse of dimensionality. Although the training dataset consists of many
more individuals than in the LC dataset, this use case shows a higher percentage of class
imbalance than in the previous case, which makes it more difficult for the model to learn
to discriminate well both classes.
2Three feature selection methods: ANOVA, RFE-LR, RLR-L1, by four sampling techniques: No sam-
pling, Down-sampling, Up-sampling and SMOTE-sampling, by three classification algorithms: Linear
SVM, RF, KNN.
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All of the Test scores (F1, Precision and Recall) have low differences with their CV
counterparts. This is a good sign that the models are not over-fitting the data and these
Test scores are good approximations of the generalization scores.
For instance, the first eight models, have almost identical CV and Test scores. We
consider the first one to be the “best” model, since it has a simpler configuration than
the rest, consisting of the combination of ANOVA filter feature selection (of 13 features)
without performing any sampling to the data and applying a linear support vector ma-
chine for classification (with C = 0.001). Remember these parameters correspond to
the final step of the framework where the pipeline configuration is applied to the fil-
tered/merged data from all of the 22 chromosomes. Table 4.8 shows the particular
setting and results obtained in each of the 22 chromosomes during the partial analysis.
It is important to stand out that in each of the partial analysis, the data consisted of
all the epidemiological features combined with the genomic features of the particular
chromosome. The ‘# of features selected by FS’ column corresponds to the number of
features selected by the ANOVA feature selection step; it varies depending on the num-
ber of SNPs available for each chromosome. The C corresponds to the cost parameter
of the Linear SVM with the highest CV score during grid-search, which corresponds
to the last column identified by CV F1. It can be seen that some results using data
from different chromosomes output the same CV F1 score. This is due to the “com-
mon” epidemiological features mentioned above, included in each of the chromosome’s
datasets.
The reason why this epidemiological/clinical features overcome the predictive value of
the genomic variants may be because the characteristics of the epidemiological/clinical
features may already contain a genetic component similar to the filtered genomic features
they are analyzed with. As a consequence, by mutual correlation, the genetic variants
do not improve the performance of the model. The last column ‘# of features selected
by stability’ represents the final number of features selected in each chromosome using
the stability score. Features selected by the “best” model a total of W = 100 times,
are selected and used to create the final training and test datasets. The epidemiological
features selected in each partial analysis were all the same, independent of the genomic
features they were combined with (Table 4.9). The latter makes sense when we look in
detail what are the epidemiological features; since they are closely related to the T2D
disease.
Similarly to the LC case, the Recall is an important metric from a medical and/or
biological point of view, because we want to aim to have low values of false negatives
(FN ). The idea is to avoid predicting that a certain patient is completely healthy, when
in reality he/she is suffering of T2D.
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CHR
# of features
selected by FS
C CV F1
# of features selected
by stability (W = 100)
chr1 2258 0.001 0.909 ± 0.004 18 (5 epidemiological and 13 genomic)
chr2 2532 0.001 0.909 ± 0.004 16 (5 epidemiological and 11 genomic)
chr3 2172 0.001 0.909 ± 0.004 13 (5 epidemiological and 8 genomic)
chr4 1998 0.001 0.909 ± 0.004 12 (5 epidemiological and 7 genomic)
chr5 1810 0.001 0.909 ± 0.004 6 (5 epidemiological and 1 genomic)
chr6 2148 0.001 0.909 ± 0.004 11 (5 epidemiological and 6 genomic)
chr7 1631 0.001 0.909 ± 0.004 11 (5 epidemiological and 6 genomic)
chr8 1579 0.001 0.909 ± 0.004 11 (5 epidemiological and 6 genomic)
chr9 1288 0.001 0.909 ± 0.004 9 (5 epidemiological and 4 genomic)
chr10 1466 0.001 0.909 ± 0.004 8 (5 epidemiological and 3 genomic)
chr11 1445 0.001 0.911 ± 0.004 14 (5 epidemiological and 9 genomic)
chr12 1390 0.001 0.909 ± 0.004 12 (5 epidemiological and 7 genomic)
chr13 1077 0.001 0.914 ± 0.008 7 (5 epidemiological and 2 genomic)
chr14 962 0.001 0.914 ± 0.01 18 (5 epidemiological and 13 genomic)
chr15 904 0.001 0.911 ± 0.008 13 (5 epidemiological and 8 genomic)
chr16 959 0.001 0.911 ± 0.008 8 (5 epidemiological and 3 genomic)
chr17 838 0.001 0.909 ± 0.004 8 (5 epidemiological and 3 genomic)
chr18 900 0.001 0.909 ± 0.004 9 (5 epidemiological and 4 genomic)
chr19 582 0.001 0.922 ± 0.004 9 (5 epidemiological and 4 genomic)
chr20 727 0.001 0.919 ± 0.005 9 (5 epidemiological and 4 genomic)
chr21 424 0.001 0.924 ± 0.009 5 (5 epidemiological and 0 genomic)
chr22 412 0.001 0.932 ± 0.015 5 (5 epidemiological and 0 genomic)
Table 4.8: Information related to the application of the pipeline instantiation:
‘ANOVA + No sampling + Linear SVM’ to filtered/merged data from the whole
genome.
Feature Name Feature Description
AGE YEARS
Age reported by the individual on the
baseline date
CALC AVG WAIST Average waist size in cm.
CALC AVG SYSTOLIC BP Average systolic blood pressure
DISEASES HTA Medical diagnosis of arterial hypertension
DISEASES HYPERCHOLESTEROLEMIA
Medical diagnosis of hypercholesterolemia
or triglycerids
Table 4.9: Common epidemiological features selected in the partial analysis done with
each of the 22 chromosomes data.
Unlike the third model experiment shown in Table 4.11, the first two models have good
results related to the minority class (class 1 representing individuals with T2D). 62.5%
of patients with T2D were correctly classified as having the disease. In other words,
37.5% of patients with T2D were incorrectly classified as healthy by the classifier. As
for the Precision, 100% of the patients predicted to have T2D, actually have the disease.
As for the “worst” pipeline model with the lowest CV F1 score, consisting of performing
recursive feature elimination with a wrapped logistic regression, followed by a SMOTE-
sampling and finally using a k-nearest neighbors as a classifier; we see a completely
biased model towards the minority class. These model manages to correctly classify all
patients having T2D, but at the high cost of miss-classifying all healthy individuals too.
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FS Sampling Classifier
CV F1
Mean ± Std
CV Precision
Mean ± Std
CV Recall
Mean ± Std Train F1 Test F1 Test AUC
Test
Precision
Test
Recall
Test
Accuracy
1 ANOVA No Sampling Linear SVM 0.975 ± 0.003 0.978 ± 0.002 0.977 ± 0.002 0.975 0.974 0.852 0.977 0.977 0.977
2 ANOVA Down-Sampling Linear SVM 0.975 ± 0.003 0.978 ± 0.002 0.977 ± 0.002 0.975 0.974 0.826 0.977 0.977 0.977
3 ANOVA Up-Sampling Linear SVM 0.975 ± 0.003 0.978 ± 0.002 0.977 ± 0.002 1 0.908 0.834 0.88 0.938 0.938
4 RLR-L1 No Sampling Linear SVM 0.975 ± 0.003 0.978 ± 0.002 0.977 ± 0.002 0.975 0.974 0.908 0.977 0.977 0.977
5 RLR-L1 Down-Sampling Linear SVM 0.975 ± 0.003 0.978 ± 0.002 0.977 ± 0.002 0.975 0.974 0.901 0.977 0.977 0.977
6 RLR-L1 Up-Sampling Linear SVM 0.975 ± 0.003 0.978 ± 0.002 0.977 ± 0.002 0.975 0.974 0.888 0.977 0.977 0.977
7 RLR-L1 SMOTE-Sampling Linear SVM 0.975 ± 0.003 0.978 ± 0.002 0.977 ± 0.002 0.975 0.974 0.902 0.977 0.977 0.977
8 RLR-L1 No Sampling KNN 0.975 ± 0.003 0.978 ± 0.002 0.977 ± 0.002 0.974 0.974 0.812 0.977 0.977 0.977
9 ANOVA Up-Sampling RF 0.974 ± 0.004 0.976 ± 0.005 0.976 ± 0.004 1 0.97 0.829 0.972 0.973 0.973
10 RLR-L1 Down-Sampling KNN 0.974 ± 0 0.977 ± 0 0.976 ± 0 0.975 0.974 0.902 0.977 0.977 0.977
11 ANOVA SMOTE-Sampling Linear SVM 0.973 ± 0.005 0.975 ± 0.005 0.975 ± 0.004 0.974 0.974 0.824 0.977 0.977 0.977
12 ANOVA No Sampling KNN 0.973 ± 0.006 0.975 ± 0.007 0.975 ± 0.006 0.975 0.974 0.813 0.977 0.977 0.977
13 ANOVA Down-Sampling KNN 0.97 ± 0.005 0.972 ± 0.006 0.973 ± 0.005 0.969 0.971 0.863 0.972 0.973 0.973
14 ANOVA No Sampling RF 0.969 ± 0.003 0.973 ± 0.003 0.973 ± 0.003 0.999 0.972 0.821 0.976 0.975 0.975
15 RLR-L1 No Sampling RF 0.967 ± 0.006 0.969 ± 0.007 0.969 ± 0.007 0.991 0.969 0.798 0.969 0.971 0.971
16 ANOVA SMOTE-Sampling RF 0.964 ± 0.008 0.965 ± 0.01 0.967 ± 0.008 1 0.969 0.814 0.969 0.971 0.971
17 RLR-L1 Up-Sampling RF 0.964 ± 0.012 0.966 ± 0.012 0.963 ± 0.013 0.985 0.961 0.791 0.96 0.961 0.961
18 RLR-L1 SMOTE-Sampling RF 0.958 ± 0.012 0.962 ± 0.007 0.956 ± 0.015 0.993 0.953 0.836 0.954 0.952 0.952
19 RLR-L1 Up-Sampling KNN 0.943 ± 0.004 0.951 ± 0.003 0.938 ± 0.006 0.974 0.946 0.812 0.95 0.944 0.944
20 RFE-LR No Sampling Linear SVM 0.938 ± 0.006 0.955 ± 0.003 0.953 ± 0.004 1 0.933 0.807 0.952 0.95 0.95
21 RFE-LR Up-Sampling Linear SVM 0.938 ± 0.006 0.955 ± 0.003 0.953 ± 0.004 1 0.929 0.805 0.951 0.948 0.948
22 RFE-LR SMOTE-Sampling Linear SVM 0.938 ± 0.006 0.955 ± 0.003 0.953 ± 0.004 1 0.929 0.805 0.951 0.948 0.948
23 ANOVA Up-Sampling KNN 0.931 ± 0.014 0.944 ± 0.008 0.922 ± 0.019 0.97 0.931 0.805 0.94 0.925 0.925
24 RLR-L1 SMOTE-Sampling KNN 0.922 ± 0.015 0.946 ± 0.005 0.909 ± 0.021 0.949 0.908 0.861 0.939 0.89 0.89
25 ANOVA SMOTE-Sampling KNN 0.913 ± 0.018 0.938 ± 0.008 0.897 ± 0.025 0.958 0.914 0.789 0.936 0.899 0.899
26 RFE-LR No Sampling RF 0.909 ± 0.004 0.881 ± 0.005 0.938 ± 0.003 0.998 0.908 0.773 0.88 0.938 0.938
27 RFE-LR Up-Sampling RF 0.909 ± 0.004 0.881 ± 0.005 0.938 ± 0.003 1 0.908 0.862 0.88 0.938 0.938
28 RFE-LR SMOTE-Sampling RF 0.909 ± 0.004 0.881 ± 0.005 0.938 ± 0.003 1 0.908 0.818 0.88 0.938 0.938
29 RFE-LR No Sampling KNN 0.909 ± 0.004 0.881 ± 0.005 0.938 ± 0.003 0.911 0.908 0.551 0.88 0.938 0.938
30 ANOVA Down-Sampling RF 0.88 ± 0.027 0.94 ± 0.009 0.846 ± 0.039 0.912 0.901 0.844 0.935 0.88 0.88
31 RFE-LR Up-Sampling KNN 0.878 ± 0.017 0.887 ± 0.014 0.87 ± 0.025 0.959 0.88 0.531 0.889 0.872 0.872
32 RLR-L1 Down-Sampling RF 0.875 ± 0.023 0.936 ± 0.008 0.84 ± 0.034 0.898 0.876 0.861 0.928 0.843 0.843
33 RFE-LR Down-Sampling KNN 0.828 ± 0.085 0.907 ± 0.016 0.785 ± 0.129 0.671 0.634 0.657 0.907 0.52 0.52
34 RFE-LR Down-Sampling Linear SVM 0.792 ± 0.032 0.914 ± 0.013 0.723 ± 0.048 0.867 0.834 0.712 0.91 0.783 0.783
35 RFE-LR Down-Sampling RF 0.761 ± 0.037 0.905 ± 0.011 0.679 ± 0.051 0.824 0.813 0.634 0.897 0.754 0.754
36 RFE-LR SMOTE-Sampling KNN 0.007 ± 0.001 0.004 ± 0 0.062 ± 0.003 0.007 0.007 0.507 0.004 0.062 0.062
Table 4.10: Model selection and evaluation metrics of 36 possible instantiations of extended pipeline using D2 vs. H dataset (all 22 chromosomes
and epidemiological features). They are ordered by CV F1.
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FS Sampling Classifier Test F1 (1) Test Precision (1) Test Recall (1) Test F1 (0) Test Precision (0) Test Recall (0)
1 ANOVA No Sampling Linear SVM 0.769 1 0.625 0.988 0.976 1
2 ANOVA Down-Sampling Linear SVM 0.769 1 0.625 0.988 0.976 1
3 ANOVA Up-Sampling Linear SVM 0 0 0 0.968 0.938 1
4 RLR-L1 No Sampling Linear SVM 0.769 1 0.625 0.988 0.976 1
5 RLR-L1 Down-Sampling Linear SVM 0.769 1 0.625 0.988 0.976 1
6 RLR-L1 Up-Sampling Linear SVM 0.769 1 0.625 0.988 0.976 1
7 RLR-L1 SMOTE-Sampling Linear SVM 0.769 1 0.625 0.988 0.976 1
8 RLR-L1 No Sampling KNN 0.769 1 0.625 0.988 0.976 1
9 ANOVA Up-Sampling RF 0.731 0.95 0.594 0.986 0.974 0.998
10 RLR-L1 Down-Sampling KNN 0.769 1 0.625 0.988 0.976 1
11 ANOVA SMOTE-Sampling Linear SVM 0.769 1 0.625 0.988 0.976 1
12 ANOVA No Sampling KNN 0.769 1 0.625 0.988 0.976 1
13 ANOVA Down-Sampling KNN 0.741 0.909 0.625 0.986 0.976 0.996
14 ANOVA No Sampling RF 0.745 1 0.594 0.987 0.974 1
15 RLR-L1 No Sampling RF 0.737 0.84 0.656 0.985 0.978 0.992
16 ANOVA SMOTE-Sampling RF 0.727 0.87 0.625 0.985 0.976 0.994
17 RLR-L1 Up-Sampling RF 0.677 0.7 0.656 0.979 0.977 0.981
18 RLR-L1 SMOTE-Sampling RF 0.627 0.6 0.656 0.974 0.977 0.971
19 RLR-L1 Up-Sampling KNN 0.592 0.538 0.656 0.97 0.977 0.963
20 RFE-LR No Sampling Linear SVM 0.316 1 0.188 0.974 0.949 1
21 RFE-LR Up-Sampling Linear SVM 0.27 1 0.156 0.973 0.947 1
22 RFE-LR SMOTE-Sampling Linear SVM 0.27 1 0.156 0.973 0.947 1
23 ANOVA Up-Sampling KNN 0.506 0.426 0.625 0.959 0.974 0.944
24 RLR-L1 SMOTE-Sampling KNN 0.447 0.324 0.719 0.939 0.98 0.901
25 ANOVA SMOTE-Sampling KNN 0.447 0.339 0.656 0.945 0.976 0.915
26 RFE-LR No Sampling RF 0 0 0 0.968 0.938 1
27 RFE-LR Up-Sampling RF 0 0 0 0.968 0.938 1
28 RFE-LR SMOTE-Sampling RF 0 0 0 0.968 0.938 1
29 RFE-LR No Sampling KNN 0 0 0 0.968 0.938 1
30 ANOVA Down-Sampling RF 0.415 0.297 0.688 0.933 0.977 0.893
31 RFE-LR Up-Sampling KNN 0.108 0.095 0.125 0.931 0.941 0.922
32 RLR-L1 Down-Sampling RF 0.341 0.231 0.656 0.911 0.974 0.856
33 RFE-LR Down-Sampling KNN 0.151 0.085 0.688 0.666 0.961 0.509
34 RFE-LR Down-Sampling Linear SVM 0.222 0.143 0.5 0.874 0.96 0.802
35 RFE-LR Down-Sampling RF 0.159 0.101 0.375 0.856 0.95 0.779
36 RFE-LR SMOTE-Sampling KNN 0.117 0.062 1 0 0 0
Table 4.11: Model evaluation metrics per class of 36 possible instantiations of extended pipeline using D2 vs. H dataset (all 22 chromosomes and
epidemiological features). They are ordered by CV F1.
77Figure 4.12: CV F1 mean scores with their corresponding standard deviations for all 36 pipeline instantiations using D2 vs. H dataset.
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Figure 4.13: Confusion matrix of
D2. vs. H test dataset, using “best”
pipeline model: ANOVA + No sam-
pling + Linear SVM.
Figure 4.14: Predicted probabili-
ties of D2 vs. H test dataset, using
“best” pipeline model: ANOVA +
No sampling + Linear SVM.
Figures 4.12 and 4.14 shows detailed results regarding the “best” pipeline model using
the analysis case, consisting of performing ANOVA as the feature selection step, followed
by applying a linear support vector machine classifier (Linear SVM) without previously
applying any sampling technique. Figure 4.13 shows that the classifier is able to classify
perfectly all of the test samples belonging to the negative class, and more than 60%
of the positive class samples. As for the predicted probabilities, Figure 4.14 shows two
clear groups around 0 and 1, meaning that the pipeline model discriminates samples
belonging to each class with high certainty and that the classifier can perfectly use a
threshold of 0.5 to calculate the final prediction class. For class 1 instances that are
miss-classified (12 samples), having such a strong belief (high predicted probability of
class 0) it is not so good. Looking deeper into outliers could give an explanation to this
result.
Feature Ranking Results
Table 4.12 shows the list of features used by the final step of the “best” pipeline model
(Linear SVM) in descending order by the absolute value of the coefficient associated to
this method, in this case, the coefficients refer to the weights assigned to the features by
the Linear SVM (coefficients in the primal problem). We use the absolute value of the
coefficients, since they can be equally important as positive and negative values. The
table shows only the features with assigned weights different from zero (13 out of 127
variables). The column ‘sign’ of the table shows the corresponding sign of the weights.
It can be seen that features ‘Variant679611’, ‘Variant481340’ and ‘Variant269216’ have
a negative effect in the final classification result.
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Finally, the ‘p-value’ column shows the associated p-value of a certain SNP obtained from
PLINK using logistic regression. For this analysis case, none of the SNPs identified as
significant by the tool, were used by the classifier to make the final classification of
the test dataset. All SNPs have p-values much greater than 0.0001 (corresponding to
threshold = 4 defined in Section 4.2.2.2).
SNP | coefficients | sign p-value
DISEASES HYPERCHOLESTEROLEMIA 0.271268 +
> 1e-4
DISEASES HTA 0.265137 +
AGE YEARS 0.112288 +
CALC AVG WAIST 0.0775696 +
Variant531787 0.0548795 +
Variant496976 0.0436169 +
Variant22724 0.043515 +
Variant679611 0.0422826 −
Variant481340 0.0384467 −
CALC AVG SYSTOLIC BP 0.0344734 +
Variant269216 0.031254 −
Variant543613 0.027711 +
Variant543614 0.0277024 +
Table 4.12: Feature ranking from “best” pipeline model (ANOVA + No sampling +
Linear SVM) using the D2 vs. H dataset.
Functional In Silico Analysis Results
Using the R library seq2pathway, we map genome features on the hg38 assembly, followed
by a search for associated traits or diseases using the GWAS Catalog of the National
Human Genome Research Institute (NHGRI) [123] using the following keywords: dia-
betes and insulin. The genes in the regions identified in the “best” model have not been
associated directly to T2D, but to insulin-related functions (Table 4.13).
4.2.2.2 GWAS Classical Approach
The pre-processing steps described in Section 4.1.1.2 were applied to the genomic data
in order to filter the dataset and only analyze the individuals corresponding to the use
case of D2 vs. H individuals.
A simple test of association using logistic regression was applied to the genomic data of
the analysis case. A Manhattan plot from the obtained results is shown in Figure 4.15.
A total of 128 SNPs above the defined threshold = 4 are considered significant. Table
4.14 shows the top 50 most significant SNPs with their corresponding p-values.
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Associated Trait
Obesity-related traits.
Diabetes related insulin traits.
Cataracts in type 2 diabetes.
Cystic fibrosis-related diabetes.
Pediatric autoimmune diseases.
Fasting insulin (interaction).
Fasting insulin-related traits.
Fasting insulin-related traits (interaction with BMI).
Modified Stumvoll Insulin Sensitivity Index.
Modified Stumvoll Insulin Sensitivity Index (interaction with BMI).
Metabolite levels.
Protein quantitative trait loci.
Homeostasis model assessment of insulin resistance (interaction).
Table 4.13: Some traits associated to genes with insulin-related and diabetes re-
sponses.
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Figure 4.15: Manhattan plot of SNPs from all 22 chromosomes. In this case, since we are dealing with much more SNPs, all SNPs above the blue
line (p-value < 0.0001) are considered significant and are kept and stored for future comparison with the machine learning approach.
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SNP p-value
Variant560621 2,89e-7
Variant560622 3,95e-7
Variant69196 4,16e-7
Variant67085 4,63e-7
Variant378698 4,87e-7
Variant658055 5,97e-7
Variant171148 8,00e-7
Variant213942 1,02e-6
Variant429402 4,29e-6
Variant421349 5,17e-6
Variant58257 5,29e-6
Variant149441 6,08e-6
Variant207163 7,02e-6
Variant149442 7,81e-6
Variant235601 8,55e-6
Variant189161 8,78e-6
Variant355109 9,97e-6
Variant310929 1,09e-5
Variant412391 1,13e-5
Variant116145 1,16e-5
Variant149443 1,18e-5
Variant142601 1,19e-5
Variant450721 1,21e-5
Variant542471 1,57e-5
Variant319189 1,61e-5
Variant145753 1,62e-5
Variant581672 1,65e-5
Variant149433 1,65e-5
Variant5991 1,67e-5
Variant297567 1,69e-5
Variant316512 1,76e-5
Variant569572 1,84e-5
Variant412390 1,86e-5
Variant202112 1,96e-5
Variant58812 1,97e-5
Variant149436 2,06e-5
Variant265148 2,20e-5
Variant352078 2,20e-5
Variant149438 2,28e-5
Variant490399 2,33e-5
Variant560619 2,51e-5
Variant318480 2,58e-5
Variant364490 2,59e-5
Variant500456 2,70e-5
Variant393122 2,75e-5
Variant154757 2,77e-5
Variant32435 2,77e-5
Variant609811 3,00e-5
Variant319147 3,01e-5
Variant569568 3,10e-5
Table 4.14: Top 50 most significant SNPs, according to GWAS analysis using logistic
regression. They are ordered in ascending order by p-value.
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4.2.3 Type 2 Diabetes vs. No Type 2 Diabetes and Comorbidities (D2
vs. CD2F) Dataset Results
4.2.3.1 Pipeline Approach
Model Selection and Model Evaluation Results
Using the diabetes dataset consisting of D2 vs. CD2F individuals, and the extended
general framework (Figure 3.3 and Section 2.6), 36 3 experiments were executed. The
obtained the results are shown in Tables 4.17 and 4.18. The latter corresponds to results
of metrics related to each class of the target variable (which represents the disease
diagnostic of type 2 diabetes). Both tables are ordered by the CV F1 score.
Reviewing Table 4.17 in detail, it can be seen that performance scores have decreased
with respect to the previous D2 vs. H use case. None of the CV F1 scores are above
0.9, which was the common case with D2 vs. H experiments; but still more than 60%
of the experiments have CV F1 scores above 0.7, which we consider good generalization
scores. The majority of the top pipeline models use wrapper (RFE-LR) feature selection
methods, followed by ANOVA. The worst pipeline models (at the bottom) mostly use
embedded feature selection (RLR-L1). Down-sampling seems to affect negatively the
performance of the pipeline model, since the majority of the experiments using this type
of sampling are in the bottom of the list. On the contrary, not performing any sampling
translates into better performance. For the rest of the sampling techniques (Up-sampling
or SMOTE-sampling), there is no clear option that shows signs of improving more the
model’s performance. Similarly, the top 10 pipeline models use the three available
classifications methods, so there is no clear method that can be said that performs
better than another to classify D2 vs. CD2F individuals.
In general, all experiments show very low standard deviations of CV F1 scores. Unlike
the previous D2 vs. H case, here only the top 9 pipeline models along with the last model
have standard deviations smaller than 0.01 (Figure 4.16). Although the values remain
small and beneficial to their purpose, compared to the previous case, it is clear how the
classification problem, in general, is more difficult. Probably the lack of discrimination
of the model is due to the presence of sub-clinical forms of T2D in the CD2F group, as
well as the lack of consideration of comorbidities in the D2 group, resulting in a clear
incapability to distinguish between both groups that have quite similar characteristics.
These problems, the presence of sub-clinical forms, and the problem of causality with
some of the comorbidity phenotypes, is one of the active focus of research in this domain.
3Three feature selection methods: ANOVA, RFE-LR, RLR-L1, by four sampling techniques: No sam-
pling, Down-sampling, Up-sampling and SMOTE-sampling, by three classification algorithms: Linear
SVM, RF, KNN.
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All of the Test scores (F1, Precision and Recall) have low differences with their CV
counterparts. This is a good sign that the models are not over-fitting the data and these
Test scores are good approximations of the generalization scores.
In this particular case, we do not choose the first model to be the “best” pipeline model.
Reviewing Table 4.18 in detail it can be seen that all the Test metrics related to the class
of interest (T2D class) are either zero or too low, meaning that these models are almost
completely unable to discriminate individuals with T2D from individuals suffering from
any of the comorbidities. In this analysis case, since we are still using the CV F1 score
to choose the “best” pipeline model, the one to be selected will have a CV F1 score
very close to the top pipeline models, but we also took into account, the Test scores to
choose a good model that generalizes well with independent data. Despite this, since
there are very few test samples belonging to the class of interest (class 1), further tests
should be done with more data.
We consider the sixteenth model to be the “best” model for several reasons. It has a high
CV F1 score, only 0.049 of difference from the model with the highest CV F1 score and
also has a very low standard deviation. This model is able to correctly classify 31,3% of
the of patients who actually have T2D without affecting too much the class 0 metrics.
In Table 4.18 it can clearly be seen that as the Test Recall (1) increases (lower values
of false negatives and class 1 miss-classifications), all of the Test scores of the negative
class tend to decrease. This “best” model consists of performing down-sampling followed
by a wrapper feature selection of recursive feature elimination with a wrapped logistic
regression model (selecting 2509 features), and finally using k-nearest neighbors as a
classification method (with n neighbors = 20).
Table 4.15 shows the particular setting and results obtained in each of the 22 chro-
mosomes during the partial analysis. It is important to stand out that in each of the
partial analysis, the data consisted of all the epidemiological features combined with
the genomic features of the particular chromosome. The ‘# of features selected by FS’
column corresponds to the number of features selected by the RFE-LR feature selection
step; it varies depending on the number of SNPs available for each chromosome. The
n neighbors corresponds to the parameter of the number of neighbors used by the KNN
classifier that has the highest CV score during grid-search, which corresponds to the last
column identified by CV F1. It can be seen that some results using data from different
chromosomes output the same CV F1 score. This is due to the “common” epidemio-
logical features mentioned above, included in each of the chromosome’s datasets (total
of 27 features). The latter could imply that the epidemiological features overwhelm the
effect of the genetic variants. It is probable that a well though filtering of some of the
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epidemiological features, eliminating obvious correlations between these variables, could
make more sense and throw better results.
The last column ‘# of features selected by stability’ represents the final number of fea-
tures selected in each chromosome using the stability score. Features selected by the
“best” model a total of W = 100 times, are selected and used to create the final train-
ing and test datasets. Table 4.16 shows a description of the common epidemiological
features among the 22 datasets corresponding to each chromosome of the genome. The
numbers that appear in parentheses next to the name of the feature represent the dif-
ferent categories of that variable, which were selected by the partial analysis of the 22
chromosomes.
CHR
# of features
selected by FS
n neighbors CV F1
# of features selected
by stability (W = 100)
chr1 2259 20 0.871 ± 0.005 1947 (138 epidemiological and 1809 genomic)
chr2 2532 20 0.87 ± 0.004 2257 (141 epidemiological and 2116 genomic)
chr3 2173 20 0.871 ± 0.005 1875 (141 epidemiological and 1734 genomic)
chr4 1999 50 0.871 ± 0.005 1683 (141 epidemiological and 1542 genomic)
chr5 1810 20 0.871 ± 0.005 1468 (141 epidemiological and 1327 genomic)
chr6 2149 20 0.871 ± 0.005 1837 (141 epidemiological and 1696 genomic)
chr7 1631 20 0.871 ± 0.005 1306 (141 epidemiological and 1165 genomic)
chr8 1579 20 0.87 ± 0.004 1271 (141 epidemiological and 1130 genomic)
chr9 1288 20 0.875 ± 0.006 940 (141 epidemiological and 799 genomic)
chr10 1466 5 0.872 ± 0.014 1189 (140 epidemiological and 1049 genomic)
chr11 1446 20 0.884 ± 0.023 1121 (140 epidemiological and 981 genomic)
chr12 1390 20 0.871 ± 0.005 1072 (141 epidemiological and 931 genomic)
chr13 1078 20 0.871 ± 0.005 740 (141 epidemiological and 599 genomic)
chr14 963 20 0.871 ± 0.005 620 (141 epidemiological and 479 genomic)
chr15 905 20 0.871 ± 0.005 578 (141 epidemiological and 437 genomic)
chr16 960 20 0.871 ± 0.005 661 (138 epidemiological and 523 genomic)
chr17 838 20 0.871 ± 0.005 525 (141 epidemiological and 384 genomic)
chr18 900 20 0.871 ± 0.005 531 (114 epidemiological and 417 genomic)
chr19 582 20 0.871 ± 0.005 266 (91 epidemiological and 175 genomic)
chr20 728 20 0.871 ± 0.005 426 (122 epidemiological and 304 genomic)
chr21 424 5 0.876 ± 0.015 99 (48 epidemiological and 51 genomic)
chr22 413 5 0.874 ± 0.012 135 (61 epidemiological and 74 genomic)
Table 4.15: Information related to the application of the pipeline instantiation: ‘RFE-
LR + Down-sampling + KNN’ to filtered/merged data from the whole genome.
In the same way as in the previous case of D2 vs. H, the “worst” pipeline model
with the lowest CV F1 score, consists of performing recursive feature elimination with
a wrapped logistic regression, followed by a SMOTE-sampling and finally using a k-
nearest neighbors as a classifier. The model is completely biased towards the minority
class and is useless. These model manages to correctly classify all patients having T2D,
but at the high cost of miss-classifying all healthy individuals too.
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Feature Name Feature Description
OUTDOOR ACTIV ITY WALK(0, 1, 2)
Currently, how many days a week do you walk for at
least 10 minutes: 1 = One or more; 2 = None;
3 = Inability to walk; 0 = Do not know / No answer
CALC AVG HEIGHT Average standing height
HOME COHABITATION (4)
How many people in total live in your household
including yourself: 1 = 1; 2 = 2; 3 = 3; 4 = 4;
5 = 5; 6 = 6; 7 = 7; 8 = 8; 9 = 9; 10 = 10;
11 = More than 10; 0 = Do not know / Do not answer
COUPLE COHABITATION
Do you live in a couple: 1 = Yes; 2 = No;
0 = Do not know / No answer
COUPLE COHABITATION YEAR How many years ago do you live with your couple
DISEASES GESTATIONAL DIABETES
Have you ever been diagnosed by a doctor of
gestational diabetes: 1 = Yes; 2 = No; 0 = Do not
know / No answer
DISEASES HEREDITARY GENETICS
Have you ever been diagnosed by a doctor of any
heraditary genetic disease: 1 = Yes; 2 = No;
0 = Do not know / No answer
DISEASES MIGRAINE
Have you ever been diagnosed by a doctor of migraine:
1 = Yes; 2 = No; 0 = Do not know / No answer
DISEASES OTHER
Have you ever been diagnosed by a doctor of some other
disease not asked specifically before: 1 = Yes; 2 = No;
0 = Do not know / No answer
CIVIL STATUS (2, 3, 4, 5)
What is your current marital status: 1 = Single;
2 = Married; 3 = Widowed; 4 = Divorced / separated;
5 = Partner in fact; 0 = Do not know / No answer
MAXIMUM WEIGHT STATE What has been your maximum weight during the last 5 years
MINIMUM WEIGHT STATE What has been your minimum weight during the last 5 years
STUDIES (0)
What is the highest level of education you completed:
1 = No studies 2 = Primary or equivalent studies (EGB or
Primary, 3 = Secondary general education, 1st cycle
(completed EGB or ESO); Secondary general education,
2nd cycle (BUP or baccalaureate; 6 = Higher professional
education (FP2 or higher); 7 = University studies or
equivalent (studies University and postgraduate);
0 = Do not know / No answer
ETNIA MOTHER (1)
Which race / ethnicity would you say your biological
mother belongs: to 1 = White / Caucasian; 2 = Black;
3 = Asiatic; 4 = Gypsy; 5 = Maghrebi; 6 = Hispanic or
Latino; 7 = Other; 0 = Do not know /Does not answer
ETNIA FATHER (1, 6)
Which race / ethnicity would you say your biological
father belongs: to 1 = White / Caucasian; 2 = Black;
3 = Asiatic; 4 = Gypsy; 5 = Maghrebi; 6 = Hispanic or
Latino; 7 = Other; 0 = Do not know /Does not answer
ETNIA PARTAKER (1, 6)
Which race / ethnicity would you say you belong to:
to 1 = White / Caucasian; 2 = Black; 3 = Asiatic;
4 = Gypsy; 5 = Maghrebi; 6 = Hispanic or Latino;
7 = Other; 0 = Do not know /Does not answer
FAMILY FATHER AGE How old is or at what age his biological father died?
INCOME (0, 1, 2, 4, 5)
What is the total annual gross income of the household:
1 = Less than 18,000 EUR, 2 = From 18,000 to 30,999;
3 = From 31,000 to 51,999; 4 = From 52,000 to 100,000;
5 = More than 100,000; 0 = Do not know / No answer
LABOR ACTIVE ENPLOYMENT YEAR
Have you had any work during the last 12 months: 1 = Yes;
2 = No; 0 = Do not know / No answer
LABOR(1, 2, 3, 4, 5, 8)
Which of these situations best describes your present
situation: 1 = Working paid or self-employed; 2 = Retired;
3 = I take over the house / family; 4 = Job incapacity;
5 = Unemployed; 6 = Volunteer o Working without pay;
7 = Studying; 8 = None of the above; 0 = Do not
know / No answer
LABOR NUMBER OF JOBS YEAR How many jobs have you had during the last 12 months
HEALTH MEN HEALTH STATUS PROFILE Which of these images will look more like today
HEALTH WOMEN HEALTH STATUS PROFILE Which of these images will look more like today
HEALTH WOMEN FIRST MENSTRUATION AGE At what age did you first menstruate
HEALTH WOMEN LAST MENSTRUATION AGE At what age did you last have your menstruation period
DIRECT SOCIALIZATION FRIENDS (1, 2, 3, 4, 5, 6)
Frequency of direct socialization with friends:
1 = Practically every day; 2 = 2-4 times a week;
3 = 1 time a week; 4 = 1 time a month; 5 = 1 time
every few months; 6 = Never or almost never;
7 = I do not have Friends / family away from home;
0 = Do not know / Do not answer
DIRECT SOCIALIZATION FAMILY (1, 2)
Frequency of direct socialization with family:
1 = Practically every day; 2 = 2-4 times a week;
3 = 1 time a week; 4 = 1 time a month; 5 = 1 time
every few months; 6 = Never or almost never;
7 = I do not have Friends / family away from home;
0 = Do not know / Do not answer
NETWORK SOCIALIZATION FRIENDS (1, 2, 3, 4, 5, 6)
Frequency of socialization with friends network:
1 = Practically every day; 2 = 2-4 times a week;
3 = 1 time a week; 4 = 1 time a month; 5 = 1 time
every few months; 6 = Never or almost never;
7 = I do not have Friends / family away from home;
0 = Do not know / Do not answer
NETWORK SOCIALIZATION FAMILY (1, 2, 3, 4, 5)
Frequency of socialization with family network:
1 = Practically every day; 2 = 2-4 times a week;
3 = 1 time a week; 4 = 1 time a month; 5 = 1 time
every few months; 6 = Never or almost never;
7 = I do not have Friends / family away from home;
0 = Do not know / Do not answer
Table 4.16: Common epidemiological features selected in the partial analysis done
with each of the 22 chromosomes data.
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FS Sampling Classifier
CV F1
Mean ± Std
CV Precision
Mean ± Std
CV Recall
Mean ± Std Train F1 Test F1 Test AUC
Test
Precision
Test
Recall
Test
Accuracy
1 ANOVA No sampling KNN 0.871 ± 0.005 0.833 ± 0.007 0.913 ± 0.004 0.871 0.871 0.469 0.833 0.913 0.913
2 RFE-LR No sampling RF 0.871 ± 0.005 0.833 ± 0.007 0.913 ± 0.004 0.997 0.871 0.458 0.833 0.913 0.913
3 RFE-LR Up-sampling RF 0.871 ± 0.005 0.833 ± 0.007 0.913 ± 0.004 1 0.871 0.515 0.833 0.913 0.913
4 RFE-LR SMOTE-sampling RF 0.871 ± 0.005 0.833 ± 0.007 0.913 ± 0.004 1 0.871 0.495 0.833 0.913 0.913
5 RFE-LR No sampling KNN 0.871 ± 0.005 0.833 ± 0.007 0.913 ± 0.004 0.871 0.871 0.459 0.833 0.913 0.913
6 RLR-L1 No sampling KNN 0.871 ± 0.005 0.833 ± 0.007 0.913 ± 0.004 0.871 0.871 0.459 0.833 0.913 0.913
7 RFE-LR No sampling Linear SVM 0.87 ± 0.006 0.833 ± 0.007 0.91 ± 0.006 1 0.877 0.435 0.922 0.915 0.915
8 RFE-LR Up-sampling Linear SVM 0.87 ± 0.006 0.833 ± 0.007 0.91 ± 0.006 1 0.877 0.437 0.922 0.915 0.915
9 RFE-LR SMOTE-sampling Linear SVM 0.87 ± 0.006 0.833 ± 0.007 0.91 ± 0.006 1 0.877 0.437 0.922 0.915 0.915
10 ANOVA SMOTE-sampling RF 0.863 ± 0.03 0.851 ± 0.037 0.879 ± 0.033 0.967 0.843 0.511 0.828 0.858 0.858
11 RFE-LR Up-sampling KNN 0.852 ± 0.018 0.841 ± 0.022 0.864 ± 0.021 0.966 0.835 0.46 0.832 0.839 0.839
12 ANOVA No sampling RF 0.847 ± 0.031 0.841 ± 0.023 0.856 ± 0.048 0.963 0.855 0.481 0.837 0.874 0.874
13 RLR-L1 Up-sampling KNN 0.845 ± 0.027 0.854 ± 0.017 0.839 ± 0.038 0.901 0.841 0.441 0.833 0.85 0.85
14 ANOVA Up-sampling RF 0.828 ± 0.038 0.841 ± 0.017 0.819 ± 0.06 0.959 0.834 0.477 0.831 0.836 0.836
15 RLR-L1 SMOTE-sampling KNN 0.826 ± 0.027 0.826 ± 0.006 0.827 ± 0.051 0.765 0.737 0.45 0.825 0.672 0.672
16 RFE-LR Down-sampling KNN 0.822 ± 0.046 0.836 ± 0.011 0.816 ± 0.082 0.818 0.767 0.549 0.848 0.71 0.71
17 ANOVA Up-sampling KNN 0.757 ± 0.029 0.844 ± 0.015 0.697 ± 0.042 0.903 0.769 0.445 0.835 0.719 0.719
18 ANOVA SMOTE-sampling KNN 0.725 ± 0.019 0.847 ± 0.009 0.65 ± 0.025 0.875 0.74 0.476 0.833 0.675 0.675
19 RFE-LR Down-sampling Linear SVM 0.723 ± 0.05 0.835 ± 0.025 0.65 ± 0.065 0.887 0.765 0.426 0.824 0.716 0.716
20 ANOVA SMOTE-sampling Linear SVM 0.719 ± 0.031 0.836 ± 0.016 0.643 ± 0.043 0.746 0.7 0.483 0.828 0.617 0.617
21 ANOVA No sampling Linear SVM 0.707 ± 0.024 0.838 ± 0.014 0.626 ± 0.032 0.757 0.7 0.48 0.831 0.617 0.617
22 ANOVA Up-sampling Linear SVM 0.704 ± 0.019 0.831 ± 0.011 0.623 ± 0.026 0.753 0.702 0.487 0.832 0.62 0.62
23 RFE-LR Down-sampling RF 0.684 ± 0.038 0.841 ± 0.025 0.596 ± 0.049 0.793 0.706 0.512 0.84 0.626 0.626
24 ANOVA Down-sampling Linear SVM 0.68 ± 0.043 0.86 ± 0.011 0.593 ± 0.051 0.726 0.692 0.454 0.83 0.607 0.607
25 RLR-L1 No sampling RF 0.677 ± 0.056 0.83 ± 0.02 0.589 ± 0.073 0.684 0.69 0.493 0.848 0.604 0.604
26 RLR-L1 SMOTE-sampling RF 0.658 ± 0.072 0.826 ± 0.021 0.568 ± 0.098 0.656 0.633 0.443 0.829 0.533 0.533
27 ANOVA Down-sampling KNN 0.643 ± 0.059 0.848 ± 0.028 0.548 ± 0.071 0.667 0.642 0.479 0.831 0.544 0.544
28 ANOVA Down-sampling RF 0.64 ± 0.046 0.85 ± 0.028 0.544 ± 0.054 0.752 0.679 0.474 0.842 0.59 0.59
29 RLR-L1 Down-sampling RF 0.621 ± 0.057 0.834 ± 0.016 0.523 ± 0.061 0.562 0.56 0.443 0.832 0.454 0.454
30 RLR-L1 Up-sampling RF 0.598 ± 0.047 0.849 ± 0.032 0.497 ± 0.054 0.585 0.57 0.479 0.834 0.464 0.464
31 RLR-L1 Down-sampling Linear SVM 0.563 ± 0.065 0.832 ± 0.027 0.461 ± 0.064 0.474 0.447 0.575 0.803 0.344 0.344
32 RLR-L1 Down-sampling KNN 0.557 ± 0.092 0.841 ± 0.02 0.459 ± 0.089 0.577 0.563 0.453 0.827 0.456 0.456
33 RLR-L1 SMOTE-sampling Linear SVM 0.527 ± 0.085 0.828 ± 0.008 0.427 ± 0.088 0.517 0.463 0.436 0.802 0.358 0.358
34 RLR-L1 Up-sampling Linear SVM 0.498 ± 0.072 0.816 ± 0.023 0.395 ± 0.07 0.423 0.364 0.466 0.82 0.284 0.284
35 RLR-L1 No sampling Linear SVM 0.48 ± 0.054 0.816 ± 0.023 0.377 ± 0.049 0.49 0.451 0.507 0.836 0.355 0.355
36 RFE-LR SMOTE-sampling KNN 0.014 ± 0.001 0.008 ± 0.001 0.087 ± 0.004 0.014 0.014 0.512 0.008 0.087 0.087
Table 4.17: Model selection and evaluation metrics of 36 possible instantiations of extended pipeline using D2 vs. CD2F dataset (all 22 chromosomes
and epidemiological features). They are ordered by CV F1.
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FS Sampling Classifier Test F1 (1) Test Precision (1) Test Recall (1) Test F1 (0) Test Precision (0) Test Recall (0)
1 ANOVA No sampling KNN 0 0 0 0.954 0.913 1
2 RFE-LR No sampling RF 0 0 0 0.954 0.913 1
3 RFE-LR Up-sampling RF 0 0 0 0.954 0.913 1
4 RFE-LR SMOTE-sampling RF 0 0 0 0.954 0.913 1
5 RFE-LR No sampling KNN 0 0 0 0.954 0.913 1
6 RLR-L1 No sampling KNN 0 0 0 0.954 0.913 1
7 RFE-LR No sampling Linear SVM 0.061 1 0.031 0.956 0.915 1
8 RFE-LR Up-sampling Linear SVM 0.061 1 0.031 0.956 0.915 1
9 RFE-LR SMOTE-sampling Linear SVM 0.061 1 0.031 0.956 0.915 1
10 ANOVA SMOTE-sampling RF 0 0 0 0.924 0.908 0.94
11 RFE-LR Up-sampling KNN 0.033 0.034 0.031 0.912 0.908 0.916
12 ANOVA No sampling RF 0.042 0.063 0.031 0.933 0.911 0.955
13 RLR-L1 Up-sampling KNN 0.035 0.04 0.031 0.919 0.909 0.928
14 ANOVA Up-sampling RF 0.032 0.033 0.031 0.91 0.908 0.913
15 RLR-L1 SMOTE-sampling KNN 0.077 0.051 0.156 0.801 0.899 0.722
16 RFE-LR Down-sampling KNN 0.159 0.106 0.313 0.825 0.919 0.749
17 ANOVA Up-sampling KNN 0.104 0.072 0.188 0.833 0.908 0.769
18 ANOVA SMOTE-sampling KNN 0.105 0.069 0.219 0.801 0.906 0.719
19 RFE-LR Down-sampling Linear SVM 0.055 0.038 0.094 0.833 0.899 0.775
20 ANOVA SMOTE-sampling Linear SVM 0.103 0.065 0.25 0.757 0.901 0.653
21 ANOVA No sampling Linear SVM 0.114 0.071 0.281 0.756 0.904 0.65
22 ANOVA Up-sampling Linear SVM 0.115 0.072 0.281 0.758 0.905 0.653
23 RFE-LR Down-sampling RF 0.138 0.087 0.344 0.761 0.912 0.653
24 ANOVA Down-sampling Linear SVM 0.111 0.069 0.281 0.747 0.903 0.638
25 RLR-L1 No sampling RF 0.162 0.099 0.438 0.741 0.92 0.62
26 RLR-L1 SMOTE-sampling RF 0.123 0.074 0.375 0.682 0.901 0.548
27 ANOVA Down-sampling KNN 0.126 0.075 0.375 0.691 0.903 0.56
28 ANOVA Down-sampling RF 0.148 0.09 0.406 0.73 0.914 0.608
29 RLR-L1 Down-sampling RF 0.138 0.08 0.5 0.6 0.904 0.449
30 RLR-L1 Up-sampling RF 0.14 0.082 0.5 0.611 0.906 0.461
31 RLR-L1 Down-sampling Linear SVM 0.118 0.067 0.5 0.478 0.873 0.329
32 RLR-L1 Down-sampling KNN 0.131 0.076 0.469 0.604 0.899 0.455
33 RLR-L1 SMOTE-sampling Linear SVM 0.113 0.064 0.469 0.497 0.872 0.347
34 RLR-L1 Up-sampling Linear SVM 0.144 0.08 0.688 0.385 0.891 0.246
35 RLR-L1 No sampling Linear SVM 0.151 0.085 0.656 0.48 0.908 0.326
36 RFE-LR SMOTE-sampling KNN 0.161 0.087 1 0 0 0
Table 4.18: Model evaluation metrics per class of 36 possible instantiations of extended pipeline using D2 vs. CD2F dataset (all 22 chromosomes
and epidemiological features). They are ordered by CV F1.
89Figure 4.16: CV F1 mean scores with their corresponding standard deviations for all 36 pipeline instantiations using D2 vs. CD2F dataset.
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Figure 4.17: Confusion matrix of
D2. vs. CD2F test dataset.
Figure 4.18: Predicted probabili-
ties of D2 vs. CD2F test dataset.
Figures 4.16 and 4.18 shows detailed results regarding the “best” pipeline model using
the analysis case, consisting of performing RFE-LR as the feature selection step, followed
by applying down sampling and KNN as a classification method. Figure 4.17 shows
that the classifier is able to correctly classify 75% of the test samples belonging to
the negative class, and a bit more than 30% of the positive class samples. As for the
predicted probabilities, Figure 4.18 shows a similar distribution of the probabilities as
the lung cancer dataset. The majority of the predicted probabilities are around the
default threshold of 0.5 used by the classifier, which implies the problem is difficult and
the classifier is not able to give more “certain” results (values close to 0 or 1).
Feature Ranking Results
Since the KNN classifier does not have an intrinsic coefficient measure associated to it,
like the Linear SVM with the weights, and the RF with the variable importance, we take
as a measure to rank the final selected features, the coefficients associated to each feature
given by the LR wrapped by the RFE. Table 4.19 shows the list of the top 50 features (out
of 2509) in descending order by the absolute value of the coefficient, since they can be
equally important as positive and negative values. The column ‘sign’ of the table shows
the corresponding sign of the coefficient, which represents the tendency to have T2D or
not. It can be seen that features ‘Variant592793’, ‘Variant119675’, ‘Variant56373’, ‘Vari-
ant682067’, ‘Variant224599’, ‘Variant269219’, ‘Variant568820’, ‘Variant120320’, ‘Vari-
ant592379’, ‘Variant223901’ and ‘Variant541879’ have a negative effect in the final clas-
sification result. A positive coefficient means that the individual is more likely to have
T2D, and vice-versa for a negative coefficient; a larger absolute value means a stronger
tendency than a smaller value.
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Finally, the ‘p-value’ column shows the associated p-value of a certain SNP obtained
from PLINK using logistic regression. For the analysis case, none of the SNPs identified
as significant by the tool, were used by the classifier to make the final classification of
the test dataset. All SNPs have p-values much greater than 0.0001 (corresponding to
threshold = 4 defined in Section 4.2.3.2).
Functional In Silico Analysis Results
Using the R library seq2pathway, we map genome features on the hg38 assembly, followed
by a search for associated traits or diseases using the GWAS Catalog of the National Hu-
man Genome Research Institute (NHGRI) [123] using the following keywords: diabetes,
insulin, cholesterol, hypercholesterolemia, hypertension, hypertensive, tension, cardiovas-
cular, stroke and heart attack. The genes in the regions identified in the “best” model
have been associated directly to T2D and insulin-related functions (Table 4.20). There
were also other associations found directly to cholesterol-related functions (Table 4.21),
hypertension (Table 4.22) and cardiovascular-related functions (Table 4.23).
4.2.3.2 GWAS Classical Approach
The pre-processing steps described in Section 4.1.1.2 were applied to the genomic data
in order to filter the dataset and only analyze the individuals corresponding to the use
case of D2 vs. CD2F individuals.
A simple test of association using logistic regression was applied to the genomic data of
the analysis case. Figure 4.19 shows the Manhattan plot from the obtained results. A
total of 106 SNPs above the defined threshold = 4 are considered significant. Table 4.24
shows the top 50 most significant SNPs with their corresponding p-values.
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SNP | coefficients | sign p-value
Variant592770 0.389 +
> 1e-4
Variant592793 0.348 −
Variant119675 0.317 −
Variant434914 0.314 +
Variant470968 0.292 +
Variant268902 0.277 +
Variant434923 0.272 +
Variant57417 0.255 +
Variant638848 0.250 +
Variant434595 0.229 +
Variant471399 0.226 +
Variant403115 0.217 +
Variant682209 0.214 +
Variant119816 0.214 +
Variant56373 0.213 −
Variant568388 0.208 +
Variant56784 0.204 +
Variant269410 0.200 +
Variant403205 0.199 +
Variant402964 0.199 +
Variant57418 0.194 +
Variant322309 0.194 +
Variant682067 0.194 −
Variant696555 0.190 +
Variant56398 0.189 +
Variant224599 0.188 −
ESTADO PESO MAXIMO 0.188 +
Variant714532 0.187 +
Variant402594 0.187 +
Variant269219 0.186 −
Variant568820 0.183 −
Variant174502 0.183 +
Variant120320 0.182 −
Variant174163 0.179 +
Variant434904 0.174 +
Variant174198 0.174 +
SALUD HOMBRE CALVICIE 40 3 0.172 +
Variant174706 0.172 +
Variant592379 0.171 −
Variant403073 0.165 +
Variant224020 0.164 +
Variant434611 0.163 +
Variant714462 0.160 +
Variant223901 0.160 −
Variant57222 0.159 +
Variant471405 0.159 +
Variant223763 0.158 +
Variant560 0.156 +
Variant541879 0.152 −
Variant56783 0.150 +
Table 4.19: Feature ranking from “best” pipeline model (RFE-LR + Down-sampling
+ KNN) using the D2 vs. CD2F dataset.
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Associated Trait
Obesity-related traits.
Diabetes related insulin traits.
Protein quantitative trait loci.
Metabolite levels.
Fasting insulin-related traits (interaction with BMI).
Modified Stumvoll Insulin Sensitivity Index.
Modified Stumvoll Insulin Sensitivity Index (interaction with BMI).
Fasting insulin (interaction).
Fasting insulin-related traits.
Pediatric autoimmune diseases.
Diabetic retinopathy.
Diabetic nephropathy in type 1 diabetes.
Diabetic retinopathy in type 2 diabetes.
Sight-threatening diabetic retinopathy in type 2 diabetes.
Glucose homeostasis traits.
Erectile dysfunction in type 1 diabetes.
Skin fluorescence in type 1 diabetes.
Type 1 diabetes autoantibodies.
Type 1 diabetes.
Type 1 diabetes and autoimmune thyroid diseases.
End-stage renal disease in Type 1 diabetics.
End-stage renal disease or diabetic nephropathy in type 1 diabetes.
End-stage renal disease (non-diabetic).
Glomerular filtration rate in diabetics (creatinine).
Glomerular filtration rate in non diabetics (creatinine).
Type 2 diabetes and 6 quantitative traits.
Type 2 diabetes and other traits.
Yu-Zhi constitution type in type 2 diabetes.
Cardiovascular heart disease in diabetics.
Cystic fibrosis-related diabetes.
Type 2 diabetes.
Advanced glycation end-product levels.
Cataracts in type 2 diabetes.
Glycemic traits.
Neuropathic pain in type 2 diabetes.
Type 2 diabetes (dietary heme iron intake interaction).
Type 2 diabetes (young onset) and obesity.
Table 4.20: Some traits associated to genes with insulin-related functions and diabetes
responses.
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Associated Trait
Obesity-related traits.
Response to statin therapy (LDL cholesterol subfractions).
Response to statins (LDL cholesterol change).
Hematological and biochemical traits.
Cardiovascular disease risk factors.
Metabolite levels.
Body mass index and cholesterol (psychopharmacological treatment).
Quantitative traits.
Response to statins (HDL cholesterol change).
Hematological and biochemical traits.
Response to fenofibrate (HDL cholesterol levels).
Response to fenofibrate (LDL cholesterol levels).
Response to fenofibrate (total cholesterol levels).
Biochemical measures.
HDL Cholesterol in HIV-infection.
Table 4.21: Some traits associated to genes with cholesterol-related functions.
Associated Trait
Thiazide-induced adverse metabolic effects in hypertensive patients.
Blood pressure response to hydrochlorothiazide in hypertension.
Diastolic blood pressure response to hydrochlorothiazide in hypertension.
Systolic blood pressure response to hydrochlorothiazide in hypertension.
Response to chemotherapy in breast cancer (hypertension) (bevacizumab).
Response to chemotherapy in breast cancer hypertensive cases
(cumulative dose) (bevacizumab).
Glaucoma (low intraocular pressure).
Orthostatic hypotension.
Cardiovascular disease in hypertension (ACE inhibitor interaction).
Cardiovascular disease in hypertension (beta-blocker interaction).
Cardiovascular disease in hypertension (calcium channel blocker interaction).
Cardiovascular disease in hypertension (diuretic interaction).
Table 4.22: Some traits associated to genes related to hypertension.
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Associated Trait
Cardiovascular disease risk factors.
Cardiovascular event reduction in the elderly at risk for vascular
disease (statin therapy interaction).
Stroke.
Stroke (ischemic).
Coronary artery disease or ischemic stroke.
Ischemic stroke.
Thrombosis.
Stroke (pediatric).
Vitamin B levels in ischemic stroke.
Creatinine levels in ischemic stroke.
Cardiovascular heart disease in diabetics.
Alzheimer’s disease or small vessel stroke.
Cardiovascular disease in hypertension (ACE inhibitor interaction).
Cardiovascular disease in hypertension (beta-blocker interaction).
Cardiovascular disease in hypertension (calcium channel blocker interaction).
Cardiovascular disease in hypertension (diuretic interaction).
Major CVD.
Vascular constriction.
Table 4.23: Some traits associated to genes with cardiovascular-related functions.
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Figure 4.19: Manhattan plot of SNPs from all 22 chromosomes. All SNPs above the blue line (p-value < 0.0001) are considered significant and
are kept and stored for future comparison with the machine learning approach.
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SNP p-value
Variant678084 1,95e-7
Variant678083 5,61e-7
Variant480660 1,80e-6
Variant402879 3,64e-6
Variant197815 4,81e-6
Variant569413 4,87e-6
Variant248352 5,89e-6
Variant480659 6,68e-6
Variant284794 7,25e-6
Variant40701 8,62e-6
Variant480654 9,35e-6
Variant479629 1,04e-5
Variant578610 1,04e-5
Variant353515 1,08e-5
Variant261297 1,19e-5
Variant353512 1,41e-5
Variant722327 1,46e-5
Variant42586 1,52e-5
Variant656421 1,58e-5
Variant105677 1,58e-5
Variant543073 1,64e-5
Variant112371 1,81e-5
Variant224222 1,82e-5
Variant362289 1,86e-5
Variant722341 1,92e-5
Variant176962 1,98e-5
Variant77122 1,98e-5
Variant237504 2,04e-5
Variant520096 2,04e-5
Variant534952 2,52e-5
Variant164548 2,63e-5
Variant105667 2,74e-5
Variant105689 2,75e-5
Variant667637 2,77e-5
Variant87383 3,21e-5
Variant667639 3,52e-5
Variant165419 3,88e-5
Variant717483 3,94e-5
Variant310054 4,07e-5
Variant353516 4,23e-5
Variant617954 4,24e-5
Variant261289 4,37e-5
Variant700348 4,38e-5
Variant479626 4,42e-5
Variant678082 4,49e-5
Variant388474 4,50e-5
Variant565255 4,50e-5
Variant12305 4,59e-5
Variant318434 4,75e-5
Variant50631 4,91e-5
Table 4.24: Top 50 most significant SNPs, according to GWAS analysis using logistic
regression. They are ordered in ascending order by p-value.
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4.2.4 Type 2 Diabetes and Comorbidities vs. No Type 2 Diabetes and
Comorbidities (CD2W vs. CD2F) Dataset Results
4.2.4.1 Pipeline Approach
Model Selection and Model Evaluation Results
Using the diabetes dataset consisting of CD2W vs. CD2F individuals, and the extended
general framework (Figure 3.3 and Section 2.6), 36 4 experiments were executed. The
obtained results are shown in Tables 4.26 and 4.27. The latter corresponds to results
of metrics related to each class of the target variable, which in this case represents the
disease diagnostic of complex type 2 diabetes. Both tables are ordered by the CV F1
score.
Table 4.26 shows the performance scores have increased with respect to the previous D2
vs. CD2F use case. This makes sense, since the discrimination problem seems to be
more easier because both groups of individuals suffer of one or more comorbidities and
what differentiates them is having T2D or not. More than 60% of the experiments have
CV F1 scores above 0.764.
There is no clear best feature selection method for these experiments, but it is clear that
the embedded feature selection (RLR-L1) in general, has the worst results, regardless
of the sampling method applied that follows in the pipeline. Similarly, in the top 10
pipeline models all the four sampling methods appear at least once, so there is no clear
advantages of one over another. Almost all Down-sampling experiments, are in the
bottom half of the experiment configurations. This result is expected at least for this
kind of problems, where we are dealing with a very high number of dimensions and
a “reduced” number of individuals for training and testing. Down-sampling reduces
the number of samples of the majority class to match the number of samples of the
minority class, and directly reduces the number of training samples that is scarce and
so valuable for training the models. On the contrary, not performing any sampling
technique reflects in a better performance. For the rest of the sampling techniques (Up-
sampling or SMOTE-sampling), there is no clear option that shows signs of improving
or not the model’s performance. As for the classification methods, KNN and RF are
clearly at the top of the list, associated to the highest CV F1 scores, which implies that
non-linear learning models are more appropriate for this type of data.
4Three feature selection methods: ANOVA, RFE-LR, RLR-L1, by four sampling techniques: No sam-
pling, Down-sampling, Up-sampling and SMOTE-sampling, by three classification algorithms: Linear
SVM, RF, KNN.
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In the same way as all the previous use cases, all experiments show very low standard
deviations of CV F1 scores. Figure 4.20 shows a visual representation of them, where the
last three model configurations show low performance scores and signs of instability, since
they have too large standard deviations and this introduces uncertainty on the obtained
results. Almost all the rest of the model’s Test scores (F1, Precision and Recall) have
low differences with their CV counterparts, indicating there is no over-fitting and the
scores are reliable.
Similarly to the previous D2 vs. CD2F use case, we do not choose the first model to
be the “best” pipeline model. Table 4.27 shows the top models are unable to correctly
identify any of the interesting individuals (with T2D and one or more comorbidities),
resulting in Test scores equal to zero or very low values. Taking into account both
the CV F1 score along with the Test scores, specially the ones related to class 1, the
twenty-second model was selected to be the “best” pipeline model (‘ANOVA + SMOTE-
sampling + KNN’). This model has a high CV F1 score of 0.765 and a standard deviation
of 0.016. Having a Test Recall (1) equal to 0.455 means that almost half of the patients
belonging to the CD2W group, were correctly classified as having T2D and suffering
from one or more of the comorbidities. The ANOVA filter feature selection selects a
total of (21 features) and the final classification step of KNN uses n neighbors equal to
5. See that this model has lower Test scores associated to class 0, compared to the top
models, but at the expense of being able to identify T2D individuals.
In this case, since there is a “bigger” difference (0.15) between the CV F1 scores of the
top pipeline model and the model selected as the “best” pipeline, in further work we
should look in detail if the Train scores of the class of interest have similar values than
the ones obtained in Test. We suspect the latter is true because we can see the Test F1
score is very close to the Train F1, because they have a small difference of 0.062.
Table 4.25 shows the particular setting and results obtained in each of the 22 chro-
mosomes during the partial analysis. It is important to stand out that in each of the
partial analysis, the data consisted of all the epidemiological features combined with
the genomic features of the particular chromosome. The ‘# of features selected by FS’
column corresponds to the number of features selected by the ANOVA feature selection
step; it varies depending on the number of SNPs available for each chromosome. The
n neighbors corresponds to the parameter of the number of neighbors used by the KNN
classifier that has the highest CV score during grid-search, which corresponds to the
last column identified by CV F1. See that CV F1 scores are close but not equal, as it
happened in the D2 vs. CD2F use case.
Since this sample of individuals is much more homogeneous than the previous analysis
cases, the fact that in the partial analysis of the 22 chromosomes no epidemiological
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variables have been selected could be due to the fact that the genetic components that
can be common between both groups weigh more than non-genetic risk factors.
The last column ‘# of features selected by stability’ represents the final number of
features selected in each chromosome using the stability score. Features selected by the
“best” model a total of W = 100 times, are selected and used to create the final training
and test datasets.
CHR
# of features
selected by FS
n neighbors CV F1
# of features selected
by stability (W = 100)
chr1 2259 20 0.906 ± 0.005 16 (0 epidemiological and 16 genomic)
chr2 2532 50 0.908 ± 0.004 16 (0 epidemiological and 16 genomic)
chr3 2172 50 0.907 ± 0.004 15 (0 epidemiological and 15 genomic)
chr4 1998 20 0.91 ± 0.007 9 (0 epidemiological and 9 genomic)
chr5 1809 20 0.908 ± 0.005 7 (0 epidemiological and 7 genomic)
chr6 2149 50 0.891 ± 0.013 15 (0 epidemiological and 15 genomic)
chr7 1631 35 0.901 ± 0.012 11 (0 epidemiological and 11 genomic)
chr8 1579 50 0.906 ± 0.004 12 (0 epidemiological and 12 genomic)
chr9 1287 50 0.906 ± 0.005 8 (0 epidemiological and 8 genomic)
chr10 1466 50 0.906 ± 0.006 10 (0 epidemiological and 10 genomic)
chr11 1446 50 0.903 ± 0.007 19 (0 epidemiological and 19 genomic)
chr12 1390 50 0.905 ± 0.004 8 (0 epidemiological and 8 genomic)
chr13 1078 5 0.867 ± 0.015 13 (0 epidemiological and 13 genomic)
chr14 963 50 0.906 ± 0.009 6 (0 epidemiological and 6 genomic)
chr15 904 50 0.882 ± 0.033 4 (0 epidemiological and 4 genomic)
chr16 959 50 0.913 ± 0.009 12 (0 epidemiological and 12 genomic)
chr17 838 50 0.877 ± 0.019 6 (0 epidemiological and 6 genomic)
chr18 900 50 0.891 ± 0.019 6 (0 epidemiological and 6 genomic)
chr19 582 50 0.898 ± 0.013 0 (0 epidemiological and 0 genomic)
chr20 727 20 0.875 ± 0.022 2 (0 epidemiological and 2 genomic)
chr21 424 50 0.897 ± 0.014 4 (0 epidemiological and 4 genomic)
chr22 412 50 0.891 ± 0.026 3 (0 epidemiological and 3 genomic)
Table 4.25: Information related to the application of the pipeline instantiation: ‘RFE-
LR + Down-sampling + KNN’ to filtered/merged data from the whole genome.
In the same way as in the previous case of D2 vs. H, the “worst” pipeline model
with the lowest CV F1 score, consists of performing recursive feature elimination with
a wrapped logistic regression, followed by a SMOTE-sampling and finally using a k-
nearest neighbors as a classifier. The model is completely biased towards the minority
class and is useless. These model manages to correctly classify all patients having T2D,
but at the high cost of miss-classifying all healthy individuals too.
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Sampling FS Classifier
CV F1
Mean ± Std
CV Precision
Mean ± Std
CV Recall
Mean ± Std Train F1 Test F1 Test AUC
Test
Precision
Test
Recall
Test
Accuracy
1 Down-sampling RFE-LR KNN 0.914 ± 0.012 0.897 ± 0.022 0.936 ± 0.009 0.918 0.909 0.498 0.881 0.938 0.938
2 No sampling ANOVA RF 0.908 ± 0.005 0.88 ± 0.006 0.938 ± 0.003 1 0.906 0.502 0.88 0.933 0.933
3 No sampling ANOVA KNN 0.908 ± 0.005 0.88 ± 0.006 0.938 ± 0.003 0.908 0.909 0.514 0.881 0.938 0.938
4 No sampling RFE-LR RF 0.908 ± 0.005 0.88 ± 0.006 0.938 ± 0.003 0.998 0.909 0.554 0.881 0.938 0.938
5 Up-sampling RFE-LR RF 0.908 ± 0.005 0.88 ± 0.006 0.938 ± 0.003 1 0.909 0.433 0.881 0.938 0.938
6 SMOTE-sampling RFE-LR RF 0.908 ± 0.005 0.88 ± 0.006 0.938 ± 0.003 1 0.909 0.522 0.881 0.938 0.938
7 No sampling RFE-LR KNN 0.908 ± 0.005 0.88 ± 0.006 0.938 ± 0.003 0.908 0.909 0.475 0.881 0.938 0.938
8 No sampling RLR-L1 KNN 0.908 ± 0.005 0.88 ± 0.006 0.938 ± 0.003 0.908 0.909 0.5 0.881 0.938 0.938
9 Up-sampling RLR-L1 KNN 0.908 ± 0.005 0.88 ± 0.006 0.938 ± 0.003 0.908 0.909 0.393 0.881 0.938 0.938
10 SMOTE-sampling RLR-L1 KNN 0.908 ± 0.005 0.88 ± 0.006 0.938 ± 0.003 0.908 0.909 0.408 0.881 0.938 0.938
11 SMOTE-sampling ANOVA RF 0.907 ± 0.006 0.88 ± 0.006 0.936 ± 0.007 1 0.904 0.483 0.88 0.93 0.93
12 Up-sampling ANOVA RF 0.905 ± 0.008 0.88 ± 0.006 0.933 ± 0.01 1 0.901 0.498 0.88 0.924 0.924
13 No sampling RFE-LR Linear SVM 0.905 ± 0.005 0.88 ± 0.006 0.933 ± 0.006 1 0.907 0.478 0.88 0.936 0.936
14 Up-sampling RFE-LR Linear SVM 0.905 ± 0.005 0.88 ± 0.006 0.933 ± 0.006 1 0.907 0.477 0.88 0.936 0.936
15 SMOTE-sampling RFE-LR Linear SVM 0.905 ± 0.005 0.88 ± 0.006 0.933 ± 0.006 1 0.907 0.478 0.88 0.936 0.936
16 Up-sampling RFE-LR KNN 0.893 ± 0.016 0.882 ± 0.013 0.904 ± 0.023 0.984 0.893 0.475 0.879 0.908 0.908
17 Up-sampling ANOVA KNN 0.839 ± 0.019 0.878 ± 0.009 0.805 ± 0.035 0.927 0.843 0.513 0.887 0.807 0.807
18 SMOTE-sampling ANOVA Linear SVM 0.82 ± 0.03 0.891 ± 0.007 0.769 ± 0.05 0.848 0.782 0.439 0.874 0.711 0.711
19 No sampling ANOVA Linear SVM 0.796 ± 0.04 0.885 ± 0.009 0.733 ± 0.064 0.817 0.749 0.441 0.881 0.661 0.661
20 Up-sampling ANOVA Linear SVM 0.794 ± 0.034 0.887 ± 0.008 0.73 ± 0.055 0.825 0.74 0.428 0.876 0.65 0.65
21 Down-sampling RFE-LR Linear SVM 0.794 ± 0.019 0.883 ± 0.016 0.73 ± 0.028 0.917 0.841 0.501 0.879 0.807 0.807
22 SMOTE-sampling ANOVA KNN 0.765 ± 0.016 0.883 ± 0.017 0.687 ± 0.025 0.874 0.812 0.564 0.904 0.751 0.751
23 Down-sampling RFE-LR RF 0.739 ± 0.017 0.88 ± 0.014 0.649 ± 0.027 0.817 0.754 0.471 0.87 0.669 0.669
24 Down-sampling ANOVA RF 0.732 ± 0.015 0.884 ± 0.014 0.639 ± 0.021 0.773 0.724 0.488 0.893 0.627 0.627
25 Down-sampling ANOVA Linear SVM 0.718 ± 0.072 0.878 ± 0.027 0.627 ± 0.099 0.756 0.72 0.48 0.889 0.622 0.622
26 Down-sampling ANOVA KNN 0.697 ± 0.041 0.897 ± 0.007 0.595 ± 0.052 0.677 0.691 0.578 0.894 0.585 0.585
27 SMOTE-sampling RLR-L1 RF 0.672 ± 0.034 0.905 ± 0.015 0.564 ± 0.044 0.673 0.652 0.392 0.866 0.535 0.535
28 SMOTE-sampling RLR-L1 Linear SVM 0.655 ± 0.016 0.904 ± 0.014 0.544 ± 0.02 0.638 0.603 0.379 0.862 0.479 0.479
29 No sampling RLR-L1 RF 0.655 ± 0.016 0.904 ± 0.014 0.544 ± 0.02 0.673 0.654 0.383 0.871 0.538 0.538
30 Up-sampling RLR-L1 Linear SVM 0.622 ± 0.023 0.907 ± 0.015 0.508 ± 0.026 0.616 0.596 0.393 0.861 0.471 0.471
31 Up-sampling RLR-L1 RF 0.62 ± 0.024 0.9 ± 0.015 0.504 ± 0.028 0.619 0.598 0.38 0.861 0.473 0.473
32 No sampling RLR-L1 Linear SVM 0.616 ± 0.024 0.907 ± 0.015 0.501 ± 0.026 0.617 0.596 0.383 0.861 0.471 0.471
33 Down-sampling RLR-L1 RF 0.585 ± 0.045 0.896 ± 0.023 0.468 ± 0.05 0.514 0.477 0.413 0.86 0.356 0.356
34 Down-sampling RLR-L1 Linear SVM 0.479 ± 0.253 0.889 ± 0.043 0.412 ± 0.245 0.767 0.753 0.471 0.885 0.667 0.667
35 Down-sampling RLR-L1 KNN 0.383 ± 0.195 0.909 ± 0.027 0.315 ± 0.182 0.293 0.3 0.451 0.873 0.224 0.224
36 SMOTE-sampling RFE-LR KNN 0.011 ± 0.007 0.192 ± 0.376 0.064 ± 0.004 0.011 0.007 0.47 0.004 0.062 0.062
Table 4.26: Model selection and evaluation metrics of 36 possible instantiations of extended pipeline using CD2W vs. CD2F dataset (all 22
chromosomes and epidemiological features). They are ordered by CV F1.
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Sampling FS Classifier Test F1 (1) Test Precision (1) Test Recall (1) Test F1 (0) Test Precision (0) Test Recall (0)
1 Down-sampling RFE-LR KNN 0 0 0 0.968 0.938 1
2 No sampling ANOVA RF 0 0 0 0.965 0.938 0.994
3 No sampling ANOVA KNN 0 0 0 0.968 0.938 1
4 No sampling RFE-LR RF 0 0 0 0.968 0.938 1
5 Up-sampling RFE-LR RF 0 0 0 0.968 0.938 1
6 SMOTE-sampling RFE-LR RF 0 0 0 0.968 0.938 1
7 No sampling RFE-LR KNN 0 0 0 0.968 0.938 1
8 No sampling RLR-L1 KNN 0 0 0 0.968 0.938 1
9 Up-sampling RLR-L1 KNN 0 0 0 0.968 0.938 1
10 SMOTE-sampling RLR-L1 KNN 0 0 0 0.968 0.938 1
11 SMOTE-sampling ANOVA RF 0 0 0 0.964 0.938 0.991
12 Up-sampling ANOVA RF 0 0 0 0.961 0.938 0.985
13 No sampling RFE-LR Linear SVM 0 0 0 0.967 0.938 0.997
14 Up-sampling RFE-LR Linear SVM 0 0 0 0.967 0.938 0.997
15 SMOTE-sampling RFE-LR Linear SVM 0 0 0 0.967 0.938 0.997
16 Up-sampling RFE-LR KNN 0 0 0 0.952 0.936 0.967
17 Up-sampling ANOVA KNN 0.104 0.073 0.182 0.892 0.94 0.848
18 SMOTE-sampling ANOVA Linear SVM 0.055 0.034 0.136 0.83 0.93 0.749
19 No sampling ANOVA Linear SVM 0.09 0.054 0.273 0.792 0.935 0.687
20 Up-sampling ANOVA Linear SVM 0.074 0.044 0.227 0.784 0.93 0.678
21 Down-sampling RFE-LR Linear SVM 0.055 0.039 0.091 0.892 0.935 0.854
22 SMOTE-sampling ANOVA KNN 0.183 0.115 0.455 0.853 0.956 0.77
23 Down-sampling RFE-LR RF 0.048 0.029 0.136 0.8 0.925 0.704
24 Down-sampling ANOVA RF 0.131 0.076 0.455 0.763 0.947 0.639
25 Down-sampling ANOVA Linear SVM 0.118 0.069 0.409 0.759 0.942 0.636
26 Down-sampling ANOVA KNN 0.129 0.074 0.5 0.728 0.947 0.591
27 SMOTE-sampling RLR-L1 RF 0.067 0.038 0.273 0.69 0.92 0.552
28 SMOTE-sampling RLR-L1 Linear SVM 0.07 0.039 0.318 0.638 0.916 0.49
29 No sampling RLR-L1 RF 0.078 0.045 0.318 0.692 0.925 0.552
30 Up-sampling RLR-L1 Linear SVM 0.069 0.039 0.318 0.63 0.915 0.481
31 Up-sampling RLR-L1 RF 0.069 0.039 0.318 0.633 0.915 0.484
32 No sampling RLR-L1 Linear SVM 0.069 0.039 0.318 0.63 0.915 0.481
33 Down-sampling RLR-L1 RF 0.087 0.048 0.5 0.502 0.913 0.346
34 Down-sampling RLR-L1 Linear SVM 0.105 0.063 0.318 0.795 0.939 0.69
35 Down-sampling RLR-L1 KNN 0.109 0.059 0.773 0.313 0.926 0.188
36 SMOTE-sampling RFE-LR KNN 0.116 0.062 1 0 0 0
Table 4.27: Model evaluation metrics per class of 36 possible instantiations of extended pipeline using CD2W vs. CD2F dataset (all 22 chromosomes
and epidemiological features). They are ordered by CV F1.
103Figure 4.20: CV F1 mean scores with their corresponding standard deviations for all 36 pipeline instantiations using CD2W vs. CD2F dataset.
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Figure 4.21: Confusion matrix of
CD2W. vs. CD2F test dataset.
Figure 4.22: Predicted probabili-
ties of CD2W vs. CD2F test dataset.
Figure 4.23: Specific result plots of “best” pipeline model using lung cancer dataset:
RFE-LR + Down-sampling + KNN.
Figure 4.23 shows detailed results regarding the “best” pipeline model using the analysis
case, consisting of performing ANOVA as the feature selection step, followed by applying
SMOTE-sampling and KNN as a classification method. Figure 4.21 shows that the
classifier is able to correctly classify 77% of the test samples belonging to the negative
class, and a bit more than 31% of the positive class samples. As for the predicted
probabilities, Figure 4.22 reflects the “easiness” of discriminating most of the CD2F
individuals (high frequency of probabilities arount 0), but the difficulty of identifying
individuals suffering from T2D (low frequency of probabilities around 1, and instead
distributed around 0.5). This is an expected result, since both groups of individuals
suffering from one or more of the comorbidities, which are all closely related to the T2D
disease.
Feature Ranking Results
Since the KNN classifier does not have an intrinsic coefficient measure associated to it,
like the Linear SVM with the weights, and the RF with the variable importance, we
take as a measure to rank the final selected features, the p-values associated to each
feature given by the ANOVA. Table 4.28 shows the list of the 21 features selected by the
feature selection method with its corresponding ‘ANOVA p-value’ in ascending order,
since the smaller p-value the more significance the feature has. Finally, the ‘PLINK
p-value’ column shows the associated p-value of a certain SNP obtained from PLINK
using logistic regression.
For this analysis, again, none of the SNPs identified as significant by the logistic regres-
sion, were used by the classifier to make the final classification of the test dataset. All
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SNPs have p-values much greater than 0.0001 (corresponding to threshold = 4 defined
in Section 4.2.4.2).
SNP ANOVA p-value p-value
Variant353699 1,93e-3
> 1e-4
Variant326988 2,55e-3
Variant558024 1,22e-2
Variant100556 1,26e-2
Variant662874 1,35e-2
Variant672064 1,54e-2
Variant559354 2,12e-2
Variant559355 2,19e-2
Variant321236 3,21e-2
Variant390454 3,24e-2
Variant187098 4,72e-2
Variant187100 4,72e-2
Variant187089 5,60e-2
Variant94090 5,76e-2
Variant187068 6,10e-2
Variant558025 6,31e-2
Variant222577 7,60e-2
Variant389838 8,01e-2
Variant510023 8,44e-2
Variant343716 8,76e-2
Variant147952 9,25e-2
Table 4.28: Feature ranking from “best” pipeline model (ANOVA + SMOTE-
sampling + KNN) using the CD2W vs. CD2F dataset.
Functional In Silico Analysis Results
Using the R library seq2pathway, we map genome features on the hg38 assembly, followed
by a search for associated traits or diseases using the GWAS Catalog of the National Hu-
man Genome Research Institute (NHGRI) [123] using the following keywords: diabetes,
insulin, cholesterol, hypercholesterolemia, hypertension, hypertensive, tension, cardiovas-
cular, stroke and heart attack. The genes in the regions identified in the “best” model
have been associated directly to T2D and insulin-related functions (Table 4.29). There
were also other associations found directly to cholesterol-related functions (Table 4.30),
hypertension (Table 4.31) and cardiovascular-related functions (Table 4.32).
4.2.4.2 GWAS Classical Approach
The pre-processing steps described in Section 4.1.1.2 were applied to the genomic data
in order to filter the dataset and only analyze the individuals corresponding to the use
case of CD2W vs. CD2F individuals.
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Associated Trait
Fasting insulin-related traits (interaction with BMI).
Modified Stumvoll Insulin Sensitivity Index.
Modified Stumvoll Insulin Sensitivity Index (interaction with BMI).
Obesity-related traits.
Type 2 diabetes and 6 quantitative traits.
Type 2 diabetes and other traits.
Yu-Zhi constitution type in type 2 diabetes.
Cardiovascular heart disease in diabetics.
Cystic fibrosis-related diabetes.
Diabetic retinopathy in type 2 diabetes.
Sight-threatening diabetic retinopathy in type 2 diabetes.
Type 2 diabetes.
Advanced glycation end-product levels.
Cataracts in type 2 diabetes.
Glycemic traits.
Neuropathic pain in type 2 diabetes.
Type 2 diabetes (dietary heme iron intake interaction).
Type 2 diabetes (young onset) and obesity.
Diabetes related insulin traits.
Protein quantitative trait loci.
Metabolite levels.
Chronic kidney disease (chronic kidney disease vs normal or mildly reduced
eGFR) in type 1 diabetes.
Chronic kidney disease (severe chronic kidney disease vs normal kidney function)
in type 1 diabetes.
End-stage renal disease (non-diabetic).
Kidney disease (early and late stages) in type 1diabetes.
Kidney disease (early stage) in type 1 diabetes.
Kidney disease (end stage renal disease vs non-end stage renal disease) in
type 1 diabetes.
Kidney disease (end stage renal disease vs normoalbuminuria) in type 1 diabetes.
Kidney disease (late stage) in type 1 diabetes.
Diabetic nephropathy in type 1 diabetes.
Erectile dysfunction in type 1 diabetes.
Skin fluorescence in type 1 diabetes.
Type 1 diabetes and autoimmune thyroid diseases.
Type 1 diabetes autoantibodies.
Type 1 diabetes.
End-stage renal disease in Type 1 diabetics.
End-stage renal disease or diabetic nephropathy in type 1diabetes.
Pediatric autoimmune diseases.
Glomerular filtration rate in diabetics (creatinine).
Glomerular filtration rate in non diabetics (creatinine).
Table 4.29: Some traits associated to genes with insulin-related functions and diabetes
responses.
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Associated Trait
Body mass index and cholesterol (psychopharmacological treatment).
Obesity-related traits.
Quantitative traits.
HDL Cholesterol in HIV-infection.
Metabolite levels.
Response to statins (HDL cholesterol change).
Response to statin therapy (LDL cholesterol subfractions).
Response to statins (LDL cholesterol change).
Hematological and biochemical traits.
Table 4.30: Some traits associated to genes with cholesterol-related functions.
Associated Trait
Thiazide-induced adverse metabolic effects in hypertensive patients.
Response to chemotherapy in breast cancer (hypertension) (bevacizumab).
Response to chemotherapy in breast cancer hypertensive cases
(cumulative dose) (bevacizumab).
Myocardial infarction in hypertension (ACE inhibitor interaction).
Myocardial infarction in hypertension (beta blocker interaction).
Myocardial infarction in hypertension (calcium channel blocker interaction).
Myocardial infarction in hypertension (diuretic interaction).
Table 4.31: Some traits associated to genes related to hypertension.
Associated Trait
Cardiovascular heart disease in diabetics.
Cardiovascular event reduction in the elderly at risk for vascular
disease (statin therapy interaction).
Creatinine levels in ischemic stroke.
Table 4.32: Some traits associated to genes with cardiovascular-related functions.
A simple test of association using logistic regression was applied to the genomic data of
the CD2W vs. CD2F dataset. Figure 4.24 shows the Manhattan plot from the obtained
results. A total of 201 SNPs above the defined threshold = 4 are considered significant.
Table 4.33 shows the top 50 most significant SNPs with their corresponding chromosome
position and p-values.
108
Figure 4.24: Manhattan plot of SNPs from all 22 chromosomes. All SNPs above the blue line (p-value < 0.0001) are considered significant and
are kept and stored for future comparison with the machine learning approach.
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SNP p-value
Variant678084 8,17e-8
Variant396447 1,27e-6
Variant188065 1,53e-6
Variant248352 1,63e-6
Variant188317 2,34e-6
Variant188342 2,45e-6
Variant188307 2,92e-6
Variant678083 3,40e-6
Variant188306 3,50e-6
Variant188335 3,57e-6
Variant188277 4,35e-6
Variant188281 4,35e-6
Variant188286 4,35e-6
Variant188289 4,35e-6
Variant188293 4,35e-6
Variant188294 4,35e-6
Variant188297 4,35e-6
Variant188303 4,35e-6
Variant42586 5,12e-6
Variant188056 5,90e-6
Variant188057 5,90e-6
Variant188061 5,90e-6
Variant717483 5,98e-6
Variant188003 7,81e-6
Variant188007 7,81e-6
Variant188019 7,81e-6
Variant188021 7,81e-6
Variant188026 7,81e-6
Variant188027 7,81e-6
Variant188034 7,81e-6
Variant188052 7,81e-6
Variant188053 7,81e-6
Variant188054 7,81e-6
Variant188055 7,81e-6
Variant188060 7,81e-6
Variant432865 7,86e-6
Variant714412 8,52e-6
Variant188276 9,33e-6
Variant479629 9,58e-6
Variant27728 1,09e-5
Variant518741 1,11e-5
Variant188318 1,12e-5
Variant479626 1,16e-5
Variant381973 1,26e-5
Variant358561 1,32e-5
Variant188024 1,34e-5
Variant188266 1,34e-5
Variant612718 1,67e-5
Variant612720 1,71e-5
Variant187958 1,87e-5
Table 4.33: Top 50 most significant SNPs, according to GWAS analysis using logistic
regression. They are ordered in ascending order by p-value.
Chapter 5
Conclusions and Future Work
This chapter presents a detailed set of conclusions for each framework design proposed
and its application to the described datasets. Then overall remarks and future work
suggestions are described.
5.1 Conclusions
The problem of missing heritability has been the focus of research and interest for many
biologists and geneticists over several past years. With the onset of the GWAS approach,
the hope of identifying many genes involved in complex diseases arose. Indeed, many
of these studies applied to large case-control groups have identified hundreds of genetic
variants associated with complex diseases, but the effect of most of these is too small
to explain the estimated heritability of these diseases, still holding many doubts about
this issue.
In this study we proposed an alternative methodology to the GWAS approach, based
on machine learning methods to analyze large-scale genetic data of complex diseases.
This study was part of a larger project resulting from the collaboration between the
Eurecat Foundation, the Program for Predictive and Personalized Medicine of Cancer
at the Health Science Research Germans Trias i Pujol (PMPPC-IGTP) and the Poly-
technichal University of Catalonia (UPC). We must highlight that the work presented
here, encompasses only part of the overall project objectives, and further development
is necessary.
Based on the type of data provided and the problems associated with it, we designed
and implemented two pipelines and frameworks; the second ones being an improvement
and generalization of the first ones.
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The proposed preliminary pipeline configuration consisted of three general steps applied
subsequently: feature selection, sampling and a classification algorithm. The Scikit-
learn library used, made it quite easy for the pipeline design to be extensible, to be able
to instantiate each step with different techniques and algorithms and even be able to
add new steps to the pipeline.
In fact, having more data available on the whole genome, an extension of the preliminary
pipeline configuration was required. It consisted of the same three steps of feature selec-
tion, sampling and classification, plus other pre-processing steps added at the beginning
of the pipeline: missing value management, variance filter and standardization.
The execution of the extended pipeline configuration, following the preliminary frame-
work on a much bigger dataset (SNPs from 22 chromosomes, plus around 250 extra
epidemiological features), the execution came to consume the available memory limit,
preventing us from finishing the experiments with success. This setback led us to make
an extension to the preliminary framework. Since we were unable to analyze all the
features from the 22 chromosomes together, we performed a partial analysis by chro-
mosome. This would make a sort of feature filtering of each chromosome, selecting
the most “stable”/relevant features to construct a single final model that could analyze
interactions between features of the whole genome.
All of the models from the preliminary and extended frameworks were properly validated
using cross-validation and grid-search.
In order to reduce the overfit caused by this “filter” done with the stability score out of
the cross-validation loop of the final model, we proposed to use an independent dataset
to calculate this score, denoted as the stability dataset.
Using the different instantiations of each of the steps conforming the pipeline configu-
rations, 36 different experiments (three methods of feature selection, by four sampling
options, by three classification methods) were executed and validated following both
frameworks.
Only the “best” models of each framework (the one with higher CV F1 score out of the
36 experiments) were further analyzed. Using different ranking metrics over the features
of the final model of each framework (stability scores for the preliminary framework, and
coefficients for the extended framework), we choose the top ranked features to search for
genes associated to these variants, to later search for genome-wide significant matches
of these genes with the trait under study.
After applying the 36 different experiments of preliminary pipeline and framework to
the LC dataset and the extended version of the latter to the T2D datasets, no general
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candidate can be selected as a better method of feature selection, sampling or classifi-
cation, because the results obtained for each case were very different. We did not find
a general pattern in the application of any of these methods, which would clearly show
the increase in the performance of the final models using large-scale genetic data. For
this, specific conclusions are described below, corresponding to each use case in which
the pipelines and frameworks were applied.
A constant factor among all the experiments executed in different datasets is that the
standard deviations of almost all the CV F1 scores had very low values, except in some
specific cases of the experiments applied to the dataset of CD2W vs. CD2F. Almost all of
the standard deviations had values below or equal to 0.09. This common feature is very
important because it demonstrates that the model selection process applied using cross-
validation is robust and gives us the certainty that the CV F1 scores obtained in each
experiment are values close to the true values. This is also a sign that the final models,
regardless of their performance, are stable and trustworthy models, because all of the
steps belonging to the pipelines were performed inside the k -fold cross-validation loop,
in contrast to applying the pre-processing steps (missing value management, variance
filter and standardization), and even the feature selection and sampling steps to the
whole dataset upfront, before splitting into training and test sets, and before splitting
the training data into folds, and only applying the cross-validation to the classification
model with the pre-filtered data. Not doing the latter, avoids looking at the validation
data information during model selection.
Another common characteristic among almost all the experiments performed was that
the Test F1 scores were very close to their CV F1 counterpart. This is important because
this suggests the final models are not over-fitting the data and have better capabilities
to generalize and perform similarly on new unseen data.
The general criterion for choosing the best models for each case study was to use the
model with the highest CV F1 score. Only in some cases besides looking at the CV
F1 score, we have taken into account the general Test Recall and the class 1 recall
(Test Recall (1)) which is the class we are most interested in predicting well. This is
relevant because in these medical scenarios, what interests us the most is to have few
false negatives (FN) and avoid making predictions that ultimately hurt patients.
A final common remark among the results obtained in the functional in silico analysis
is that the ML approach applied to all the analysis cases, managed to detect different
signals (in almost all cases, top ranked SNPs of “best” pipeline model were not found
significant by the GWAS applied to the same data). This is interesting because in further
research we could draw conclusions of the complement of both results. In general, finding
genes involved in phenotypes related to the phenotype under study is also a good result,
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since we must take into account that sometimes the phenotypes that we use can be
created artificially/clinically, and therefore may not respond to their genetic base.
Alternatively, given the difference in performance between the Train F1 and CV F1
scores, we believe there is room for improvement when the different models are trained
with new data that will be released by the IGTP-IMPPC research group.
5.1.1 Lung Cancer Dataset
Regarding the specific results obtained in the application of the preliminary pipeline and
framework, we saw better generalization scores when wrapper RFE-LR and embedded
RLR-L1 methods were applied. The ANOVA filter method was clearly outperformed
by the other feature selection methods, regardless of the sampling and classification
methods it was paired with.
The combination of Down-sampling with RF showed a tendency to have higher CV
F1 scores (appears three times in the top 5 results in Table 4.2), independently of the
feature selection method applied along with these steps in the pipeline.
Also, applying any sampling technique to the data, favored higher CV F1 scores, since
almost all the experiments that do not apply sampling to the data (“No sampling” label),
are in the bottom half of the table of results. This makes sense since this specific dataset
has very few samples and supervised classification methods cannot generalize well when
trained with small samples of data. More specifically, a good portion of the experiments
that use Down-sampling have lower performance scores, but it is interesting to see that
all their corresponding Test metrics, show un-biased models towards class 0 (i. e. Test
F1 (1), Test Precision (1) and Test Recall (1) different from 0).
The pipeline with the highest CV F1 score selected as the “best” pipeline model con-
sisted of the combination of regularized L1 logistic regression embedded feature selection,
followed by performing down-sampling and finally using a random forest classifier.
As for the GWAS classical approach results, this use case was the only one were SNPs
considered significant by the classical approach applied (i. e., with p-values smaller than
1e − 3), were also selected as relevant by our ML approach, having a stability score
higher or equal than 40.
The SNPs identified as relevant/stable by the “best” pipeline model were mapped to the
hg19 assembly were associated to lung-related functions and other cancers other than
lung cancer.
114
5.1.2 Type 2 Diabetes vs. Healthy (D2 vs. H) Dataset
Concerning the specific results obtained in the application of the extended pipeline
and framework over this dataset, Linear SVM shows clear advantages over the other
classification algorithms. Almost all the top ten pipeline models use Linear SVM as a
classification step and have the same model selection and evaluation metrics.
In this case, the RFE-LR wrapper method was outperformed by the other two methods
(RLR-L1 and ANOVA), with all appearances in the bottom half of the table of results.
In spite of this, it is important to emphasize that the use of this method of feature
selection, also reflects high CV F1 scores, almost all values greater than 0.8.
The sampling technique applied does not seem to affect directly the performance of the
pipeline models, since there is no clear order of a specific sampling technique in the
top “best” pipeline models. Perhaps the Down-sampling method, shows consistent bad
performance, regardless of the feature selection and classification methods it was paired
with.
By having different combinations of methods that have equal performances, the model
with the simpler steps (that consumes less resources during training) was chosen to be
the “best” pipeline model for this use case. The latter consisted of the combination of
ANOVA filter feature selection, followed by applying No sampling at all and using a
Linear SVM as a classifier.
Our ML approach identified different signals, from the ones detected by the GWAS
approach. Some of the genes associated to these SNPs showed associations to insuline-
related functions, but not direct association to T2D.
5.1.3 Type 2 Diabetes vs. No Type 2 Diabetes and Comorbidities (D2
vs. CD2F) Dataset
In regard to the D2 vs. CD2F use case, the majority of the experiments using the RFE-
LR wrapper feature selection correspond to the top pipeline models with the highest
performance, no matter what classifier was used at the end of the pipeline.
It seems that not applying any sampling technique reflects in better performance and
using Down-sampling affects negatively the performance of the models.
As for the classifier, there is no clear option that shows signs of improving or aggravating
the model’s performance. The top 10 pipeline models have very similar CV F1 scores
and use the three classification models.
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We considered the combination of RFE-LR with Down-sampling and KNN as the “best”
pipeline model for this case.
In spite of being one of the most complicated use cases, because it is made up of a group
of individuals more homogeneous than the previous case, but still distinguishable among
them (one group only suffers from type 2 diabetes and the other only suffers from one
or more of the comorbidities associated with type 2 diabetes), the functional in silico
analysis yielded more promising results. The genes in the regions identified in the “best”
model have been associated directly to T2D and insulin-related functions. There were
also found associations to the comorbidities: cholesterol-related functions, hypertension
and cardiovascular-related functions.
5.1.4 Type 2 Diabetes and Comorbidities vs. No Type 2 Diabetes and
Comorbidities (CD2W vs. CD2F) Dataset
The execution of the 36 different experiments using the extended pipeline and framework
threw very similar results to the previous use case, regarding the best feature selection
method for this type of data. RFE-LR and ANOVA show clear better performances
than the embedded feature selection (RLR-L1).
In this case it is difficult to highlight a specific classifier, since the results do not show
a clear order of one predominating over the others, but if we look only at the top 10
pipeline models, none of them use the Linear SVM as a classifier option.
Most of the experiments that did not apply sampling to the data have higher perfor-
mances, but changing the sampling step does not seem to influence to a great extent the
performance of the model, since there are models that use Up-sampling and SMOTE-
sampling that throw the same CV F1 scores.
The pipeline combining ANOVA with SMOTE-sampling and KNN was chosen to be the
“best” pipeline model for this use case. We are aware that further analysis should be
done to corroborate this model is the “best” one to discriminate between individuals
with complex type 2 diabetes and individuals only suffering from one or more of the
comorbidities associates to type 2 diabetes. We should look deeper into the Train metrics
associated to the class of interest, to be definitely certain of our choice. For now, we
consider that this model has a high score CV F1 score for practical use and shows signs
of good performance over unseen data, being able to identify class 1 individuals, without
miss-classifying a large amount of class 0 patients.
Even though none of the SNPs identified as relevant by the “best” pipeline model, had
p-values lower than 1e − 4 to be considered significant by the GWAS approach, the
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mapping of genome features to the hg38 assembly, resulted in genes directly associated
to T2D and insulin-related functions as well as cholesterol-related, hypertension and
cardiovascular-related functions.
5.2 Final Remarks
Overall, the solution proposed in this study is a state-of-the-art, scalable and flexible
alternative to the classical GWAS approach, to analyze large-scale data. It is clear that
further work should be done in order to asses which methods (from feature selection,
sampling and classification) work best with this type of data. At this point we can not
discard any possibility or conclude that a specific method unconditionally yields better
results. Some methods stand out in some situations, that when used with other sub-
samples of the same cohort does not work well. We must deepen and extend this study
to draw more robust and general conclusions.
The satisfactory results obtained in this study is one of the reasons that led to the
extension of the project between Eurecat, IGTP-IMPPC and UPC, to validate the results
obtained with other independent cohorts of patients and to start working with other
types of large-scale data.
5.3 Future Work
Further work can be foreseen in order to improve the performances reported in the
results of this study. Given the nature of the pipelines and frameworks described, new
experiments could easily be setup by simply replacing more sophisticated techniques
regarding data sampling, feature selection or classification algorithms. In this sense
we intend to expand the applied options of the different feature selection techniques,
trying mutual information [129] as a filter method, sequential forward selection [86] as
a wrapper method and regularized L2 logistic regression as an embedded method. We
also intend to expand the number of experiments using other scoring functions during
model selection, to emphasize the recall of class 1 and avoid misleading predictions.
We would like to propose a new ranking score that in some way merges the already
recorded coefficient measures along with the stability score, since each metric measures
different and important things.
Regarding the extended framework, we would like to try out different instantiations of
the extended pipeline used in the partial analysis by chromosome and in the construction
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of the final model. Even though they are both validated using k -fold cross-validation
and grid-search (for hyper-parameter tuning), the instantiation of a given pipeline may
give better results with data from different chromosomes, and also in the final model
that has “filtered/merged” features from all of the 22 chromosomes.
A deeper pre-processing of the epidemiological features could be done before applying
the proposed framework. The obtained results can be compared with the results of this
study. Using a priori knowledge, we could filter some variables that by common sense,
we know are highly correlated with each other.
During model selection, it would be interesting to see if a more fine-grained grid-search
(for hyper-parameter tuning) can improve the current performance results.
In this study we only recorded general CV Recall and Train Recall scores, and we are
aware that in further research we need to record more specific CV Recall and Train Recall
scores related to each class, specifically the class of interest, and use these metrics and
not the Test metrics to make decisions and conclusions of the final model to be used
with new unseen data.
As for the results obtained with all the four datasets, from the process of functional
in silico analysis, it is important to note that, even though all of these results seem
functionally appealing, they are not a 100% relevant/conclusive from the clinical point
of view for several reasons:
• In the LC case, we did a partial analysis using data from only one chromosome
(chromosome 12), we should extend the analysis to data from the whole genome.
• In the T2D cases, we only used a sub-sample of approximately 4,000 individuals,
from a bigger sample of approximately 13,700 individuals. This was due to time
reasons. GCAT is an ongoing independent project that collects data from volun-
teers from the general population, and we used the data available at the time we
finished the design of the extended pipeline and framework.
• We should further validate the results related to the SNPs identified as relevant
by our method, by applying the same pipeline and framework to an independent
cohort of individuals, with similar characteristics, to see if the same SNPs are
ranked as significant and perform deeper biological and genetic analysis.
Also, a graphical visualization of the results could be improved to facilitate the valida-
tion/evaluation of the results (e.g. SNPs vs. target phenotype in sort of heatmap, or
predicted probabilities against real class labels, etc.).
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We would also like to translate the design and implementation of the proposed pipeline
and frameworks, so that they can be executed in a distributed environment, to take
advantage of the scalability feature and be able to work with even more features and
samples.
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Abstract. During the last decade, the interest to apply machine learn-
ing algorithms to genomic data has significantly increased for a variety of
bioinformatics applications. Analyzing this type of data entails tackling
difficulties related to high-dimensionality and class imbalance for knowl-
edge extraction and identifying important features. In this study, we pro-
pose a general framework to tackle those challenges by stacking different
machine learning algorithms and techniques to choose the best configu-
ration as the final model to be used for classification and identify relevant
SNPs (e.g. single nucleotide polymorphism). We test the machine learn-
ing framework in a real lung cancer data-set and compare with the results
obtained from the classical Genome Wide Association Studies (GWAS)
approach. Our results show that combining down-sampling, regularized
L1 logistic regression feature selection and random forest classification
we obtain the best generalization performance. We also found that some
of the variants identified as important by the latter model, showed some
correlation with GWAS traits reported for lung/pulmonary functions and
smoking interactions.
Keywords: GWAS, SNP, machine learning, classification, feature selec-
tion
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21 Introduction
Lung cancer (LC) is the most common cancer in the world, and the lead-
ing cause of mortality among cancer-related deaths. The Non-Small-Cell-Lung-
Cancer (NSCLC), being the most common form, has an overall 5-years survival
of less than 15%. Despite the enormous heterogeneity, these tumors have been
treated homogeneously for a long time with cytotoxic chemotherapy as the choice
treatment, but response rates are only 15%-30%, and median OS is less than
12 months. Resistance to treatment can arise from genotype variants on tar-
get/resistance factors that impact disease progression or response to treatment.
Moreover, LC is an important cause of admission to the ICU after surgery and
is also considered an important co-morbidity in critical care.
Array based genotyping and sequencing technologies has enabled genome-
wide characterization of the effect of DNA variation (e.g. single nucleotide poly-
morphisms (SNPs)) on diseases and their complex traits. Many studies have
identified genetic variants, which affect the risk of multiple diseases. However,
a single variant confers a small risk with low prediction power. To identify in-
dividuals at high risk it is appropriate to consider mixed models with genetic
and epidemiological data. The huge number of genetic variants available from
OMIC data, and the single SNP approach of the classical genome wide associa-
tion studies (GWAS) analysis present the limitation of not being able to identify
potential interactions. This analysis is challenging because of the high dimen-
sionality of genomic data (up to millions of SNPs), the relatively small number
of analyzed individuals and the uneven proportion of individuals belonging to
each class (class imbalance). This is why the interest of applying machine learn-
ing algorithms to array-based SNP data has recently become so popular [2] [3]
[4] [7] [5].
In cancer therapy there are clear evidences that response to treatment is a
complex trait where genomic and environmental factors play overlapping roles
as modifiers. In this scenario, GWAS analysis is commonly used to investigate
the predictive role of genomic variants in response to treatment in a case-control
design.
Our main goal in this short study is to identify a reduced set of SNPs with
the highest prognostic value in a cohort of lung cancer patients treated with
platinum-based chemotherapy. We accomplish this task by designing a specific
framework/pipeline to deal with the multi-dimensionality problem using differ-
ent feature selection techniques, applying sampling techniques to deal with class
imbalance, and, finally, making predictions using machine learning classification
methods [8]. We also propose different metrics to rank and select a relevant sub-
set of SNPs. These ranked SNPs are compared with the p-value obtained from
the classical GWAS approach, which is usually based on single SNP logistic
regression.
In the following sections, we describe the design of the pipeline-based anal-
ysis and the results obtained of its application to a lung cancer data-set. The
concluding remarks, as well as future refinements of this approach, are provided
in the conclusions section of this paper.
32 Methodology
2.1 Data-set
The study data-set comprises raw data and results from a GWAS analysis
conducted at PMPPC (Programa de Medicina Predictiva i Personalitzada del
ca`ncer). The data-set contains a series of 178 patients with advanced NSCLC
and measurable disease (at least one target lesion). Subjects are classified accord-
ing to RECIST (response evaluation criteria in solid tumors) as Non responders
(Disease progression) (n=41) and Responder (partial/complete response and sta-
ble disease) (n=137). All relevant clinical and sociodemographic variables were
included in the analysis. Genome-wide genotypes were generated using arrays-
SNP technology using the Infinium HTS Assay, HumanCoreExome-24v1-0 Bead-
Chip, (ILLUMINA, San Diego, CA) at the Genomic Units of PMPPC. A total
of 325,762 SNPs remain after systematic quality control on the raw genotyping
data (overall call rate of 99.89%). In silico methods were used for genome wide
imputation to generate a data-set of 24,873,940 SNPs, from which 10,307,177
SNPs were retained for the association analysis. For the purposes of this anal-
ysis we consider only chromosome 12, where several significant GWAS signals
were identified. Raw genotype data from 423,929 common variants (hg19 assem-
bly, minor allele frequency > 0.01) and the p-values from uni-variate analysis
(additive model) were analyzed.
Genetic variants are encoded using the additive model, using 0, 1, or 2 as
numerical values [14]. Responders and non responders to treatment are classified
as class 0 and 1 respectively. This data-set is split 80-20 into training and test
sets resulting in 142 individuals for training (109 from class 0 and 33 from class
1) and 36 for test (28 from class 0 and 8 from class 1). The split is performed in
a stratified way, to ensure the same proportion of individuals of each class as in
the original data-set.
2.2 Pipeline configuration
To identify combinations of features with significant prediction power, a machine
learning pipeline framework has been designed and tested (see Figure 1). The
instantiation of these methods and algorithms, unfold a series of different models
and their corresponding results.
We first add into the pipeline a feature selection method to deal with the
multi-dimensionality problem. The main idea is to find irrelevant (noisy) or re-
dundant features that do not contribute to the increase of the accuracy/performance
of the final classification model, discard those, and keep the relevant ones to move
forward in the pipeline process.
Feature selection methods are usually classified into three categories, depend-
ing on how they combine the feature selection search with the construction of
the predictive model: filter, wrapper and embedded methods. Filter methods
work independently of the classifier design, and perform feature selection by
4Fig. 1. General Pipeline Framework
looking at the intrinsic properties of the data. In contrast, wrapper and embed-
ded methods perform feature selection by making use of a specific classification
model. While wrapper methods employ a search strategy in the space of possible
feature subsets, guided by the predictive performance of a classification model,
embedded methods make use of the classification model internal parameters to
perform feature selection [1]. In our pipeline design we use one of each type of
feature selection methods [24] to instantiate this step of the pipeline: ANOVA
as a filter method, recursive feature elimination with logistic regression (RFE-
LR) as a wrapper method and regularized L1 logistic regression (RLR-L1) as an
embedded method.
To deal with the class imbalance problem of having highly unequal number
of individuals for each class of the target column, we propose to add a sampling
step to the pipeline. The main objective of using a sampling technique is to
adjust the class distribution of a data-set contributing to create a good model
using a balanced training data-set [16]. We try down-sampling, up-sampling [18]
and SMOTE-sampling [12] as alternatives of instantiation of the sampling step
of the pipeline.
The final classifier building step of the pipeline consists of a machine learning
supervised model. We try out linear support vector machines (Linear SVM) [10],
random forests (RF) [9] and K nearest neighbors (KNN) [11] as classification
methods based on very different strategies to discriminate between classes.
In general, the feature selection and sampling steps, should not be decou-
pled from the process of creating an accurate classification model to avoid over-
optimistic estimates of the error [13]. For this reason, we evaluate the whole
pipeline process using cross-validation (CV) as a model selection tool. We apply
grid-search with cross-validation to find the best combination of parameters for
a specific pipeline using a training set, and afterwards having chosen a set of
specific parameters (the model with highest CV score), we test the predictive
5power of the model with a separate and independent test set, for which sampling
has not been applied, preserving the original distribution of the data.
To identify the most important features, we also use the best model found
with highest CV score, and measure the stability of the features selected by the
feature selection step, by re-training this model several times using S different
samplings/shuﬄes without replacement of 80% of the data of the training set [6].
Each feature of the original data-set will have a stability score associated to it.
After re-training the whole pipeline, we add 1 to the stability score of the features
that were selected. At the end of this process, features that were consistently
selected S times, will have a score of S points. The larger the score, the more
stable will be the feature. During this process of stability check, we also record
other metrics useful to perform a ranking over the SNPs, based on characteristics
of specific instantiations of the classification step in the pipeline. For example,
if the classifier of the pipeline in analysis is a linear SVM, we save the values
of the weights assigned by the algorithm to each feature. In a similar way, for
the case of random forests, we keep record of the variable importance metric
[15] associated to each feature while using this classification model. Regardless
of the ranking measure used, let us refer to these values as coefficients. The
sign of the coefficients can be used to measure the feature effect in the final
classification result. A positive coefficient should be interpreted as a contribution
to the classifier with no response to treatment and tumor progression (class 1).
After the iterative process is finished, we define the following aggregated
metrics: the mean of the coefficients (MC), the mean of the absolute value of the
coefficients, (MAC) since some coefficients can be equally important as positive
and negative values, and the scaled version of the previously mentioned measure
(MSC), to compare the importance of each feature in terms of its coefficient
measure. We also intend to compare the results obtained of the most important
features with the results of the single SNP logistic regression applied using the
PLINK tool [17]. The output of applying this method gives a p-value associated
to each SNP, and using a threshold = − log(p − value) = 2 we can filter the
most significant SNPs by selecting those whose nominal value is greater than
this threshold (p− value ≤ 0.01).
2.3 Functional in silico analysis
Evaluation of the potential functional impact of the identified variants was an-
alyzed by gene annotation on GRch37 (hg19) using the seq2pathway R library
[23], and GWAS Catalog of the National Human Genome Research Institute
(NHGRI) for genome-wide significant matches [21].
3 Results
The whole pipeline model was validated using 5-fold cross-validation and using
the F1 weighted measure as scoring function. We use the latter scoring function
due to the nature and distribution of the data, since we know a priori that classes
6are imbalanced and we want to give equal importance to the precision and recall
of both classes. The tuning of parameters associated to each step was performed
using a grid-search. The different parameters tried are shown in Table 1. The
C parameter in RLR-L1 refers to the inverse of regularization strength. In the
case of Linear SVM it refers to the penalty parameter of the error term. In
both of the latter cases, the smaller the values, the stronger the regularization.
The n estimators parameter in RF refers to the number of trees in the forest
and n neighbors in KNN is the number of neighbors to take into account in the
neighbors voting step of the classifier.
Table 1. Parameter evaluated using grid-search and 5-fold cross-validation.
Pipeline Step Parameter Options
RLR-L1 C = [10, 50, 500, 1000, 1500]
Linear SVM C = [0.001, 0.01, 0.1, 1, 10, 100, 1000]
RF n estimators = [30, 47, 75, 119, 189, 299, 475, 753, 1194, 1892, 2999]
KNN n neighbors = [5, 20, 35, 50]
For the training process we obtained the results shown in Table 2. They
are listed in descending order by CV F1 score. For all 36 experiments, we only
show the top 5 pipelines with the best performances. There were no significant
differences between the top 5 classifiers in CV F1 score (from 0.702 to 0.681).
The pipeline with the highest CV F1 score (0.702) consisted of the combination
of down-sampling, followed by a regularized L1 logistic regression embedded
feature selection (of 5,464 features using C = 1000) and finally using a random
forest classifier (with 30 decision trees). The KNN pipeline reached the same CV
F1 performance score as RF. However given that the former pipeline did not
outperformed the latter in F1 Test score, we chose this one (RF) as the best
pipeline given it’s better capability to generalize on unseen observations.
The performance of the best pipeline (RF) was adjusted by -0.061 of F1 score
in the Test set. This was partially due to the score achieved in Test Recall (0.611)
which is affected by the errors made on the class with less number of instances
(class 1, non-responders to treatment).
In the top 5 pipelines (Table 2), RF is the most common classifier. Its perfor-
mance is in concordance with previous published results in similar data-sets like
multiple sclerosis [26], age-related macular degeneration [27], Crohn’s disease
[28], rheumatoid arthritis [29] and lung cancer [30] [31]. Also, the top 5 pipelines
incorporate sampling techniques to improve the prediction, being up-sampling
the most common among them.
As for the feature ranking, we performed S = 50 different samplings/shuﬄes
without replacement of 80% of the training set and calculated the stability score.
After experimentation and to avoid being too restrictive, we select features with
7Table 2. Top 5 results obtained in training process of all possible combinations of
instantiations of every step in the general pipeline.
R height
Feature
Selection
Sampling Classifier
CV
F1
Train
F1
Test
F1
Test
Precision
Test
Recall
Embedded:
RLR-L1
Down Sample RF 0.702 0.849 0.641 0.700 0.611
Wrapper:
RFE-LR
Up Sample KNN 0.702 0.751 0.592 0.601 0.583
Wrapper:
RFE-LR
Up Sample Linear SVM 0.693 1.000 0.606 0.577 0.639
Filter:
ANOVA
Smote Sample RF 0.682 1.000 0.681 0.605 0.778
Embedded:
RLR-L1
Up Sample RF 0.681 1.000 0.667 0.600 0.750
a stability score greater or equal to 45 (see Table 3), along side other coefficient
metrics recorded throughout this stability process. The PLINK p-value column,
refers to the associated p-value obtained from single SNP logistic regression using
PLINK.
Table 3. Subset of most important SNPs listed in descending order by stability score.
SNP Stability MC MSC
PLINK
p-value
Variant1 49 1.423e-4 2.360e-3 >1e-2
Variant2 49 5.939e-4 9.851e-3 2.917e-3
Variant3 49 1.589e-4 2.635e-3 >1e-2
Variant4 47 4.839e-4 8.028e-3 >1e-2
Variant5 47 1.065e-3 1.767e-2 4.850e-4
Variant6 46 6.091e-4 1.010e-2 3.101e-3
Variant7 46 1.600e-3 2.655e-2 2.686e-3
Variant8 46 4.328e-4 7.179e-3 >1e-2
Variant9 46 7.398e-4 1.227e-2 >1e-2
Variant10 45 3.058e-4 5.073e-3 3.101e-3
Variant11 45 5.178e-4 8.590e-3 >1e-2
Variant12 45 1.789e-4 2.968e-3 1.543e-3
With the help of the R library seq2pathway, we map genome features on the
hg19 assembly. Subsequently, using the GWAS Catalog of the National Human
Genome Research Institute (NHGRI) [21] and the European Bioinformatics In-
stitute (EMBL-EBI) [22], we were able to search associated traits or diseases to
these genes. The genes in the regions identified in the top-5 models have not
been associated directly to cancer, but to lung-related functions (see Table 4).
8Table 4. Some associated traits to genes with lung-related functions.
Associated Trait
Body mass in chronic obstructive pulmonary disease.
Pulmonary function in asthmatics.
Asthma or chronic obstructive pulmonary disease.
Post-bronchodilator lung function in asthma (FEV1).
Post-bronchodilator lung function in asthma (FEV1/FVC).
Post bronchodilator FEV1.
Post bronchodilator FEV1 in COPD.
Post bronchodilator FEV1/FVC ratio.
Post bronchodilator FEV1/FVC ratio in COPD.
Pulmonary function.
Pulmonary function decline.
Lung function (FEV1).
Pre bronchodilator FEV1/FVC ratio.
3-hydroxy-1-methylpropylmercapturic acid levels in smokers.
3-hydroxypropylmercapturic acid levels in smokers.
Exhaled carbon monoxide levels.
MGMT methylation in smokers.
Smoking behavior.
Blood pressure (smoking interaction).
Fibrinogen levels (smoking status, alcohol consumption
or body mass index interaction).
Both lung cancer, and its response to treatment are regarded as complex
conditions, influenced by a combination of environmental factors as well as mul-
tiples genes. Genes are organized in functional pathways, not correlated across
the genome, and for this reason we must be cautious to infer any direct clinical
application until whole genome is analyzed.
The whole pipeline design in this study was implemented using the Sklearn
library [24]. Sklearn is a simple and efficient open source tool for data mining
and data analysis. Several of the implementations of the algorithms used, are
designed to be able to run in parallel over multiple cores. All of the experiments
were executed on a single computer with 12 CPU cores of 3.30GHz each, and
47GB of RAM memory. Figure 2 shows the computational time efficiency of the
36 different experiments executed. Regardless of the sampling technique, using
RLR-L1 as the feature selection step and RF as the classification step, have the
most computational cost (approximately 10 minutes). It makes sense looking at
the number of parameter options of both RLR-L1 (5 options for parameter C)
and RF (11 options for parameter n estimators), resulting on 55 different settings
and 275 different model fits (because of the 5-fold cross-validation) during the
grid-search process. In this case, the “Embedded” type of feature selection took
a lot more time than the “Wrapper” type because of the configuration we gave
9to the RFE method. Previously knowing the huge number of features that we
were going to deal with, the method was configured to drop 25% of the features
at each iteration, reaching very fast to the final goal of keeping 2000 features.
Fig. 2. Computational time efficiency of all 36 experiments during model selection
(grid-search + cross-validation).
4 Conclusions
We defined an extensible and flexible framework to build classification pipelines
based on machine learning techniques that can be applied to high dimensional
and imbalanced SNP data. Using this approach, we were able to identify the
best model configuration and underscore genome variants that could be relevant
as prognosis biomarkers in lung cancer patients.
With this general framework we try to fill the gap of commonly used methods
that do not take into account cross-validation, class imbalance and the joined
predictive power of multiple features to identify relevant features and perform
classification tasks. From the set of 36 different experiments done using only
SNPs from chromosome 12, the pipeline that performs down-sampling, regular-
ized L1 logistic regression feature selection and random forest classification, was
the one with best CV F1 score.
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Even if our approach has not been able to find out some of the genome
signals (1e-6) identified by PLINK, the annotation analysis of the variants iden-
tified showed some correlation with GWAS traits reported for lung/pulmonary
functions and smoking interactions, as well as with pathways involved in the
carcinogenic process.
Clinical relevance of the results presented here are functionally appealing,
but we must recognize it has limited value due to the partially analyzed genome
data. Moreover, we are aware of data dimensionality in genome wide analyses
as a major concern when applied to complete clinical cohort series, generally
composed by a small number of available patients. Further work can be foreseen
in order to improve the performances reported in the results section. Given the
nature of the framework described, easily new experiments could be setup to
build new pipelines by simply replacing more sophisticated techniques regarding
data sampling, feature selection or classification algorithms. In this sense we
intend to expand the applied options of the different feature selection techniques,
trying mutual information [19] as a filter method, sequential forward selection
[20] as a wrapper method and regularized L2 logistic regression as an embedded
method. We also intend to expand the number of experiments using other scoring
functions during model selection, to emphasize the recall of class 0 and avoid
misleading predictions.
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